Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods</title><author><name sortKey="Ahmed, Rafay" sort="Ahmed, Rafay" uniqKey="Ahmed R" first="Rafay" last="Ahmed">Rafay Ahmed</name><affiliation><nlm:aff id="af1-cmar-6-149">Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Oborski, Matthew J" sort="Oborski, Matthew J" uniqKey="Oborski M" first="Matthew J" last="Oborski">Matthew J. Oborski</name><affiliation><nlm:aff id="af2-cmar-6-149">Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Hwang, Misun" sort="Hwang, Misun" uniqKey="Hwang M" first="Misun" last="Hwang">Misun Hwang</name><affiliation><nlm:aff id="af1-cmar-6-149">Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Lieberman, Frank S" sort="Lieberman, Frank S" uniqKey="Lieberman F" first="Frank S" last="Lieberman">Frank S. Lieberman</name><affiliation><nlm:aff id="af3-cmar-6-149">Department of Neurology and Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Mountz, James M" sort="Mountz, James M" uniqKey="Mountz J" first="James M" last="Mountz">James M. Mountz</name><affiliation><nlm:aff id="af1-cmar-6-149">Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24711712</idno><idno type="pmc">3969256</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969256</idno><idno type="RBID">PMC:3969256</idno><idno type="doi">10.2147/CMAR.S54726</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001F28</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001F28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods</title><author><name sortKey="Ahmed, Rafay" sort="Ahmed, Rafay" uniqKey="Ahmed R" first="Rafay" last="Ahmed">Rafay Ahmed</name><affiliation><nlm:aff id="af1-cmar-6-149">Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Oborski, Matthew J" sort="Oborski, Matthew J" uniqKey="Oborski M" first="Matthew J" last="Oborski">Matthew J. Oborski</name><affiliation><nlm:aff id="af2-cmar-6-149">Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Hwang, Misun" sort="Hwang, Misun" uniqKey="Hwang M" first="Misun" last="Hwang">Misun Hwang</name><affiliation><nlm:aff id="af1-cmar-6-149">Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Lieberman, Frank S" sort="Lieberman, Frank S" uniqKey="Lieberman F" first="Frank S" last="Lieberman">Frank S. Lieberman</name><affiliation><nlm:aff id="af3-cmar-6-149">Department of Neurology and Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Mountz, James M" sort="Mountz, James M" uniqKey="Mountz J" first="James M" last="Mountz">James M. Mountz</name><affiliation><nlm:aff id="af1-cmar-6-149">Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Cancer Management and Research</title><idno type="eISSN">1179-1322</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high morbidity and mortality. Even with optimal treatment, median survival is only 12–15 months for glioblastomas and 2–5 years for anaplastic gliomas. However, recent advances in imaging and quantitative analysis of image data have led to earlier diagnosis of tumors and tumor response to therapy, providing oncologists with a greater time window for therapy management. In addition, improved understanding of tumor biology, genetics, and resistance mechanisms has enhanced surgical techniques, chemotherapy methods, and radiotherapy administration. After proper diagnosis and institution of appropriate therapy, there is now a vital need for quantitative methods that can sensitively detect malignant glioma response to therapy at early follow-up times, when changes in management of nonresponders can have its greatest effect. Currently, response is largely evaluated by measuring magnetic resonance contrast and size change, but this approach does not take into account the key biologic steps that precede tumor size reduction. Molecular imaging is ideally suited to measuring early response by quantifying cellular metabolism, proliferation, and apoptosis, activities altered early in treatment. We expect that successful integration of quantitative imaging biomarker assessment into the early phase of clinical trials could provide a novel approach for testing new therapies, and importantly, for facilitating patient management, sparing patients from weeks or months of toxicity and ineffective treatment. This review will present an overview of epidemiology, molecular pathogenesis and current advances in diagnoses, and management of malignant gliomas.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Ferlay, J" uniqKey="Ferlay J">J Ferlay</name></author><author><name sortKey="Shin, Hr" uniqKey="Shin H">HR Shin</name></author><author><name sortKey="Bray, F" uniqKey="Bray F">F Bray</name></author><author><name sortKey="Forman, D" uniqKey="Forman D">D Forman</name></author><author><name sortKey="Mathers, C" uniqKey="Mathers C">C Mathers</name></author><author><name sortKey="Parkin, Dm" uniqKey="Parkin D">DM Parkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Louis, Dn" uniqKey="Louis D">DN Louis</name></author><author><name sortKey="Ohgaki, H" uniqKey="Ohgaki H">H Ohgaki</name></author><author><name sortKey="Wiestler, Od" uniqKey="Wiestler O">OD Wiestler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ostrom, Qt" uniqKey="Ostrom Q">QT Ostrom</name></author><author><name sortKey="Gittleman, H" uniqKey="Gittleman H">H Gittleman</name></author><author><name sortKey="Farah, P" uniqKey="Farah P">P Farah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kleihues, P" uniqKey="Kleihues P">P Kleihues</name></author><author><name sortKey="Louis, Dn" uniqKey="Louis D">DN Louis</name></author><author><name sortKey="Scheithauer, Bw" uniqKey="Scheithauer B">BW Scheithauer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fisher, Jl" uniqKey="Fisher J">JL Fisher</name></author><author><name sortKey="Schwartzbaum, Ja" uniqKey="Schwartzbaum J">JA Schwartzbaum</name></author><author><name sortKey="Wrensch, M" uniqKey="Wrensch M">M Wrensch</name></author><author><name sortKey="Wiemels, Jl" uniqKey="Wiemels J">JL Wiemels</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnholtz Sloan, Js" uniqKey="Barnholtz Sloan J">JS Barnholtz-Sloan</name></author><author><name sortKey="Sloan, Ae" uniqKey="Sloan A">AE Sloan</name></author><author><name sortKey="Davis, Fg" uniqKey="Davis F">FG Davis</name></author><author><name sortKey="Vigneau, Fd" uniqKey="Vigneau F">FD Vigneau</name></author><author><name sortKey="Lai, P" uniqKey="Lai P">P Lai</name></author><author><name sortKey="Sawaya, Re" uniqKey="Sawaya R">RE Sawaya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Davis, Fg" uniqKey="Davis F">FG Davis</name></author><author><name sortKey="Dolecek, Ta" uniqKey="Dolecek T">TA Dolecek</name></author><author><name sortKey="Mccarthy, Bj" uniqKey="Mccarthy B">BJ McCarthy</name></author><author><name sortKey="Villano, Jl" uniqKey="Villano J">JL Villano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gupta, K" uniqKey="Gupta K">K Gupta</name></author><author><name sortKey="Salunke, P" uniqKey="Salunke P">P Salunke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olar, A" uniqKey="Olar A">A Olar</name></author><author><name sortKey="Aldape, Kd" uniqKey="Aldape K">KD Aldape</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clark, Kh" uniqKey="Clark K">KH Clark</name></author><author><name sortKey="Villano, Jl" uniqKey="Villano J">JL Villano</name></author><author><name sortKey="Nikiforova, Mn" uniqKey="Nikiforova M">MN Nikiforova</name></author><author><name sortKey="Hamilton, Rl" uniqKey="Hamilton R">RL Hamilton</name></author><author><name sortKey="Horbinski, C" uniqKey="Horbinski C">C Horbinski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cairncross, G" uniqKey="Cairncross G">G Cairncross</name></author><author><name sortKey="Wang, M" uniqKey="Wang M">M Wang</name></author><author><name sortKey="Shaw, E" uniqKey="Shaw E">E Shaw</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lassman, Ab" uniqKey="Lassman A">AB Lassman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Den Bent, Mj" uniqKey="Van Den Bent M">MJ van den Bent</name></author><author><name sortKey="Brandes, Aa" uniqKey="Brandes A">AA Brandes</name></author><author><name sortKey="Taphoorn, Mj" uniqKey="Taphoorn M">MJ Taphoorn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bello, Mj" uniqKey="Bello M">MJ Bello</name></author><author><name sortKey="De Campos, Jm" uniqKey="De Campos J">JM de Campos</name></author><author><name sortKey="Kusak, Me" uniqKey="Kusak M">ME Kusak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reifenberger, J" uniqKey="Reifenberger J">J Reifenberger</name></author><author><name sortKey="Reifenberger, G" uniqKey="Reifenberger G">G Reifenberger</name></author><author><name sortKey="Liu, L" uniqKey="Liu L">L Liu</name></author><author><name sortKey="James, Cd" uniqKey="James C">CD James</name></author><author><name sortKey="Wechsler, W" uniqKey="Wechsler W">W Wechsler</name></author><author><name sortKey="Collins, Vp" uniqKey="Collins V">VP Collins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ichimura, K" uniqKey="Ichimura K">K Ichimura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hartmann, C" uniqKey="Hartmann C">C Hartmann</name></author><author><name sortKey="Hentschel, B" uniqKey="Hentschel B">B Hentschel</name></author><author><name sortKey="Wick, W" uniqKey="Wick W">W Wick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olson, Ra" uniqKey="Olson R">RA Olson</name></author><author><name sortKey="Brastianos, Pk" uniqKey="Brastianos P">PK Brastianos</name></author><author><name sortKey="Palma, Da" uniqKey="Palma D">DA Palma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hegi, Me" uniqKey="Hegi M">ME Hegi</name></author><author><name sortKey="Diserens, Ac" uniqKey="Diserens A">AC Diserens</name></author><author><name sortKey="Gorlia, T" uniqKey="Gorlia T">T Gorlia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brandes, Aa" uniqKey="Brandes A">AA Brandes</name></author><author><name sortKey="Franceschi, E" uniqKey="Franceschi E">E Franceschi</name></author><author><name sortKey="Tosoni, A" uniqKey="Tosoni A">A Tosoni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ohgaki, H" uniqKey="Ohgaki H">H Ohgaki</name></author><author><name sortKey="Kleihues, P" uniqKey="Kleihues P">P Kleihues</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olar, A" uniqKey="Olar A">A Olar</name></author><author><name sortKey="Raghunathan, A" uniqKey="Raghunathan A">A Raghunathan</name></author><author><name sortKey="Albarracin, Ct" uniqKey="Albarracin C">CT Albarracin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Verhaak, Rg" uniqKey="Verhaak R">RG Verhaak</name></author><author><name sortKey="Hoadley, Ka" uniqKey="Hoadley K">KA Hoadley</name></author><author><name sortKey="Purdom, E" uniqKey="Purdom E">E Purdom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Phillips, Hs" uniqKey="Phillips H">HS Phillips</name></author><author><name sortKey="Kharbanda, S" uniqKey="Kharbanda S">S Kharbanda</name></author><author><name sortKey="Chen, R" uniqKey="Chen R">R Chen</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Noushmehr, H" uniqKey="Noushmehr H">H Noushmehr</name></author><author><name sortKey="Weisenberger, Dj" uniqKey="Weisenberger D">DJ Weisenberger</name></author><author><name sortKey="Diefes, K" uniqKey="Diefes K">K Diefes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gan, Hk" uniqKey="Gan H">HK Gan</name></author><author><name sortKey="Kaye, Ah" uniqKey="Kaye A">AH Kaye</name></author><author><name sortKey="Luwor, Rb" uniqKey="Luwor R">RB Luwor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mellinghoff, Ik" uniqKey="Mellinghoff I">IK Mellinghoff</name></author><author><name sortKey="Schultz, N" uniqKey="Schultz N">N Schultz</name></author><author><name sortKey="Mischel, Ps" uniqKey="Mischel P">PS Mischel</name></author><author><name sortKey="Cloughesy, Tf" uniqKey="Cloughesy T">TF Cloughesy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mellinghoff, Ik" uniqKey="Mellinghoff I">IK Mellinghoff</name></author><author><name sortKey="Cloughesy, Tf" uniqKey="Cloughesy T">TF Cloughesy</name></author><author><name sortKey="Mischel, Ps" uniqKey="Mischel P">PS Mischel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Yh" uniqKey="Kim Y">YH Kim</name></author><author><name sortKey="Nonoguchi, N" uniqKey="Nonoguchi N">N Nonoguchi</name></author><author><name sortKey="Paulus, W" uniqKey="Paulus W">W Paulus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Salama, Ak" uniqKey="Salama A">AK Salama</name></author><author><name sortKey="Flaherty, Kt" uniqKey="Flaherty K">KT Flaherty</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoang Xuan, K" uniqKey="Hoang Xuan K">K Hoang-Xuan</name></author><author><name sortKey="Capelle, L" uniqKey="Capelle L">L Capelle</name></author><author><name sortKey="Kujas, M" uniqKey="Kujas M">M Kujas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hegi, Me" uniqKey="Hegi M">ME Hegi</name></author><author><name sortKey="Liu, L" uniqKey="Liu L">L Liu</name></author><author><name sortKey="Herman, Jg" uniqKey="Herman J">JG Herman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haas Kogan, Da" uniqKey="Haas Kogan D">DA Haas-Kogan</name></author><author><name sortKey="Prados, Md" uniqKey="Prados M">MD Prados</name></author><author><name sortKey="Tihan, T" uniqKey="Tihan T">T Tihan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mellinghoff, Ik" uniqKey="Mellinghoff I">IK Mellinghoff</name></author><author><name sortKey="Wang, My" uniqKey="Wang M">MY Wang</name></author><author><name sortKey="Vivanco, I" uniqKey="Vivanco I">I Vivanco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rich, Jn" uniqKey="Rich J">JN Rich</name></author><author><name sortKey="Reardon, Da" uniqKey="Reardon D">DA Reardon</name></author><author><name sortKey="Peery, T" uniqKey="Peery T">T Peery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kienast, Y" uniqKey="Kienast Y">Y Kienast</name></author><author><name sortKey="Von Baumgarten, L" uniqKey="Von Baumgarten L">L von Baumgarten</name></author><author><name sortKey="Fuhrmann, M" uniqKey="Fuhrmann M">M Fuhrmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seike, T" uniqKey="Seike T">T Seike</name></author><author><name sortKey="Fujita, K" uniqKey="Fujita K">K Fujita</name></author><author><name sortKey="Yamakawa, Y" uniqKey="Yamakawa Y">Y Yamakawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stemmler, Hj" uniqKey="Stemmler H">HJ Stemmler</name></author><author><name sortKey="Kahlert, S" uniqKey="Kahlert S">S Kahlert</name></author><author><name sortKey="Siekiera, W" uniqKey="Siekiera W">W Siekiera</name></author><author><name sortKey="Untch, M" uniqKey="Untch M">M Untch</name></author><author><name sortKey="Heinrich, B" uniqKey="Heinrich B">B Heinrich</name></author><author><name sortKey="Heinemann, V" uniqKey="Heinemann V">V Heinemann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miller, Kd" uniqKey="Miller K">KD Miller</name></author><author><name sortKey="Weathers, T" uniqKey="Weathers T">T Weathers</name></author><author><name sortKey="Haney, Lg" uniqKey="Haney L">LG Haney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gabos, Z" uniqKey="Gabos Z">Z Gabos</name></author><author><name sortKey="Sinha, R" uniqKey="Sinha R">R Sinha</name></author><author><name sortKey="Hanson, J" uniqKey="Hanson J">J Hanson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, Nu" uniqKey="Lin N">NU Lin</name></author><author><name sortKey="Bellon, Jr" uniqKey="Bellon J">JR Bellon</name></author><author><name sortKey="Winer, Ep" uniqKey="Winer E">EP Winer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clevers, H" uniqKey="Clevers H">H Clevers</name></author><author><name sortKey="Nusse, R" uniqKey="Nusse R">R Nusse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nguyen, Dx" uniqKey="Nguyen D">DX Nguyen</name></author><author><name sortKey="Bos, Pd" uniqKey="Bos P">PD Bos</name></author><author><name sortKey="Massague, J" uniqKey="Massague J">J Massagué</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kelly, Pj" uniqKey="Kelly P">PJ Kelly</name></author><author><name sortKey="Daumas Duport, C" uniqKey="Daumas Duport C">C Daumas-Duport</name></author><author><name sortKey="Scheithauer, Bw" uniqKey="Scheithauer B">BW Scheithauer</name></author><author><name sortKey="Kall, Ba" uniqKey="Kall B">BA Kall</name></author><author><name sortKey="Kispert, Db" uniqKey="Kispert D">DB Kispert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Earnest, F" uniqKey="Earnest F">F Earnest</name></author><author><name sortKey="Kelly, Pj" uniqKey="Kelly P">PJ Kelly</name></author><author><name sortKey="Scheithauer, Bw" uniqKey="Scheithauer B">BW Scheithauer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buckner, Jc" uniqKey="Buckner J">JC Buckner</name></author><author><name sortKey="Brown, Pd" uniqKey="Brown P">PD Brown</name></author><author><name sortKey="O Eill, Bp" uniqKey="O Eill B">BP O’Neill</name></author><author><name sortKey="Meyer, Fb" uniqKey="Meyer F">FB Meyer</name></author><author><name sortKey="Wetmore, Cj" uniqKey="Wetmore C">CJ Wetmore</name></author><author><name sortKey="Uhm, Jh" uniqKey="Uhm J">JH Uhm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grant, R" uniqKey="Grant R">R Grant</name></author><author><name sortKey="Liang, Bc" uniqKey="Liang B">BC Liang</name></author><author><name sortKey="Slattery, J" uniqKey="Slattery J">J Slattery</name></author><author><name sortKey="Greenberg, Hs" uniqKey="Greenberg H">HS Greenberg</name></author><author><name sortKey="Junck, L" uniqKey="Junck L">L Junck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wilms, G" uniqKey="Wilms G">G Wilms</name></author><author><name sortKey="Marchal, G" uniqKey="Marchal G">G Marchal</name></author><author><name sortKey="Demaerel, Ph" uniqKey="Demaerel P">PH Demaerel</name></author><author><name sortKey="Van Hecke, P" uniqKey="Van Hecke P">P Van Hecke</name></author><author><name sortKey="Baert, Al" uniqKey="Baert A">AL Baert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Valk, Pe" uniqKey="Valk P">PE Valk</name></author><author><name sortKey="Dillon, Wp" uniqKey="Dillon W">WP Dillon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mountz, Jm" uniqKey="Mountz J">JM Mountz</name></author><author><name sortKey="Deutsch, G" uniqKey="Deutsch G">G Deutsch</name></author><author><name sortKey="Kuzniecky, R" uniqKey="Kuzniecky R">R Kuzniecky</name></author><author><name sortKey="Rosenfeld, Ss" uniqKey="Rosenfeld S">SS Rosenfeld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwartz, Rb" uniqKey="Schwartz R">RB Schwartz</name></author><author><name sortKey="Holman, Bl" uniqKey="Holman B">BL Holman</name></author><author><name sortKey="Polak, Jf" uniqKey="Polak J">JF Polak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaplan, Wd" uniqKey="Kaplan W">WD Kaplan</name></author><author><name sortKey="Takvorian, T" uniqKey="Takvorian T">T Takvorian</name></author><author><name sortKey="Morris, Jh" uniqKey="Morris J">JH Morris</name></author><author><name sortKey="Rumbaugh, Cl" uniqKey="Rumbaugh C">CL Rumbaugh</name></author><author><name sortKey="Connolly, Bt" uniqKey="Connolly B">BT Connolly</name></author><author><name sortKey="Atkins, Hl" uniqKey="Atkins H">HL Atkins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Black, Kl" uniqKey="Black K">KL Black</name></author><author><name sortKey="Hawkins, Ra" uniqKey="Hawkins R">RA Hawkins</name></author><author><name sortKey="Kim, Kt" uniqKey="Kim K">KT Kim</name></author><author><name sortKey="Becker, Dp" uniqKey="Becker D">DP Becker</name></author><author><name sortKey="Lerner, C" uniqKey="Lerner C">C Lerner</name></author><author><name sortKey="Marciano, D" uniqKey="Marciano D">D Marciano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wen, Py" uniqKey="Wen P">PY Wen</name></author><author><name sortKey="Macdonald, Dr" uniqKey="Macdonald D">DR Macdonald</name></author><author><name sortKey="Reardon, Da" uniqKey="Reardon D">DA Reardon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oborski, Mj" uniqKey="Oborski M">MJ Oborski</name></author><author><name sortKey="Laymon, Cm" uniqKey="Laymon C">CM Laymon</name></author><author><name sortKey="Lieberman, Fs" uniqKey="Lieberman F">FS Lieberman</name></author><author><name sortKey="Mountz, Jm" uniqKey="Mountz J">JM Mountz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shah, Ah" uniqKey="Shah A">AH Shah</name></author><author><name sortKey="Snelling, B" uniqKey="Snelling B">B Snelling</name></author><author><name sortKey="Bregy, A" uniqKey="Bregy A">A Bregy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cha, S" uniqKey="Cha S">S Cha</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Young, Gs" uniqKey="Young G">GS Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levivier, M" uniqKey="Levivier M">M Levivier</name></author><author><name sortKey="Becerra, A" uniqKey="Becerra A">A Becerra</name></author><author><name sortKey="De Witte, O" uniqKey="De Witte O">O De Witte</name></author><author><name sortKey="Brotchi, J" uniqKey="Brotchi J">J Brotchi</name></author><author><name sortKey="Goldman, S" uniqKey="Goldman S">S Goldman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Del Sole, A" uniqKey="Del Sole A">A Del Sole</name></author><author><name sortKey="Falini, A" uniqKey="Falini A">A Falini</name></author><author><name sortKey="Ravasi, L" uniqKey="Ravasi L">L Ravasi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ginsberg, Le" uniqKey="Ginsberg L">LE Ginsberg</name></author><author><name sortKey="Fuller, Gn" uniqKey="Fuller G">GN Fuller</name></author><author><name sortKey="Hashmi, M" uniqKey="Hashmi M">M Hashmi</name></author><author><name sortKey="Leeds, Ne" uniqKey="Leeds N">NE Leeds</name></author><author><name sortKey="Schomer, Df" uniqKey="Schomer D">DF Schomer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scott, Jn" uniqKey="Scott J">JN Scott</name></author><author><name sortKey="Brasher, Pm" uniqKey="Brasher P">PM Brasher</name></author><author><name sortKey="Sevick, Rj" uniqKey="Sevick R">RJ Sevick</name></author><author><name sortKey="Rewcastle, Nb" uniqKey="Rewcastle N">NB Rewcastle</name></author><author><name sortKey="Forsyth, Pa" uniqKey="Forsyth P">PA Forsyth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Den Bent, Mj" uniqKey="Van Den Bent M">MJ van den Bent</name></author><author><name sortKey="Vogelbaum, Ma" uniqKey="Vogelbaum M">MA Vogelbaum</name></author><author><name sortKey="Wen, Py" uniqKey="Wen P">PY Wen</name></author><author><name sortKey="Macdonald, Dr" uniqKey="Macdonald D">DR Macdonald</name></author><author><name sortKey="Chang, Sm" uniqKey="Chang S">SM Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taal, W" uniqKey="Taal W">W Taal</name></author><author><name sortKey="Brandsma, D" uniqKey="Brandsma D">D Brandsma</name></author><author><name sortKey="De Bruin, Hg" uniqKey="De Bruin H">HG de Bruin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamstra, Da" uniqKey="Hamstra D">DA Hamstra</name></author><author><name sortKey="Galban, Cj" uniqKey="Galban C">CJ Galbán</name></author><author><name sortKey="Meyer, Cr" uniqKey="Meyer C">CR Meyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamstra, Da" uniqKey="Hamstra D">DA Hamstra</name></author><author><name sortKey="Chenevert, Tl" uniqKey="Chenevert T">TL Chenevert</name></author><author><name sortKey="Moffat, Ba" uniqKey="Moffat B">BA Moffat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nowosielski, M" uniqKey="Nowosielski M">M Nowosielski</name></author><author><name sortKey="Recheis, W" uniqKey="Recheis W">W Recheis</name></author><author><name sortKey="Goebel, G" uniqKey="Goebel G">G Goebel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pope, Wb" uniqKey="Pope W">WB Pope</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Huo, J" uniqKey="Huo J">J Huo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Norden, Ad" uniqKey="Norden A">AD Norden</name></author><author><name sortKey="Young, Gs" uniqKey="Young G">GS Young</name></author><author><name sortKey="Setayesh, K" uniqKey="Setayesh K">K Setayesh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Castillo, M" uniqKey="Castillo M">M Castillo</name></author><author><name sortKey="Kwock, L" uniqKey="Kwock L">L Kwock</name></author><author><name sortKey="Mukherji, Sk" uniqKey="Mukherji S">SK Mukherji</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miller, Bl" uniqKey="Miller B">BL Miller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Castillo, M" uniqKey="Castillo M">M Castillo</name></author><author><name sortKey="Kwock, L" uniqKey="Kwock L">L Kwock</name></author><author><name sortKey="Scatliff, J" uniqKey="Scatliff J">J Scatliff</name></author><author><name sortKey="Mukherji, Sk" uniqKey="Mukherji S">SK Mukherji</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michaelis, T" uniqKey="Michaelis T">T Michaelis</name></author><author><name sortKey="Merboldt, Kd" uniqKey="Merboldt K">KD Merboldt</name></author><author><name sortKey="Bruhn, H" uniqKey="Bruhn H">H Bruhn</name></author><author><name sortKey="H Nicke, W" uniqKey="H Nicke W">W Hänicke</name></author><author><name sortKey="Frahm, J" uniqKey="Frahm J">J Frahm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Herminghaus, S" uniqKey="Herminghaus S">S Herminghaus</name></author><author><name sortKey="Pilatus, U" uniqKey="Pilatus U">U Pilatus</name></author><author><name sortKey="Moller Hartmann, W" uniqKey="Moller Hartmann W">W Möller-Hartmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kreis, R" uniqKey="Kreis R">R Kreis</name></author><author><name sortKey="Ernst, T" uniqKey="Ernst T">T Ernst</name></author><author><name sortKey="Ross, Bd" uniqKey="Ross B">BD Ross</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Lu, Y" uniqKey="Lu Y">Y Lu</name></author><author><name sortKey="Pirzkall, A" uniqKey="Pirzkall A">A Pirzkall</name></author><author><name sortKey="Mcknight, T" uniqKey="Mcknight T">T McKnight</name></author><author><name sortKey="Nelson, Sj" uniqKey="Nelson S">SJ Nelson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hattingen, E" uniqKey="Hattingen E">E Hattingen</name></author><author><name sortKey="Delic, O" uniqKey="Delic O">O Delic</name></author><author><name sortKey="Franz, K" uniqKey="Franz K">K Franz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hattingen, E" uniqKey="Hattingen E">E Hattingen</name></author><author><name sortKey="Raab, P" uniqKey="Raab P">P Raab</name></author><author><name sortKey="Franz, K" uniqKey="Franz K">K Franz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Imani, F" uniqKey="Imani F">F Imani</name></author><author><name sortKey="Boada, Fe" uniqKey="Boada F">FE Boada</name></author><author><name sortKey="Lieberman, Fs" uniqKey="Lieberman F">FS Lieberman</name></author><author><name sortKey="Davis, Dk" uniqKey="Davis D">DK Davis</name></author><author><name sortKey="Deeb, El" uniqKey="Deeb E">EL Deeb</name></author><author><name sortKey="Mountz, Jm" uniqKey="Mountz J">JM Mountz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elkhaled, A" uniqKey="Elkhaled A">A Elkhaled</name></author><author><name sortKey="Jalbert, Le" uniqKey="Jalbert L">LE Jalbert</name></author><author><name sortKey="Phillips, Jj" uniqKey="Phillips J">JJ Phillips</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kalinina, J" uniqKey="Kalinina J">J Kalinina</name></author><author><name sortKey="Carroll, A" uniqKey="Carroll A">A Carroll</name></author><author><name sortKey="Wang, L" uniqKey="Wang L">L Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pope, Wb" uniqKey="Pope W">WB Pope</name></author><author><name sortKey="Prins, Rm" uniqKey="Prins R">RM Prins</name></author><author><name sortKey="Albert Thomas, M" uniqKey="Albert Thomas M">M Albert Thomas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Le Bihan, D" uniqKey="Le Bihan D">D Le Bihan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arvinda, Hr" uniqKey="Arvinda H">HR Arvinda</name></author><author><name sortKey="Kesavadas, C" uniqKey="Kesavadas C">C Kesavadas</name></author><author><name sortKey="Sarma, Ps" uniqKey="Sarma P">PS Sarma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jensen, Jh" uniqKey="Jensen J">JH Jensen</name></author><author><name sortKey="Helpern, Ja" uniqKey="Helpern J">JA Helpern</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raab, P" uniqKey="Raab P">P Raab</name></author><author><name sortKey="Hattingen, E" uniqKey="Hattingen E">E Hattingen</name></author><author><name sortKey="Franz, K" uniqKey="Franz K">K Franz</name></author><author><name sortKey="Zanella, Fe" uniqKey="Zanella F">FE Zanella</name></author><author><name sortKey="Lanfermann, H" uniqKey="Lanfermann H">H Lanfermann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cha, S" uniqKey="Cha S">S Cha</name></author><author><name sortKey="Knopp, Ea" uniqKey="Knopp E">EA Knopp</name></author><author><name sortKey="Johnson, G" uniqKey="Johnson G">G Johnson</name></author><author><name sortKey="Wetzel, Sg" uniqKey="Wetzel S">SG Wetzel</name></author><author><name sortKey="Litt, Aw" uniqKey="Litt A">AW Litt</name></author><author><name sortKey="Zagzag, D" uniqKey="Zagzag D">D Zagzag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boxerman, Jl" uniqKey="Boxerman J">JL Boxerman</name></author><author><name sortKey="Schmainda, Km" uniqKey="Schmainda K">KM Schmainda</name></author><author><name sortKey="Weisskoff, Rm" uniqKey="Weisskoff R">RM Weisskoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hu, Ls" uniqKey="Hu L">LS Hu</name></author><author><name sortKey="Baxter, Lc" uniqKey="Baxter L">LC Baxter</name></author><author><name sortKey="Pinnaduwage, Ds" uniqKey="Pinnaduwage D">DS Pinnaduwage</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Law, M" uniqKey="Law M">M Law</name></author><author><name sortKey="Yang, S" uniqKey="Yang S">S Yang</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Provenzale, Jm" uniqKey="Provenzale J">JM Provenzale</name></author><author><name sortKey="York, G" uniqKey="York G">G York</name></author><author><name sortKey="Moya, Mg" uniqKey="Moya M">MG Moya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, C" uniqKey="Roberts C">C Roberts</name></author><author><name sortKey="Issa, B" uniqKey="Issa B">B Issa</name></author><author><name sortKey="Stone, A" uniqKey="Stone A">A Stone</name></author><author><name sortKey="Jackson, A" uniqKey="Jackson A">A Jackson</name></author><author><name sortKey="Waterton, Jc" uniqKey="Waterton J">JC Waterton</name></author><author><name sortKey="Parker, Gj" uniqKey="Parker G">GJ Parker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spampinato, Mv" uniqKey="Spampinato M">MV Spampinato</name></author><author><name sortKey="Smith, Jk" uniqKey="Smith J">JK Smith</name></author><author><name sortKey="Kwock, L" uniqKey="Kwock L">L Kwock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Danchaivijitr, N" uniqKey="Danchaivijitr N">N Danchaivijitr</name></author><author><name sortKey="Waldman, Ad" uniqKey="Waldman A">AD Waldman</name></author><author><name sortKey="Tozer, Dj" uniqKey="Tozer D">DJ Tozer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Warburg, O" uniqKey="Warburg O">O Warburg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Krohn, Ka" uniqKey="Krohn K">KA Krohn</name></author><author><name sortKey="Mankoff, Da" uniqKey="Mankoff D">DA Mankoff</name></author><author><name sortKey="Muzi, M" uniqKey="Muzi M">M Muzi</name></author><author><name sortKey="Link, Jm" uniqKey="Link J">JM Link</name></author><author><name sortKey="Spence, Am" uniqKey="Spence A">AM Spence</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Padma, Mv" uniqKey="Padma M">MV Padma</name></author><author><name sortKey="Said, S" uniqKey="Said S">S Said</name></author><author><name sortKey="Jacobs, M" uniqKey="Jacobs M">M Jacobs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Witte, O" uniqKey="De Witte O">O De Witte</name></author><author><name sortKey="Levivier, M" uniqKey="Levivier M">M Levivier</name></author><author><name sortKey="Violon, P" uniqKey="Violon P">P Violon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Delbeke, D" uniqKey="Delbeke D">D Delbeke</name></author><author><name sortKey="Meyerowitz, C" uniqKey="Meyerowitz C">C Meyerowitz</name></author><author><name sortKey="Lapidus, Rl" uniqKey="Lapidus R">RL Lapidus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spence, Am" uniqKey="Spence A">AM Spence</name></author><author><name sortKey="Muzi, M" uniqKey="Muzi M">M Muzi</name></author><author><name sortKey="Mankoff, Da" uniqKey="Mankoff D">DA Mankoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, Tz" uniqKey="Wong T">TZ Wong</name></author><author><name sortKey="Van Der Westhuizen, Gj" uniqKey="Van Der Westhuizen G">GJ van der Westhuizen</name></author><author><name sortKey="Coleman, Re" uniqKey="Coleman R">RE Coleman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wurker, M" uniqKey="Wurker M">M Würker</name></author><author><name sortKey="Herholz, K" uniqKey="Herholz K">K Herholz</name></author><author><name sortKey="Voges, J" uniqKey="Voges J">J Voges</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ricci, Pe" uniqKey="Ricci P">PE Ricci</name></author><author><name sortKey="Karis, Jp" uniqKey="Karis J">JP Karis</name></author><author><name sortKey="Heiserman, Je" uniqKey="Heiserman J">JE Heiserman</name></author><author><name sortKey="Fram, Ek" uniqKey="Fram E">EK Fram</name></author><author><name sortKey="Bice, An" uniqKey="Bice A">AN Bice</name></author><author><name sortKey="Drayer, Bp" uniqKey="Drayer B">BP Drayer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Langleben, Dd" uniqKey="Langleben D">DD Langleben</name></author><author><name sortKey="Segall, Gm" uniqKey="Segall G">GM Segall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Franceschi, E" uniqKey="Franceschi E">E Franceschi</name></author><author><name sortKey="Tosoni, A" uniqKey="Tosoni A">A Tosoni</name></author><author><name sortKey="Bartolini, S" uniqKey="Bartolini S">S Bartolini</name></author><author><name sortKey="Mazzocchi, V" uniqKey="Mazzocchi V">V Mazzocchi</name></author><author><name sortKey="Fioravanti, A" uniqKey="Fioravanti A">A Fioravanti</name></author><author><name sortKey="Brandes, Aa" uniqKey="Brandes A">AA Brandes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Macdonald, Dr" uniqKey="Macdonald D">DR Macdonald</name></author><author><name sortKey="Cascino, Tl" uniqKey="Cascino T">TL Cascino</name></author><author><name sortKey="Schold, Sc" uniqKey="Schold S">SC Schold</name></author><author><name sortKey="Cairncross, Jg" uniqKey="Cairncross J">JG Cairncross</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Esteller, M" uniqKey="Esteller M">M Esteller</name></author><author><name sortKey="Garcia Foncillas, J" uniqKey="Garcia Foncillas J">J Garcia-Foncillas</name></author><author><name sortKey="Andion, E" uniqKey="Andion E">E Andion</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brandes, Aa" uniqKey="Brandes A">AA Brandes</name></author><author><name sortKey="Tosoni, A" uniqKey="Tosoni A">A Tosoni</name></author><author><name sortKey="Cavallo, G" uniqKey="Cavallo G">G Cavallo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clarke, Jl" uniqKey="Clarke J">JL Clarke</name></author><author><name sortKey="Chang, S" uniqKey="Chang S">S Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vredenburgh, Jj" uniqKey="Vredenburgh J">JJ Vredenburgh</name></author><author><name sortKey="Desjardins, A" uniqKey="Desjardins A">A Desjardins</name></author><author><name sortKey="Herndon, Je" uniqKey="Herndon J">JE Herndon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Batchelor, Tt" uniqKey="Batchelor T">TT Batchelor</name></author><author><name sortKey="Sorensen, Ag" uniqKey="Sorensen A">AG Sorensen</name></author><author><name sortKey="Di Tomaso, E" uniqKey="Di Tomaso E">E di Tomaso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Desjardins, A" uniqKey="Desjardins A">A Desjardins</name></author><author><name sortKey="Reardon, Da" uniqKey="Reardon D">DA Reardon</name></author><author><name sortKey="Herndon, Je" uniqKey="Herndon J">JE Herndon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chao, St" uniqKey="Chao S">ST Chao</name></author><author><name sortKey="Suh, Jh" uniqKey="Suh J">JH Suh</name></author><author><name sortKey="Raja, S" uniqKey="Raja S">S Raja</name></author><author><name sortKey="Lee, Sy" uniqKey="Lee S">SY Lee</name></author><author><name sortKey="Barnett, G" uniqKey="Barnett G">G Barnett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Sx" uniqKey="Wang S">SX Wang</name></author><author><name sortKey="Boethius, J" uniqKey="Boethius J">J Boethius</name></author><author><name sortKey="Ericson, K" uniqKey="Ericson K">K Ericson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schlemmer, Hp" uniqKey="Schlemmer H">HP Schlemmer</name></author><author><name sortKey="Pichler, Bj" uniqKey="Pichler B">BJ Pichler</name></author><author><name sortKey="Schmand, M" uniqKey="Schmand M">M Schmand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boss, A" uniqKey="Boss A">A Boss</name></author><author><name sortKey="Bisdas, S" uniqKey="Bisdas S">S Bisdas</name></author><author><name sortKey="Kolb, A" uniqKey="Kolb A">A Kolb</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanaka, Y" uniqKey="Tanaka Y">Y Tanaka</name></author><author><name sortKey="Nariai, T" uniqKey="Nariai T">T Nariai</name></author><author><name sortKey="Momose, T" uniqKey="Momose T">T Momose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grosu, Al" uniqKey="Grosu A">AL Grosu</name></author><author><name sortKey="Weber, Wa" uniqKey="Weber W">WA Weber</name></author><author><name sortKey="Riedel, E" uniqKey="Riedel E">E Riedel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weber, Dc" uniqKey="Weber D">DC Weber</name></author><author><name sortKey="Zilli, T" uniqKey="Zilli T">T Zilli</name></author><author><name sortKey="Buchegger, F" uniqKey="Buchegger F">F Buchegger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vees, H" uniqKey="Vees H">H Vees</name></author><author><name sortKey="Senthamizhchelvan, S" uniqKey="Senthamizhchelvan S">S Senthamizhchelvan</name></author><author><name sortKey="Miralbell, R" uniqKey="Miralbell R">R Miralbell</name></author><author><name sortKey="Weber, Dc" uniqKey="Weber D">DC Weber</name></author><author><name sortKey="Ratib, O" uniqKey="Ratib O">O Ratib</name></author><author><name sortKey="Zaidi, H" uniqKey="Zaidi H">H Zaidi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nariai, T" uniqKey="Nariai T">T Nariai</name></author><author><name sortKey="Tanaka, Y" uniqKey="Tanaka Y">Y Tanaka</name></author><author><name sortKey="Wakimoto, H" uniqKey="Wakimoto H">H Wakimoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Busch, H" uniqKey="Busch H">H Busch</name></author><author><name sortKey="Davis, Jr" uniqKey="Davis J">JR Davis</name></author><author><name sortKey="Honig, Gr" uniqKey="Honig G">GR Honig</name></author><author><name sortKey="Anderson, Dc" uniqKey="Anderson D">DC Anderson</name></author><author><name sortKey="Nair, Pv" uniqKey="Nair P">PV Nair</name></author><author><name sortKey="Nyhan, Wl" uniqKey="Nyhan W">WL Nyhan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miyagawa, T" uniqKey="Miyagawa T">T Miyagawa</name></author><author><name sortKey="Oku, T" uniqKey="Oku T">T Oku</name></author><author><name sortKey="Uehara, H" uniqKey="Uehara H">H Uehara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galldiks, N" uniqKey="Galldiks N">N Galldiks</name></author><author><name sortKey="Kracht, Lw" uniqKey="Kracht L">LW Kracht</name></author><author><name sortKey="Burghaus, L" uniqKey="Burghaus L">L Burghaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wyss, M" uniqKey="Wyss M">M Wyss</name></author><author><name sortKey="Hofer, S" uniqKey="Hofer S">S Hofer</name></author><author><name sortKey="Bruehlmeier, M" uniqKey="Bruehlmeier M">M Bruehlmeier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galldiks, N" uniqKey="Galldiks N">N Galldiks</name></author><author><name sortKey="Kracht, Lw" uniqKey="Kracht L">LW Kracht</name></author><author><name sortKey="Burghaus, L" uniqKey="Burghaus L">L Burghaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jager, Pl" uniqKey="Jager P">PL Jager</name></author><author><name sortKey="Vaalburg, W" uniqKey="Vaalburg W">W Vaalburg</name></author><author><name sortKey="Pruim, J" uniqKey="Pruim J">J Pruim</name></author><author><name sortKey="De Vries, Eg" uniqKey="De Vries E">EG de Vries</name></author><author><name sortKey="Langen, Kj" uniqKey="Langen K">KJ Langen</name></author><author><name sortKey="Piers, Da" uniqKey="Piers D">DA Piers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergmann, R" uniqKey="Bergmann R">R Bergmann</name></author><author><name sortKey="Pietzsch, J" uniqKey="Pietzsch J">J Pietzsch</name></author><author><name sortKey="Fuechtner, F" uniqKey="Fuechtner F">F Fuechtner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ullrich, Rt" uniqKey="Ullrich R">RT Ullrich</name></author><author><name sortKey="Kracht, Lw" uniqKey="Kracht L">LW Kracht</name></author><author><name sortKey="Jacobs, Ah" uniqKey="Jacobs A">AH Jacobs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weber, Wa" uniqKey="Weber W">WA Weber</name></author><author><name sortKey="Wester, Hj" uniqKey="Wester H">HJ Wester</name></author><author><name sortKey="Grosu, Al" uniqKey="Grosu A">AL Grosu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Becherer, A" uniqKey="Becherer A">A Becherer</name></author><author><name sortKey="Karanikas, G" uniqKey="Karanikas G">G Karanikas</name></author><author><name sortKey="Szab, M" uniqKey="Szab M">M Szabó</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Herholz, K" uniqKey="Herholz K">K Herholz</name></author><author><name sortKey="Holzer, T" uniqKey="Holzer T">T Hölzer</name></author><author><name sortKey="Bauer, B" uniqKey="Bauer B">B Bauer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hustinx, R" uniqKey="Hustinx R">R Hustinx</name></author><author><name sortKey="Pourdehnad, M" uniqKey="Pourdehnad M">M Pourdehnad</name></author><author><name sortKey="Kaschten, B" uniqKey="Kaschten B">B Kaschten</name></author><author><name sortKey="Alavi, A" uniqKey="Alavi A">A Alavi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ericson, K" uniqKey="Ericson K">K Ericson</name></author><author><name sortKey="Lilja, A" uniqKey="Lilja A">A Lilja</name></author><author><name sortKey="Bergstrom, M" uniqKey="Bergstrom M">M Bergström</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogawa, T" uniqKey="Ogawa T">T Ogawa</name></author><author><name sortKey="Inugami, A" uniqKey="Inugami A">A Inugami</name></author><author><name sortKey="Hatazawa, J" uniqKey="Hatazawa J">J Hatazawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chang, Cc" uniqKey="Chang C">CC Chang</name></author><author><name sortKey="Kuwana, N" uniqKey="Kuwana N">N Kuwana</name></author><author><name sortKey="Ito, S" uniqKey="Ito S">S Ito</name></author><author><name sortKey="Yokoyama, T" uniqKey="Yokoyama T">T Yokoyama</name></author><author><name sortKey="Kanno, H" uniqKey="Kanno H">H Kanno</name></author><author><name sortKey="Yamamoto, I" uniqKey="Yamamoto I">I Yamamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Witte, O" uniqKey="De Witte O">O De Witte</name></author><author><name sortKey="Goldberg, I" uniqKey="Goldberg I">I Goldberg</name></author><author><name sortKey="Wikler, D" uniqKey="Wikler D">D Wikler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ribom, D" uniqKey="Ribom D">D Ribom</name></author><author><name sortKey="Eriksson, A" uniqKey="Eriksson A">A Eriksson</name></author><author><name sortKey="Hartman, M" uniqKey="Hartman M">M Hartman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaschten, B" uniqKey="Kaschten B">B Kaschten</name></author><author><name sortKey="Stevenaert, A" uniqKey="Stevenaert A">A Stevenaert</name></author><author><name sortKey="Sadzot, B" uniqKey="Sadzot B">B Sadzot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sasaki, M" uniqKey="Sasaki M">M Sasaki</name></author><author><name sortKey="Kuwabara, Y" uniqKey="Kuwabara Y">Y Kuwabara</name></author><author><name sortKey="Yoshida, T" uniqKey="Yoshida T">T Yoshida</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bustany, P" uniqKey="Bustany P">P Bustany</name></author><author><name sortKey="Chatel, M" uniqKey="Chatel M">M Chatel</name></author><author><name sortKey="Derlon, Jm" uniqKey="Derlon J">JM Derlon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ullrich, Rt" uniqKey="Ullrich R">RT Ullrich</name></author><author><name sortKey="Kracht, L" uniqKey="Kracht L">L Kracht</name></author><author><name sortKey="Brunn, A" uniqKey="Brunn A">A Brunn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamane, T" uniqKey="Yamane T">T Yamane</name></author><author><name sortKey="Sakamoto, S" uniqKey="Sakamoto S">S Sakamoto</name></author><author><name sortKey="Senda, M" uniqKey="Senda M">M Senda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spaeth, N" uniqKey="Spaeth N">N Spaeth</name></author><author><name sortKey="Wyss, Mt" uniqKey="Wyss M">MT Wyss</name></author><author><name sortKey="Weber, B" uniqKey="Weber B">B Weber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, W" uniqKey="Chen W">W Chen</name></author><author><name sortKey="Silverman, Dh" uniqKey="Silverman D">DH Silverman</name></author><author><name sortKey="Delaloye, S" uniqKey="Delaloye S">S Delaloye</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pauleit, D" uniqKey="Pauleit D">D Pauleit</name></author><author><name sortKey="Floeth, F" uniqKey="Floeth F">F Floeth</name></author><author><name sortKey="Hamacher, K" uniqKey="Hamacher K">K Hamacher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rachinger, W" uniqKey="Rachinger W">W Rachinger</name></author><author><name sortKey="Goetz, C" uniqKey="Goetz C">C Goetz</name></author><author><name sortKey="Popperl, G" uniqKey="Popperl G">G Pöpperl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Floeth, Fw" uniqKey="Floeth F">FW Floeth</name></author><author><name sortKey="Pauleit, D" uniqKey="Pauleit D">D Pauleit</name></author><author><name sortKey="Wittsack, Hj" uniqKey="Wittsack H">HJ Wittsack</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rasey, Js" uniqKey="Rasey J">JS Rasey</name></author><author><name sortKey="Grierson, Jr" uniqKey="Grierson J">JR Grierson</name></author><author><name sortKey="Wiens, Lw" uniqKey="Wiens L">LW Wiens</name></author><author><name sortKey="Kolb, Pd" uniqKey="Kolb P">PD Kolb</name></author><author><name sortKey="Schwartz, Jl" uniqKey="Schwartz J">JL Schwartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shields, Af" uniqKey="Shields A">AF Shields</name></author><author><name sortKey="Grierson, Jr" uniqKey="Grierson J">JR Grierson</name></author><author><name sortKey="Dohmen, Bm" uniqKey="Dohmen B">BM Dohmen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barthel, H" uniqKey="Barthel H">H Barthel</name></author><author><name sortKey="Cleij, Mc" uniqKey="Cleij M">MC Cleij</name></author><author><name sortKey="Collingridge, Dr" uniqKey="Collingridge D">DR Collingridge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, W" uniqKey="Chen W">W Chen</name></author><author><name sortKey="Cloughesy, T" uniqKey="Cloughesy T">T Cloughesy</name></author><author><name sortKey="Kamdar, N" uniqKey="Kamdar N">N Kamdar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munch Petersen, B" uniqKey="Munch Petersen B">B Munch-Petersen</name></author><author><name sortKey="Cloos, L" uniqKey="Cloos L">L Cloos</name></author><author><name sortKey="Jensen, Hk" uniqKey="Jensen H">HK Jensen</name></author><author><name sortKey="Tyrsted, G" uniqKey="Tyrsted G">G Tyrsted</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hatakeyama, T" uniqKey="Hatakeyama T">T Hatakeyama</name></author><author><name sortKey="Kawai, N" uniqKey="Kawai N">N Kawai</name></author><author><name sortKey="Nishiyama, Y" uniqKey="Nishiyama Y">Y Nishiyama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jacobs, Ah" uniqKey="Jacobs A">AH Jacobs</name></author><author><name sortKey="Thomas, A" uniqKey="Thomas A">A Thomas</name></author><author><name sortKey="Kracht, Lw" uniqKey="Kracht L">LW Kracht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, W" uniqKey="Chen W">W Chen</name></author><author><name sortKey="Delaloye, S" uniqKey="Delaloye S">S Delaloye</name></author><author><name sortKey="Silverman, Dh" uniqKey="Silverman D">DH Silverman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwarzenberg, J" uniqKey="Schwarzenberg J">J Schwarzenberg</name></author><author><name sortKey="Czernin, J" uniqKey="Czernin J">J Czernin</name></author><author><name sortKey="Cloughesy, Tf" uniqKey="Cloughesy T">TF Cloughesy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hicklin, Dj" uniqKey="Hicklin D">DJ Hicklin</name></author><author><name sortKey="Ellis, Lm" uniqKey="Ellis L">LM Ellis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N Ferrara</name></author><author><name sortKey="Hillan, Kj" uniqKey="Hillan K">KJ Hillan</name></author><author><name sortKey="Novotny, W" uniqKey="Novotny W">W Novotny</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rasey, Js" uniqKey="Rasey J">JS Rasey</name></author><author><name sortKey="Koh, Wj" uniqKey="Koh W">WJ Koh</name></author><author><name sortKey="Evans, Ml" uniqKey="Evans M">ML Evans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brown, Jm" uniqKey="Brown J">JM Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Szeto, Md" uniqKey="Szeto M">MD Szeto</name></author><author><name sortKey="Chakraborty, G" uniqKey="Chakraborty G">G Chakraborty</name></author><author><name sortKey="Hadley, J" uniqKey="Hadley J">J Hadley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cher, Lm" uniqKey="Cher L">LM Cher</name></author><author><name sortKey="Murone, C" uniqKey="Murone C">C Murone</name></author><author><name sortKey="Lawrentschuk, N" uniqKey="Lawrentschuk N">N Lawrentschuk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spence, Am" uniqKey="Spence A">AM Spence</name></author><author><name sortKey="Muzi, M" uniqKey="Muzi M">M Muzi</name></author><author><name sortKey="Swanson, Kr" uniqKey="Swanson K">KR Swanson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paleologos, Ts" uniqKey="Paleologos T">TS Paleologos</name></author><author><name sortKey="Dorward, Nl" uniqKey="Dorward N">NL Dorward</name></author><author><name sortKey="Wadley, Jp" uniqKey="Wadley J">JP Wadley</name></author><author><name sortKey="Thomas, Dg" uniqKey="Thomas D">DG Thomas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robbins, Pd" uniqKey="Robbins P">PD Robbins</name></author><author><name sortKey="Yu, Ll" uniqKey="Yu L">LL Yu</name></author><author><name sortKey="Lee, M" uniqKey="Lee M">M Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanai, N" uniqKey="Sanai N">N Sanai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanaka, S" uniqKey="Tanaka S">S Tanaka</name></author><author><name sortKey="Louis, Dn" uniqKey="Louis D">DN Louis</name></author><author><name sortKey="Curry, Wt" uniqKey="Curry W">WT Curry</name></author><author><name sortKey="Batchelor, Tt" uniqKey="Batchelor T">TT Batchelor</name></author><author><name sortKey="Dietrich, J" uniqKey="Dietrich J">J Dietrich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gilbert, Mr" uniqKey="Gilbert M">MR Gilbert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weller, M" uniqKey="Weller M">M Weller</name></author><author><name sortKey="Wick, W" uniqKey="Wick W">W Wick</name></author><author><name sortKey="Hegi, Me" uniqKey="Hegi M">ME Hegi</name></author><author><name sortKey="Stupp, R" uniqKey="Stupp R">R Stupp</name></author><author><name sortKey="Tabatabai, G" uniqKey="Tabatabai G">G Tabatabai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keles, Ge" uniqKey="Keles G">GE Keles</name></author><author><name sortKey="Anderson, B" uniqKey="Anderson B">B Anderson</name></author><author><name sortKey="Berger, Ms" uniqKey="Berger M">MS Berger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pope, Wb" uniqKey="Pope W">WB Pope</name></author><author><name sortKey="Sayre, J" uniqKey="Sayre J">J Sayre</name></author><author><name sortKey="Perlina, A" uniqKey="Perlina A">A Perlina</name></author><author><name sortKey="Villablanca, Jp" uniqKey="Villablanca J">JP Villablanca</name></author><author><name sortKey="Mischel, Ps" uniqKey="Mischel P">PS Mischel</name></author><author><name sortKey="Cloughesy, Tf" uniqKey="Cloughesy T">TF Cloughesy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lacroix, M" uniqKey="Lacroix M">M Lacroix</name></author><author><name sortKey="Abi Said, D" uniqKey="Abi Said D">D Abi-Said</name></author><author><name sortKey="Fourney, Dr" uniqKey="Fourney D">DR Fourney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keles, Ge" uniqKey="Keles G">GE Keles</name></author><author><name sortKey="Chang, Ef" uniqKey="Chang E">EF Chang</name></author><author><name sortKey="Lamborn, Kr" uniqKey="Lamborn K">KR Lamborn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duffau, H" uniqKey="Duffau H">H Duffau</name></author><author><name sortKey="Capelle, L" uniqKey="Capelle L">L Capelle</name></author><author><name sortKey="Sichez, J" uniqKey="Sichez J">J Sichez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duffau, H" uniqKey="Duffau H">H Duffau</name></author><author><name sortKey="Capelle, L" uniqKey="Capelle L">L Capelle</name></author><author><name sortKey="Sichez, N" uniqKey="Sichez N">N Sichez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duffau, H" uniqKey="Duffau H">H Duffau</name></author><author><name sortKey="Capelle, L" uniqKey="Capelle L">L Capelle</name></author><author><name sortKey="Denvil, D" uniqKey="Denvil D">D Denvil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Sk" uniqKey="Lee S">SK Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Price, Sj" uniqKey="Price S">SJ Price</name></author><author><name sortKey="Gillard, Jh" uniqKey="Gillard J">JH Gillard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanai, N" uniqKey="Sanai N">N Sanai</name></author><author><name sortKey="Mirzadeh, Z" uniqKey="Mirzadeh Z">Z Mirzadeh</name></author><author><name sortKey="Berger, Ms" uniqKey="Berger M">MS Berger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Snyderman, Ch" uniqKey="Snyderman C">CH Snyderman</name></author><author><name sortKey="Pant, H" uniqKey="Pant H">H Pant</name></author><author><name sortKey="Carrau, Rl" uniqKey="Carrau R">RL Carrau</name></author><author><name sortKey="Prevedello, D" uniqKey="Prevedello D">D Prevedello</name></author><author><name sortKey="Gardner, P" uniqKey="Gardner P">P Gardner</name></author><author><name sortKey="Kassam, Ab" uniqKey="Kassam A">AB Kassam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mclaughlin, N" uniqKey="Mclaughlin N">N McLaughlin</name></author><author><name sortKey="Prevedello, Dm" uniqKey="Prevedello D">DM Prevedello</name></author><author><name sortKey="Engh, J" uniqKey="Engh J">J Engh</name></author><author><name sortKey="Kelly, Df" uniqKey="Kelly D">DF Kelly</name></author><author><name sortKey="Kassam, Ab" uniqKey="Kassam A">AB Kassam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walker, Md" uniqKey="Walker M">MD Walker</name></author><author><name sortKey="Alexander, E" uniqKey="Alexander E">E Alexander</name></author><author><name sortKey="Hunt, We" uniqKey="Hunt W">WE Hunt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walker, Md" uniqKey="Walker M">MD Walker</name></author><author><name sortKey="Strike, Ta" uniqKey="Strike T">TA Strike</name></author><author><name sortKey="Sheline, Ge" uniqKey="Sheline G">GE Sheline</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sheline, Ge" uniqKey="Sheline G">GE Sheline</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hochberg, Fh" uniqKey="Hochberg F">FH Hochberg</name></author><author><name sortKey="Pruitt, A" uniqKey="Pruitt A">A Pruitt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wallner, Ke" uniqKey="Wallner K">KE Wallner</name></author><author><name sortKey="Galicich, Jh" uniqKey="Galicich J">JH Galicich</name></author><author><name sortKey="Krol, G" uniqKey="Krol G">G Krol</name></author><author><name sortKey="Arbit, E" uniqKey="Arbit E">E Arbit</name></author><author><name sortKey="Malkin, Mg" uniqKey="Malkin M">MG Malkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choucair, Ak" uniqKey="Choucair A">AK Choucair</name></author><author><name sortKey="Levin, Va" uniqKey="Levin V">VA Levin</name></author><author><name sortKey="Gutin, Ph" uniqKey="Gutin P">PH Gutin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ten Haken, Rk" uniqKey="Ten Haken R">RK Ten Haken</name></author><author><name sortKey="Thornton, Af" uniqKey="Thornton A">AF Thornton</name></author><author><name sortKey="Sandler, Hm" uniqKey="Sandler H">HM Sandler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glatstein, E" uniqKey="Glatstein E">E Glatstein</name></author><author><name sortKey="Lichter, As" uniqKey="Lichter A">AS Lichter</name></author><author><name sortKey="Fraass, Ba" uniqKey="Fraass B">BA Fraass</name></author><author><name sortKey="Kelly, Ba" uniqKey="Kelly B">BA Kelly</name></author><author><name sortKey="Van De Geijn, J" uniqKey="Van De Geijn J">J van de Geijn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gross, Mw" uniqKey="Gross M">MW Gross</name></author><author><name sortKey="Weber, Wa" uniqKey="Weber W">WA Weber</name></author><author><name sortKey="Feldmann, Hj" uniqKey="Feldmann H">HJ Feldmann</name></author><author><name sortKey="Bartenstein, P" uniqKey="Bartenstein P">P Bartenstein</name></author><author><name sortKey="Schwaiger, M" uniqKey="Schwaiger M">M Schwaiger</name></author><author><name sortKey="Molls, M" uniqKey="Molls M">M Molls</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Douglas, Jg" uniqKey="Douglas J">JG Douglas</name></author><author><name sortKey="Stelzer, Kj" uniqKey="Stelzer K">KJ Stelzer</name></author><author><name sortKey="Mankoff, Da" uniqKey="Mankoff D">DA Mankoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Narayana, A" uniqKey="Narayana A">A Narayana</name></author><author><name sortKey="Yamada, J" uniqKey="Yamada J">J Yamada</name></author><author><name sortKey="Berry, S" uniqKey="Berry S">S Berry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jl" uniqKey="Chan J">JL Chan</name></author><author><name sortKey="Lee, Sw" uniqKey="Lee S">SW Lee</name></author><author><name sortKey="Fraass, Ba" uniqKey="Fraass B">BA Fraass</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shrieve, Dc" uniqKey="Shrieve D">DC Shrieve</name></author><author><name sortKey="Alexander, E" uniqKey="Alexander E">E Alexander</name></author><author><name sortKey="Black, Pm" uniqKey="Black P">PM Black</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prisco, Fe" uniqKey="Prisco F">FE Prisco</name></author><author><name sortKey="Weltman, E" uniqKey="Weltman E">E Weltman</name></author><author><name sortKey="De Hanriot, Rm" uniqKey="De Hanriot R">RM de Hanriot</name></author><author><name sortKey="Brandt, Ra" uniqKey="Brandt R">RA Brandt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nwokedi, Ec" uniqKey="Nwokedi E">EC Nwokedi</name></author><author><name sortKey="Dibiase, Sj" uniqKey="Dibiase S">SJ DiBiase</name></author><author><name sortKey="Jabbour, S" uniqKey="Jabbour S">S Jabbour</name></author><author><name sortKey="Herman, J" uniqKey="Herman J">J Herman</name></author><author><name sortKey="Amin, P" uniqKey="Amin P">P Amin</name></author><author><name sortKey="Chin, Ls" uniqKey="Chin L">LS Chin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mehta, Mp" uniqKey="Mehta M">MP Mehta</name></author><author><name sortKey="Masciopinto, J" uniqKey="Masciopinto J">J Masciopinto</name></author><author><name sortKey="Rozental, J" uniqKey="Rozental J">J Rozental</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koga, T" uniqKey="Koga T">T Koga</name></author><author><name sortKey="Maruyama, K" uniqKey="Maruyama K">K Maruyama</name></author><author><name sortKey="Tanaka, M" uniqKey="Tanaka M">M Tanaka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kondziolka, D" uniqKey="Kondziolka D">D Kondziolka</name></author><author><name sortKey="Flickinger, Jc" uniqKey="Flickinger J">JC Flickinger</name></author><author><name sortKey="Bissonette, Dj" uniqKey="Bissonette D">DJ Bissonette</name></author><author><name sortKey="Bozik, M" uniqKey="Bozik M">M Bozik</name></author><author><name sortKey="Lunsford, Ld" uniqKey="Lunsford L">LD Lunsford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Souhami, L" uniqKey="Souhami L">L Souhami</name></author><author><name sortKey="Seiferheld, W" uniqKey="Seiferheld W">W Seiferheld</name></author><author><name sortKey="Brachman, D" uniqKey="Brachman D">D Brachman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Park, Kj" uniqKey="Park K">KJ Park</name></author><author><name sortKey="Kano, H" uniqKey="Kano H">H Kano</name></author><author><name sortKey="Iyer, A" uniqKey="Iyer A">A Iyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koga, T" uniqKey="Koga T">T Koga</name></author><author><name sortKey="Shin, M" uniqKey="Shin M">M Shin</name></author><author><name sortKey="Saito, N" uniqKey="Saito N">N Saito</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stupp, R" uniqKey="Stupp R">R Stupp</name></author><author><name sortKey="Mason, Wp" uniqKey="Mason W">WP Mason</name></author><author><name sortKey="Van Den Bent, Mj" uniqKey="Van Den Bent M">MJ van den Bent</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stupp, R" uniqKey="Stupp R">R Stupp</name></author><author><name sortKey="Hegi, Me" uniqKey="Hegi M">ME Hegi</name></author><author><name sortKey="Mason, Wp" uniqKey="Mason W">WP Mason</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Erdem Eraslan, L" uniqKey="Erdem Eraslan L">L Erdem-Eraslan</name></author><author><name sortKey="Gravendeel, La" uniqKey="Gravendeel L">LA Gravendeel</name></author><author><name sortKey="De Rooi, J" uniqKey="De Rooi J">J de Rooi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="Jiang, T" uniqKey="Jiang T">T Jiang</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Wong, Et" uniqKey="Wong E">ET Wong</name></author><author><name sortKey="Hess, Kr" uniqKey="Hess K">KR Hess</name></author><author><name sortKey="Gleason, Mj" uniqKey="Gleason M">MJ Gleason</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lamborn, Kr" uniqKey="Lamborn K">KR Lamborn</name></author><author><name sortKey="Yung, Wk" uniqKey="Yung W">WK Yung</name></author><author><name sortKey="Chang, Sm" uniqKey="Chang S">SM Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ballman, Kv" uniqKey="Ballman K">KV Ballman</name></author><author><name sortKey="Buckner, Jc" uniqKey="Buckner J">JC Buckner</name></author><author><name sortKey="Brown, Pd" uniqKey="Brown P">PD Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gerstner, Er" uniqKey="Gerstner E">ER Gerstner</name></author><author><name sortKey="Batchelor, Tt" uniqKey="Batchelor T">TT Batchelor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vredenburgh, Jj" uniqKey="Vredenburgh J">JJ Vredenburgh</name></author><author><name sortKey="Desjardins, A" uniqKey="Desjardins A">A Desjardins</name></author><author><name sortKey="Reardon, Da" uniqKey="Reardon D">DA Reardon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haslinghuis, Lm" uniqKey="Haslinghuis L">LM Haslinghuis</name></author><author><name sortKey="Krenning, Ep" uniqKey="Krenning E">EP Krenning</name></author><author><name sortKey="De Herder, Ww" uniqKey="De Herder W">WW De Herder</name></author><author><name sortKey="Reijs, Ae" uniqKey="Reijs A">AE Reijs</name></author><author><name sortKey="Kwekkeboom, Dj" uniqKey="Kwekkeboom D">DJ Kwekkeboom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jain, Rk" uniqKey="Jain R">RK Jain</name></author><author><name sortKey="Di Tomaso, E" uniqKey="Di Tomaso E">E di Tomaso</name></author><author><name sortKey="Duda, Dg" uniqKey="Duda D">DG Duda</name></author><author><name sortKey="Loeffler, Js" uniqKey="Loeffler J">JS Loeffler</name></author><author><name sortKey="Sorensen, Ag" uniqKey="Sorensen A">AG Sorensen</name></author><author><name sortKey="Batchelor, Tt" uniqKey="Batchelor T">TT Batchelor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gupta, K" uniqKey="Gupta K">K Gupta</name></author><author><name sortKey="Radotra, Bd" uniqKey="Radotra B">BD Radotra</name></author><author><name sortKey="Banerjee, Ak" uniqKey="Banerjee A">AK Banerjee</name></author><author><name sortKey="Nijhawan, R" uniqKey="Nijhawan R">R Nijhawan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nam, Dh" uniqKey="Nam D">DH Nam</name></author><author><name sortKey="Park, K" uniqKey="Park K">K Park</name></author><author><name sortKey="Suh, Yl" uniqKey="Suh Y">YL Suh</name></author><author><name sortKey="Kim, Jh" uniqKey="Kim J">JH Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takano, S" uniqKey="Takano S">S Takano</name></author><author><name sortKey="Tsuboi, K" uniqKey="Tsuboi K">K Tsuboi</name></author><author><name sortKey="Matsumura, A" uniqKey="Matsumura A">A Matsumura</name></author><author><name sortKey="Nose, T" uniqKey="Nose T">T Nose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cohen, Mh" uniqKey="Cohen M">MH Cohen</name></author><author><name sortKey="Shen, Yl" uniqKey="Shen Y">YL Shen</name></author><author><name sortKey="Keegan, P" uniqKey="Keegan P">P Keegan</name></author><author><name sortKey="Pazdur, R" uniqKey="Pazdur R">R Pazdur</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lai, A" uniqKey="Lai A">A Lai</name></author><author><name sortKey="Tran, A" uniqKey="Tran A">A Tran</name></author><author><name sortKey="Nghiemphu, Pl" uniqKey="Nghiemphu P">PL Nghiemphu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reardon, Da" uniqKey="Reardon D">DA Reardon</name></author><author><name sortKey="Turner, S" uniqKey="Turner S">S Turner</name></author><author><name sortKey="Peters, Kb" uniqKey="Peters K">KB Peters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Norden, Ad" uniqKey="Norden A">AD Norden</name></author><author><name sortKey="Drappatz, J" uniqKey="Drappatz J">J Drappatz</name></author><author><name sortKey="Muzikansky, A" uniqKey="Muzikansky A">A Muzikansky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beal, K" uniqKey="Beal K">K Beal</name></author><author><name sortKey="Abrey, Le" uniqKey="Abrey L">LE Abrey</name></author><author><name sortKey="Gutin, Ph" uniqKey="Gutin P">PH Gutin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kreisl, Tn" uniqKey="Kreisl T">TN Kreisl</name></author><author><name sortKey="Kim, L" uniqKey="Kim L">L Kim</name></author><author><name sortKey="Moore, K" uniqKey="Moore K">K Moore</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khasraw, M" uniqKey="Khasraw M">M Khasraw</name></author><author><name sortKey="Lassman, Ab" uniqKey="Lassman A">AB Lassman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kunnakkat, S" uniqKey="Kunnakkat S">S Kunnakkat</name></author><author><name sortKey="Narayana, A" uniqKey="Narayana A">A Narayana</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Cabrera, Ar" uniqKey="Cabrera A">AR Cabrera</name></author><author><name sortKey="Cuneo, Kc" uniqKey="Cuneo K">KC Cuneo</name></author><author><name sortKey="Vredenburgh, Jj" uniqKey="Vredenburgh J">JJ Vredenburgh</name></author><author><name sortKey="Sampson, Jh" uniqKey="Sampson J">JH Sampson</name></author><author><name sortKey="Kirkpatrick, Jp" uniqKey="Kirkpatrick J">JP Kirkpatrick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cloughsey, T" uniqKey="Cloughsey T">T Cloughsey</name></author><author><name sortKey="Wick, W" uniqKey="Wick W">W Wick</name></author><author><name sortKey="Mason, W" uniqKey="Mason W">W Mason</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gilbert, Mr" uniqKey="Gilbert M">MR Gilbert</name></author><author><name sortKey="Dignam, J" uniqKey="Dignam J">J Dignam</name></author><author><name sortKey="Won, M" uniqKey="Won M">M Won</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Den Bent, Mj" uniqKey="Van Den Bent M">MJ van den Bent</name></author><author><name sortKey="Chinot, O" uniqKey="Chinot O">O Chinot</name></author><author><name sortKey="Boogerd, W" uniqKey="Boogerd W">W Boogerd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reardon, Da" uniqKey="Reardon D">DA Reardon</name></author><author><name sortKey="Galanis, E" uniqKey="Galanis E">E Galanis</name></author><author><name sortKey="Degroot, Jf" uniqKey="Degroot J">JF DeGroot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abrey, Le" uniqKey="Abrey L">LE Abrey</name></author><author><name sortKey="Louis, Dn" uniqKey="Louis D">DN Louis</name></author><author><name sortKey="Paleologos, N" uniqKey="Paleologos N">N Paleologos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deangelis, Lm" uniqKey="Deangelis L">LM DeAngelis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murrell, J" uniqKey="Murrell J">J Murrell</name></author><author><name sortKey="Board, R" uniqKey="Board R">R Board</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sampson, Jh" uniqKey="Sampson J">JH Sampson</name></author><author><name sortKey="Aldape, Kd" uniqKey="Aldape K">KD Aldape</name></author><author><name sortKey="Archer, Ge" uniqKey="Archer G">GE Archer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author><author><name sortKey="Hoos, A" uniqKey="Hoos A">A Hoos</name></author><author><name sortKey="O Ay, S" uniqKey="O Ay S">S O’Day</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Manag Res</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Manag Res</journal-id><journal-title-group><journal-title>Cancer Management and Research</journal-title></journal-title-group><issn pub-type="epub">1179-1322</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24711712</article-id><article-id pub-id-type="pmc">3969256</article-id><article-id pub-id-type="doi">10.2147/CMAR.S54726</article-id><article-id pub-id-type="publisher-id">cmar-6-149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Rafay</given-names></name><xref ref-type="aff" rid="af1-cmar-6-149">1</xref></contrib><contrib contrib-type="author"><name><surname>Oborski</surname><given-names>Matthew J</given-names></name><xref ref-type="aff" rid="af2-cmar-6-149">2</xref></contrib><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>Misun</given-names></name><xref ref-type="aff" rid="af1-cmar-6-149">1</xref></contrib><contrib contrib-type="author"><name><surname>Lieberman</surname><given-names>Frank S</given-names></name><xref ref-type="aff" rid="af3-cmar-6-149">3</xref></contrib><contrib contrib-type="author"><name><surname>Mountz</surname><given-names>James M</given-names></name><xref ref-type="aff" rid="af1-cmar-6-149">1</xref><xref ref-type="corresp" rid="c1-cmar-6-149"></xref></contrib></contrib-group><aff id="af1-cmar-6-149"><label>1</label>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="af2-cmar-6-149"><label>2</label>Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="af3-cmar-6-149"><label>3</label>Department of Neurology and Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</aff><author-notes><corresp id="c1-cmar-6-149">Correspondence: James M Mountz, Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA, Tel +1 412 647 0104, Fax +1 412 647 0700, Email <email>mountzjm@upmc.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>24</day><month>3</month><year>2014</year></pub-date><volume>6</volume><fpage>149</fpage><lpage>170</lpage><permissions><copyright-statement>© 2014 Ahmed et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high morbidity and mortality. Even with optimal treatment, median survival is only 12–15 months for glioblastomas and 2–5 years for anaplastic gliomas. However, recent advances in imaging and quantitative analysis of image data have led to earlier diagnosis of tumors and tumor response to therapy, providing oncologists with a greater time window for therapy management. In addition, improved understanding of tumor biology, genetics, and resistance mechanisms has enhanced surgical techniques, chemotherapy methods, and radiotherapy administration. After proper diagnosis and institution of appropriate therapy, there is now a vital need for quantitative methods that can sensitively detect malignant glioma response to therapy at early follow-up times, when changes in management of nonresponders can have its greatest effect. Currently, response is largely evaluated by measuring magnetic resonance contrast and size change, but this approach does not take into account the key biologic steps that precede tumor size reduction. Molecular imaging is ideally suited to measuring early response by quantifying cellular metabolism, proliferation, and apoptosis, activities altered early in treatment. We expect that successful integration of quantitative imaging biomarker assessment into the early phase of clinical trials could provide a novel approach for testing new therapies, and importantly, for facilitating patient management, sparing patients from weeks or months of toxicity and ineffective treatment. This review will present an overview of epidemiology, molecular pathogenesis and current advances in diagnoses, and management of malignant gliomas.</p></abstract><kwd-group><title>Keywords</title><kwd>glioblastoma multiforme</kwd><kwd>malignant gliomas</kwd><kwd>MRI</kwd><kwd>PET</kwd><kwd>FLT</kwd><kwd>early therapy response assessment</kwd><kwd>quantitative molecular imaging</kwd></kwd-group></article-meta></front><body><sec><title>Epidemiology and classification of brain tumors</title><p>The estimated number of new cases (adjusted for age) using the world standard population of primary malignant brain and central nervous system cancer in 2008, was 3.8 per 100,000 in males and 3.1 per 100,000 in females. The incidence rates were higher in more developed countries (males: 5.8 per 100,000; females: 4.4 per 100,000) than in less developed countries (males: 3.2 per 100,000; females: 2.8 per 100,000).<xref rid="b1-cmar-6-149" ref-type="bibr">1</xref> In the US, the annual incidence of primary malignant gliomas is approximately five cases per 100,000 people.<xref rid="b2-cmar-6-149" ref-type="bibr">2</xref>,<xref rid="b3-cmar-6-149" ref-type="bibr">3</xref> Every year, about 22,500 new cases of malignant primary brain tumor are diagnosed in adults in the US, out of which 70% are malignant gliomas.<xref rid="b2-cmar-6-149" ref-type="bibr">2</xref>,<xref rid="b3-cmar-6-149" ref-type="bibr">3</xref> Glioblastomas account for approximately 60% to 70% of malignant gliomas, anaplastic astrocytomas for 10% to 15%, and anaplastic oligodendrogliomas and anaplastic oligoastrocytomas for 10%; less common tumors, such as anaplastic ependymomas and anaplastic gangliogliomas, account for the rest.<xref rid="b2-cmar-6-149" ref-type="bibr">2</xref>,<xref rid="b3-cmar-6-149" ref-type="bibr">3</xref></p><p>The World Health Organization (WHO) classifies astrocytomas based on histologic type,<xref rid="b2-cmar-6-149" ref-type="bibr">2</xref>,<xref rid="b4-cmar-6-149" ref-type="bibr">4</xref> with grading based on the most malignant region of the tumors. Tumor grade depends upon the degree of nuclear atypia, mitotic activity, microvascular proliferation, and necrosis, with increased anaplasia corresponding to higher tumor grade. Grades include low-grade, or WHO grade I (pilocytic astrocytoma) and grade II (diffuse astrocytoma); and high-grade, or WHO grade III (anaplastic astrocytoma) and grade IV (glioblastoma multiforme, GBM). Grade III and IV tumors are considered malignant gliomas. The median age at the time of diagnosis is 64 years for glioblastomas and 45 years in the case of anaplastic gliomas.<xref rid="b5-cmar-6-149" ref-type="bibr">5</xref></p><p>Apart from primary brain tumors, brain metastases from common solid tumors that spread to the brain primarily include those of lung, breast, and melanoma. However, a recent increase in the incidence of brain metastases from other cancer types, such as renal, prostate, and colorectal cancers, has been observed.<xref rid="b6-cmar-6-149" ref-type="bibr">6</xref>,<xref rid="b7-cmar-6-149" ref-type="bibr">7</xref></p></sec><sec><title>Molecular pathology</title><sec><title>Molecular pathology of primary brain tumors</title><p>In the past 2 decades, the application of molecular pathology in diagnosis and classification has transformed the management of malignant gliomas.<xref rid="b8-cmar-6-149" ref-type="bibr">8</xref> Molecular biomarkers have been able to differentiate oligodendroglial tumors from astrocytomas, resolve controversies regarding classification of mixed oligoastrocytic tumors, and identify clinically significant subgroups of anaplastic astrocytoma and glioblastoma.<xref rid="b9-cmar-6-149" ref-type="bibr">9</xref>,<xref rid="b10-cmar-6-149" ref-type="bibr">10</xref> Recent clinical pathologic correlations between outcome and molecular biomarkers have also validated predictive markers for oligodendrogliomas and identified subgroups of glioblastoma susceptible to epidermal growth factor receptor (EGFR) signal transduction inhibitors.<xref rid="b11-cmar-6-149" ref-type="bibr">11</xref>–<xref rid="b13-cmar-6-149" ref-type="bibr">13</xref></p><p>The European Organization for Research and Treatment of Cancer has identified six different types of anaplastic oligodendrogliomas using microarray unsupervised gene expression analysis of the tumor specimens obtained as part of the European Organization for Research and Treatment of Cancer trial (EORTC 26951).<xref rid="b13-cmar-6-149" ref-type="bibr">13</xref> These intrinsic molecular subtypes had prognostic significance for progression-free survival (PFS) independent of the previously recognized prognostic factors, including 1p/19q deletion, isocitrate dehydrogenase gene (<italic>IDH1</italic>) mutation, and O<xref rid="b6-cmar-6-149" ref-type="bibr">6</xref>-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status. One subgroup, with a 1p/19q deletion and <italic>IDH1</italic> mutation, especially benefitted from the addition of chemotherapy to external beam radiation, demonstrating an overall survival (OS) of 12.8 years with adjuvant chemotherapy contrasted with 5.5 years for those patients treated with radiation alone.</p><p>It is now recognized that patients with oligodendroglial tumors with 1p/19q deletions have a consistently better prognosis for survival than those with tumors of equivalent grade and similar histologic appearance that lack the deletions.<xref rid="b14-cmar-6-149" ref-type="bibr">14</xref>,<xref rid="b15-cmar-6-149" ref-type="bibr">15</xref> In two recently reported prospective randomized trials of fractionated external beam radiotherapy (EBRT) with or without alkylator-based chemotherapy for newly diagnosed anaplastic astrocytoma, the presence of 1p deletions was a predictive marker for the cohort of patients in which the addition of chemotherapy led to prolonged OS.<xref rid="b11-cmar-6-149" ref-type="bibr">11</xref></p><p>The identification of mutations in isocitrate dehydrogenase (IDH) isoenzymes 1 and 2 in a high percentage of low grade gliomas and in subsets of anaplastic astrocytoma, oligodendroglioma, and glioblastoma has further refined the delineation of prognosis. <italic>IDH1</italic> is a good prognostic marker for anaplastic astrocytoma and glioblastoma.<xref rid="b9-cmar-6-149" ref-type="bibr">9</xref>,<xref rid="b16-cmar-6-149" ref-type="bibr">16</xref> For anaplastic astrocytoma, lack of an <italic>IDH1</italic> mutation appears to identify a subgroup of histologically indistinguishable tumors with a prognosis similar to glioblastoma.<xref rid="b17-cmar-6-149" ref-type="bibr">17</xref> The oncogenic mechanism appears to be the production of a metabolite, 2-hydroxyglutarate (2HG), which inhibits ketoglutarate-dependent dioxygenases, leading to aberrant histone and DNA methylation.<xref rid="b16-cmar-6-149" ref-type="bibr">16</xref></p><p>In clinical trials of alkylator-based chemotherapy regimens for glioblastoma, anaplastic astrocytoma, and oligodendroglioma,<xref rid="b9-cmar-6-149" ref-type="bibr">9</xref>,<xref rid="b18-cmar-6-149" ref-type="bibr">18</xref> the MGMT promoter methylation status has proven to be a prognostic, though not a specific predictive biomarker. Hegi et al demonstrated that promoter methylation silencing of the MGMT gene correlates strongly with long-term survival in patients receiving chemotherapy.<xref rid="b19-cmar-6-149" ref-type="bibr">19</xref> At the same time, Brandes et al showed that for patients receiving chemoradiation for newly diagnosed GBM, MGMT promoter methylation silencing correlates with increased frequency of vascular permeability of vessels in the radiation treatment field.<xref rid="b20-cmar-6-149" ref-type="bibr">20</xref> This may produce a transient increase in the volume of contrast taken up by the lesion, known as “pseudoprogression”.<xref rid="b20-cmar-6-149" ref-type="bibr">20</xref></p><p>GBMs that arise de novo appear to be different genetically from those that arise from prior low-grade astrocytomas.<xref rid="b9-cmar-6-149" ref-type="bibr">9</xref> IDH and p53 mutations are rare in primary GBM. In contrast, primary GBMs are characterized by EGFR amplification and mutation, loss of heterozygosity on chromosome 10q, and inactivation of the phosphatase and tensin homolog (<italic>PTEN</italic>) gene.<xref rid="b21-cmar-6-149" ref-type="bibr">21</xref> Secondary GBMs are characterized by tumor protein p53 (TP<sub>53</sub>) mutations and platelet-derived growth factor receptor activation.<xref rid="b21-cmar-6-149" ref-type="bibr">21</xref> A poor prognosis subgroup of secondary GBM in older adults, in which relapse occurs in the first year after treatment, appears to be characterized by lack of <italic>IDH1</italic> mutations, similar to primary GBM’s molecular signature.<xref rid="b22-cmar-6-149" ref-type="bibr">22</xref></p><p>Microarray-based unsupervised genome-wide analysis of gene expression in glioblastomas has identified at least four subgroups differentiable by molecular profile.<xref rid="b23-cmar-6-149" ref-type="bibr">23</xref> Phillips et al examined 107 grade III and IV astrocytomas, and using a set of 35 signature genes, segregated into three subtypes: proneural, proliferative, and mesenchymal.<xref rid="b24-cmar-6-149" ref-type="bibr">24</xref> In this study, the proneural subset had a better prognosis than the proliferative and mesenchymal subsets, which had worse prognoses.</p><p>The investigators of The Cancer Genome Atlas (TCGA) pilot project<xref rid="b25-cmar-6-149" ref-type="bibr">25</xref> proposed a four-subgroup classification based on analysis of 202 GBMs. The subtypes include proneural, neural, classical, and mesenchymal. In the context of the cancer genome atlas, Noushmehr et al profiled promoter DNA methylation alterations in 272 glioblastomas (43 low and intermediate grade gliomas and 57 additional primary GBMs).<xref rid="b26-cmar-6-149" ref-type="bibr">26</xref> They reported a distinct subset of tumors with increased DNA methylation at large number of loci, indicating the existence of a glioma–CpG island methylator phenotype (G–CIMP).<xref rid="b26-cmar-6-149" ref-type="bibr">26</xref> Within the GBM cohort, the G–CIMP phenotype correlates with <italic>IDH1</italic> mutation, younger age, proneural genotype, and a better prognosis.</p><p>The <italic>EGFR</italic> gene is the most frequently amplified gene in primary GBM and is seen in 94% of the TCGA classical type,<xref rid="b25-cmar-6-149" ref-type="bibr">25</xref> and in the proliferative and mesenchymal subtypes in the Phillips classification.<xref rid="b24-cmar-6-149" ref-type="bibr">24</xref> A specific in-frame deletion of exons 2–7 is present in 20%–30% of GBM overall and 50%–60% of GBM with <italic>EGFR</italic> gene amplification.<xref rid="b27-cmar-6-149" ref-type="bibr">27</xref> The protein product of this truncated mRNA is the EGFRvIII mutant protein. This protein is the target antigen for immunotherapy strategies, including vaccines. Although the small molecule EGFR tyrosine kinase inhibitors trials for patients with GBM and anaplastic astrocytoma demonstrated low response rates and no benefit in PFS, a small subset of patients had durable responses.<xref rid="b28-cmar-6-149" ref-type="bibr">28</xref> A specific genotype correlated with response in which EGFRvIII mutation was present in the context of intact AKT pathway function, with wild-type <italic>PTEN</italic>.<xref rid="b29-cmar-6-149" ref-type="bibr">29</xref></p><p><italic>BRAF</italic> (an oncogene located on chromosome 7) encodes a serine threonine kinase involved in cell signaling, and also involved in mitogen-activated protein kinases/extracellular signal regulated kinases pathway activation, and cell growth is most commonly associated with low-grade pediatric gliomas, but is commonly seen in high-grade diffuse gliomas as well. The most common <italic>BRAF</italic> abnormalities involve gene duplication with fusions leading to a mutant protein with a constitutively active kinase domain.<xref rid="b9-cmar-6-149" ref-type="bibr">9</xref> Mutation in p53 and BRAF appear to be mutually exclusive.<xref rid="b30-cmar-6-149" ref-type="bibr">30</xref> The presence of activating BRAF mutations may identify a therapeutic target in the high-grade gliomas in which it is expressed. BRAF inhibitor vemurafenib is US Food and Drug Administration (FDA)-approved as treatment for melanoma with BRAF<sup>V600E</sup> mutation.<xref rid="b31-cmar-6-149" ref-type="bibr">31</xref></p><p>Molecular markers are also useful to predict a response to chemotherapy in three settings: 1p and 19q loss, MGMT methylation, and possibly the EGFR–PI3 kinase pathways in response of glioblastomas to specific EGFR inhibitors.</p><sec><title>1p and 19q deletions</title><p>Allelic loss of chromosomes 1p and 19q is a powerful predictor of chemotherapeutic response and longer PFS and OS following chemotherapy with either temozolomide or procarbazine, lomustine, and vincristine (PCV) in patients with anaplastic oligodendrogliomas. Those tumors with 1p and 19q loss in the setting of polysomy of chromosomes 1 and 19 have intermediate prognoses. Allelic loss of 1p alone is also predictive of response to temozolomide in patients with grade II oligodendroglial tumors.<xref rid="b32-cmar-6-149" ref-type="bibr">32</xref> Thus, testing for 1p and 19q status is now widespread and is used to influence therapeutic decisions.</p></sec><sec><title><italic>MGMT</italic> promoter methylation</title><p>In the course of tumor development, the <italic>MGMT</italic> gene may be silenced by methylation of its promoter, thereby preventing repair of DNA damage and increasing the potential effectiveness of chemotherapy. Several clinical studies have indicated that such promoter methylation is associated with an improved survival in patients receiving adjuvant alkylating agent chemotherapy.<xref rid="b33-cmar-6-149" ref-type="bibr">33</xref></p></sec><sec><title>EGFR-PI3 kinase pathways</title><p>Two studies evaluated patients with glioblastomas treated with the EGFR inhibitors, erlotinib or gefitinib<xref rid="b34-cmar-6-149" ref-type="bibr">34</xref>,<xref rid="b35-cmar-6-149" ref-type="bibr">35</xref> and found that, in contrast to other studies that did not report objective responses,<xref rid="b36-cmar-6-149" ref-type="bibr">36</xref> patients with recurrent glioblastoma responded to these two agents. Furthermore, the studies showed associations between response and activation of EGFR itself (one report implicating the wild-type receptor<xref rid="b34-cmar-6-149" ref-type="bibr">34</xref> and the other implicating the vIII mutant EGFR<xref rid="b35-cmar-6-149" ref-type="bibr">35</xref>), as well as between response and whether the PI3 kinase pathway was functionally intact (one report measuring phosphorylated AKT and the other measuring <italic>PTEN</italic> expression). If responses continue to be documented with these agents, immunohistochemical testing for EGFR and the PI3K pathway may prove useful.</p></sec></sec><sec><title>Molecular pathology of brain metastases</title><p>The pathophysiology of brain metastasis is complex and distinct from primary brain tumors. It is dependent upon both oncogenic processes and host organ responses. Some of the multiple mechanisms that ultimately determine the development of a brain metastasis include, but are not limited to, the phenotype of the brain-trophic tumor cells, tumor cell survival in the vasculature and extravasation of those cells from the bloodstream and into a host organ, and the structure and function of the blood–brain barrier (BBB).</p><p>Since the brain does not contain lymphatics, circulating tumor cells reach the brain parenchyma only via a hematogenous route. Invading metastatic cancer cells interact with all cell types, including endothelium, pericytes, and astrocytes, to breach the BBB and gain access to brain parenchyma.<xref rid="b37-cmar-6-149" ref-type="bibr">37</xref> Once tumor cells enter the brain parenchyma, a number of factors are released by both the tumor cells and the underlying brain. In co-culture experiments, lung-cancer-derived cells release tumor-associated factors, including macrophage migration inhibitory factor, interleukin-8, and plasminogen activator inhibitor-1, which stimulate astrocytes. In turn, the activated astrocytes release interleukin-6, tumor necrosis factor-α, and interleukin-1β, which induce tumor cell proliferation.<xref rid="b38-cmar-6-149" ref-type="bibr">38</xref>,<xref rid="b39-cmar-6-149" ref-type="bibr">39</xref></p><p>Receptor biomarkers indicating an enhanced potential for the development of central nervous system metastases may be identified in the primary tumor cell and thereby define future therapeutic targets. For example, overexpression of human epidermal growth factor receptor 2 (HER2/neu) is predictive of a three-fold increase in metastases to the lungs, liver, and brain as compared with HER2/neu-negative breast carcinomas.<xref rid="b40-cmar-6-149" ref-type="bibr">40</xref>–<xref rid="b42-cmar-6-149" ref-type="bibr">42</xref> In lung adenocarcinoma, genetic alterations in homeobox protein Hox-B9 and lymphoid enhancer-binding factor 1 lead to hyperactivity of the Wnt/T Cell Factor (Wnt/TCF) pathway, which has been implicated in the growth of cancer stem cells and enhanced competence to metastasize to the bone and brain.<xref rid="b43-cmar-6-149" ref-type="bibr">43</xref>,<xref rid="b44-cmar-6-149" ref-type="bibr">44</xref></p></sec></sec><sec><title>Diagnosis</title><sec><title>Clinical signs and symptoms</title><p>Although the symptoms and signs produced by malignant gliomas will vary with the location of the tumor, a unifying characteristic of the clinical presentation is relentless progression. For tumors that are located in or subjacent to cortical regions with specific functions, the symptoms and signs will relate to the functions of the brain regions affected. Patients may present with progressive motor or sensory disturbances, language dysfunction, visual field abnormalities, or focal seizures. Tumors arising in the brain stem may cause rapidly progressing cranial neuropathies as well as motor and sensory deficits. Neurologic deficits with less localizing features may include headache, confusion, memory loss, and personality changes.</p><p>As the size of tumor increases, the edema surrounding the tumor increases, resulting in increased intracranial pressure and subsequent headaches. The headaches associated with increased intracranial pressure are typically worse when the patient is recumbent. When intracranial pressure rises to a critical threshold, changes in blood pressure due to dysfunctional autonomic reflexes may produce a syndrome of position-evoked crescendo headache, visual obscurations, lightheadedness, and exacerbation of focal symptoms. This cluster of symptoms is associated with intracranial pressure waves and is usually associated with papilledema.</p></sec><sec><title>Neuroimaging</title><p>Neuroimaging plays a crucial role in diagnosing and assessing the location, extent, and biologic activity of the tumor before, during, and after treatment. Its role in low-grade tumors lies in the monitoring of possible recurrent disease or anaplastic transformation into high-grade tumors. In high-grade tumors, neuroimaging is much needed for differentiating recurrent tumor from treatment-induced changes such as radiation necrosis.</p><p>Gliomas are often characterized by diffuse infiltration of white matter tracts,<xref rid="b45-cmar-6-149" ref-type="bibr">45</xref> and stereotactic biopsy studies have demonstrated that these regions appear normal on conventional contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).<xref rid="b46-cmar-6-149" ref-type="bibr">46</xref> Since complete resection of infiltrative high-grade neoplasms is not an option,<xref rid="b47-cmar-6-149" ref-type="bibr">47</xref> the development of improved posttreatment imaging to detect residual tumor is pivotal in clinical outcome.</p><p>MRI serves as the current gold standard in tumor treatment response monitoring; however, prognostic information cannot be obtained until weeks after the initiation of treatment.<xref rid="b48-cmar-6-149" ref-type="bibr">48</xref> Determination of recurrence versus treatment effects on CT or MRI cannot be accurately evaluated.<xref rid="b49-cmar-6-149" ref-type="bibr">49</xref>–<xref rid="b51-cmar-6-149" ref-type="bibr">51</xref> Functional imaging can distinguish cerebral necrosis from viable brain tumor, and determine viability grade.<xref rid="b52-cmar-6-149" ref-type="bibr">52</xref>–<xref rid="b54-cmar-6-149" ref-type="bibr">54</xref></p><p>The realization that the MacDonald criteria<xref rid="b1-cmar-6-149" ref-type="bibr">1</xref> for response assessment in clinical trials of treatments for high-grade gliomas failed to account for nonenhancing progression has led to the development of a new paradigm, the Response Assessment for Neuro-Oncology (RANO) criteria.<xref rid="b55-cmar-6-149" ref-type="bibr">55</xref> Differentiating tumor response related to cytotoxicity from physiologic modifications of BBB function is a major focus of translational imaging research. MRI techniques that interrogate the vascular density and permeability of tumor vasculature as well as positron emission tomography (PET) techniques<xref rid="b56-cmar-6-149" ref-type="bibr">56</xref> are being evaluated as imaging biomarkers of tumor response in treatment trials of anti-angiogenic therapy.<xref rid="b57-cmar-6-149" ref-type="bibr">57</xref></p><sec><title>CT</title><p>Most of the time, CT is the first imaging modality for evaluating symptoms of gliomas. Contrast-enhanced CT scans can delineate disruptions in the BBB, but CT sensitivity is much lower than that of MRI. The attenuation difference can offer limited information on tumor biology. For instance, slightly increased tissue density during tumor monitoring may indicate increase in tissue cellularity, or tumor growth. On the other hand, decreased attenuation in the treated region indicates low tumor cellularity or edema. However, the exact delineation of tumor borders or the extent of treatment-related changes is not feasible using this modality.</p></sec><sec><title>MRI</title><p>The clinical gold standard for brain tumor imaging, MRI, utilizes T1- and T2-weighted sequences, fluid-attenuated inversion recovery sequences, and contrast-enhanced T1-weighted imaging for tumor monitoring. Glioblastoma is classically hypointense to isointense, with a ring-pattern of enhancement on gadolinium-enhanced T1-weighted images, and is hyperintense on both T2-weighted and FLAIR (fluid-attenuated inversion recovery) images (<xref ref-type="fig" rid="f1-cmar-6-149">Figure 1</xref>).<xref rid="b58-cmar-6-149" ref-type="bibr">58</xref>,<xref rid="b59-cmar-6-149" ref-type="bibr">59</xref> It can be focal, multifocal, or diffuse (gliomatosis cerebri).</p><p>MRI provides excellent anatomic detail; however, it cannot reliably differentiate between radiation necrosis and recurrence posttreatment (<xref ref-type="fig" rid="f2-cmar-6-149">Figure 2</xref>).<xref rid="b60-cmar-6-149" ref-type="bibr">60</xref>,<xref rid="b61-cmar-6-149" ref-type="bibr">61</xref> This is of critical importance in monitoring tumor response to chemoradiation and stereotactic radiosurgery, both of which are associated with high prevalence of post-therapy necrosis.</p><p>Although BBB destruction with subsequent leakage of contrast medium is commonly seen in most high-grade tumors, such as glioblastomas, it is not a reliable distinguishing feature of tumor grade.<xref rid="b62-cmar-6-149" ref-type="bibr">62</xref> In fact, approximately one-third of nonenhancing gliomas are malignant.<xref rid="b63-cmar-6-149" ref-type="bibr">63</xref> Moreover, glioblastoma may initially present as a nonenhancing lesion, especially in older patients. In addition, contrast enhancement cannot always be used to assess response since therapy may result in BBB disruption without a corresponding change in tumor status.<xref rid="b64-cmar-6-149" ref-type="bibr">64</xref>,<xref rid="b65-cmar-6-149" ref-type="bibr">65</xref></p><p>After therapy, physiologic MRI can provide insights into changes in tumor environment related to metabolism (magnetic resonance spectroscopy [MRS]), perfusion (perfusion-weighted imaging), and microstructure (diffusion-weighted imaging [DWI]). Indeed, apparent diffusion coefficient (ADC) measurements,<xref rid="b66-cmar-6-149" ref-type="bibr">66</xref>–<xref rid="b68-cmar-6-149" ref-type="bibr">68</xref> DWI values,<xref rid="b69-cmar-6-149" ref-type="bibr">69</xref> and fluid-attenuation inversion recovery images<xref rid="b70-cmar-6-149" ref-type="bibr">70</xref> correlate with the probability of response to therapy.</p></sec><sec><title><sup>1</sup>H MRS</title><p>The magnetic resonance spectrum from <sup>1</sup>H MRS contains peaks representative of different (hydrogen-containing) metabolites. The relative concentration of each metabolite is determined from the area under the corresponding peak. Whereas single-voxel spectroscopy yields a single spectrum from a defined tissue area, two- and three-dimensional chemical shift imaging depict one or more tissue slices with several voxels in each slice to better account for tissue inhomogeneities.</p><p>In the case of tumor monitoring, tumor metabolite data are compared to those of the contralateral healthy side. The most commonly examined metabolites include lactate as a product of anaerobic glycolysis,<xref rid="b71-cmar-6-149" ref-type="bibr">71</xref> N-acetylaspartate as a sign of neuronal viability and density,<xref rid="b72-cmar-6-149" ref-type="bibr">72</xref>,<xref rid="b73-cmar-6-149" ref-type="bibr">73</xref> choline as an indicator of high membrane turnover and thus cell proliferation,<xref rid="b74-cmar-6-149" ref-type="bibr">74</xref>,<xref rid="b75-cmar-6-149" ref-type="bibr">75</xref> and creatine as a signature of cell energy expenditure used for an internal reference value.<xref rid="b76-cmar-6-149" ref-type="bibr">76</xref> Increasing choline/creatine ratios and lactate concentrations,<xref rid="b75-cmar-6-149" ref-type="bibr">75</xref> and decreasing N-acetylaspartate<xref rid="b77-cmar-6-149" ref-type="bibr">77</xref> correlate with tumor progression, and can also be seen in tumor recurrence (<xref ref-type="fig" rid="f3-cmar-6-149">Figure 3</xref>). Whereas elevated creatine values (normalized to normal brain) correlate with a shorter time-to-progression in WHO grade II and III astrocytomas,<xref rid="b78-cmar-6-149" ref-type="bibr">78</xref>,<xref rid="b79-cmar-6-149" ref-type="bibr">79</xref> no correlation was identified between tumor grading and choline/creatine ratio.<xref rid="b80-cmar-6-149" ref-type="bibr">80</xref></p><p>A study by Imani et al compared the accuracy of high-field proton MRS (<sup>1</sup>H MRS) and <sup>18</sup>F 2-fluorodeoxyglucose PET (<sup>18</sup>F-FDG PET) for identification of viable tumor recurrence in 12 grade II and III glioma patients and showed that <sup>1</sup>H MRS imaging was more accurate in low-grade glioma and <sup>18</sup>F-FDG PET provided better accuracy in high-grade gliomas.<xref rid="b80-cmar-6-149" ref-type="bibr">80</xref> The study also suggested that the combination of <sup>1</sup>H MRS data and <sup>18</sup>F-FDG PET imaging can enhance detection of glioma progression. While the sensitivity of <sup>18</sup>F-FDG PET in detecting glioma progression was very high (100%), its specificity in differentiating post-therapy inflammation from true tumor progression was low (71%), leading to a high false positive rate (29%) in post-radiation therapy patients.</p><p>Studies have looked into the significance of IDH mutational status in the diagnosis and classification of gliomas and the identification of an oncometabolite, 2HG, which accumulates in IDH mutant tumors.<xref rid="b9-cmar-6-149" ref-type="bibr">9</xref>,<xref rid="b16-cmar-6-149" ref-type="bibr">16</xref> Recent investigations using ultrahigh field strength MRI suggest that the presence of IDH mutations in a tumor can be noninvasively detected by spectroscopic measurement of 2HG.<xref rid="b81-cmar-6-149" ref-type="bibr">81</xref> Recently, investigators in the US and Europe have demonstrated that MRS can differentiate 2HG from neighboring metabolites, such as gamma amino butyric acid, glutamine, and glutamate. Kalinina et al<xref rid="b82-cmar-6-149" ref-type="bibr">82</xref> analyzed brain tumor specimens to show the feasibility of using MRS to quantitate 2HG for the classification of IDH mutant tumors. Subsequently, Pope et al<xref rid="b83-cmar-6-149" ref-type="bibr">83</xref> demonstrated detection of 2HG by MRS in glioma patients prior to resection, with analysis of IDH1 status by DNA sequencing, and measurement of concentrations of 2HG and other metabolites by liquid chromatography–mass spectroscopy. In tumors with IDH1 mutations, 2HG levels, as measured in vivo using water suppressed proton (<sup>1</sup>H) MRS, correlate with measured amounts in the resected tumor specimens. Tumors with IDH1 mutations have elevated choline and decreased glutathione levels. Elkhaled et al<xref rid="b81-cmar-6-149" ref-type="bibr">81</xref> also demonstrated that levels of 2HG correlate with levels of choline, lactate, and glutathione, as well as with histopathologic grade. While it appears that MRS can provide a noninvasive measure of 2HG in human gliomas, further studies are needed to validate the utility of 2HG quantitation and the relevance of other alterations in metabolites as prognostic biomarkers.</p></sec><sec><title>DWI-MRI</title><p>DWI relies on the microscopic motion of water molecules within tissue. The process is influenced by temperature and tissue architecture<xref rid="b84-cmar-6-149" ref-type="bibr">84</xref> and is commonly quantified by the ADC. Tumor infiltration alters tissue architecture and thus water diffusion. ADC decreases with an increase in viscosity, cellular density, and reduction of extracellular space. Low values in ADC maps in solid gliomas are associated with higher-grade tumors.<xref rid="b85-cmar-6-149" ref-type="bibr">85</xref> Complicating the interpretation is coexistent posttreatment edema which may alter ADC values. The recently introduced higher-order diffusion technique, diffusion kurtosis imaging,<xref rid="b86-cmar-6-149" ref-type="bibr">86</xref> is being studied to characterize microstructural changes, and initial findings appear promising in the differential diagnosis of brain tumors.<xref rid="b87-cmar-6-149" ref-type="bibr">87</xref></p><sec><title>Perfusion-weighted MRI</title><p>Perfusion-weighted imaging involves the quantification of cerebral blood volume (CBV) after contrast administration with a dynamic MRI sequence sensitive to T2* effects. A graph of contrast enhancement is generated to calculate the area under the signal curve as an estimate of relative CBV (rCBV). High-grade gliomas, in particular, are associated with disruption of the BBB, which causes more contrast extravasation and consequent adjustments to rCBV calculations with sophisticated mathematical models.<xref rid="b88-cmar-6-149" ref-type="bibr">88</xref> Preloading of contrast medium has been applied to minimize the effects of leakage.<xref rid="b89-cmar-6-149" ref-type="bibr">89</xref>,<xref rid="b90-cmar-6-149" ref-type="bibr">90</xref> Increased angiogenesis in high-grade gliomas is also correlated with higher CBV relative to contralateral normal white matter rCBV and tumor aggressiveness.<xref rid="b91-cmar-6-149" ref-type="bibr">91</xref>–<xref rid="b93-cmar-6-149" ref-type="bibr">93</xref> Quantitative analysis found a threshold of rCBV =1.75 for determining a high-grade glioma<xref rid="b91-cmar-6-149" ref-type="bibr">91</xref> and a higher rCBV ratio of about 2.14 for oligodendrogliomas.<xref rid="b94-cmar-6-149" ref-type="bibr">94</xref> It has also been shown that an increase in rCBV occurs up to 12 months prior to malignant transformation as assessed by new contrast enhancement.<xref rid="b95-cmar-6-149" ref-type="bibr">95</xref></p></sec></sec><sec><title>PET</title><sec><title>Imaging glucose metabolism – <sup>18</sup>F-FDG</title><p><sup>18</sup>F-FDG PET has allowed monitoring of therapeutic response in brain tumors with a greater specificity than CT or MRI. <sup>18</sup>F-FDG, a glucose analog, is taken up by high-glucose-using cells, including normal brain and cancer cells. FDG is actively transported across the BBB into the cell and the <sup>18</sup>F-FDG-6-phosphate formed when <sup>18</sup>F-FDG enters the cell and prevents its further metabolism. As a result, the distribution of <sup>18</sup>F-FDG is a good reflection of the distribution of glucose uptake and utilization by cells in the body.</p><p>Since most cancer cells, including gliomas, demonstrate a high rate of glycolysis,<sup>96 18</sup>F-FDG helps in differentiation between tumor and normal brain tissue. It should be noted, however, that the correlation between <sup>18</sup>F-FDG uptake and glucose metabolism in tumors may differ from that in normal tissue.<xref rid="b97-cmar-6-149" ref-type="bibr">97</xref> In untreated tumor, the degree of <sup>18</sup>F-FDG uptake has been correlated with tumor grade: high-grade tumors demonstrate increased tracer uptake, and high uptake in a previously categorized low-grade tumor confirms anaplastic transformation of the tumor.<xref rid="b98-cmar-6-149" ref-type="bibr">98</xref>,<xref rid="b99-cmar-6-149" ref-type="bibr">99</xref> Quantitatively, ratios of <sup>18</sup>F-FDG uptake in tumors to that of white matter (>1.5) or gray matter (>0.6) were able to distinguish low-grade (grades I and II) from high-grade tumors (grades III and IV).<xref rid="b100-cmar-6-149" ref-type="bibr">100</xref> Based on a preliminary finding, delayed imaging at 3–8 hours after injection can further distinguish tumor and normal gray matter due to the faster tracer excretion in normal brain than in tumor.<xref rid="b101-cmar-6-149" ref-type="bibr">101</xref> However, after therapy the degree of tracer uptake does not necessarily correlate with tumor grade in that high-grade tumors may have uptake similar to or slightly above that of white matter.<xref rid="b102-cmar-6-149" ref-type="bibr">102</xref></p><p><sup>18</sup>F-FDG PET also plays a role in differentiating between recurrent or residual tumor and radiation necrosis (<xref ref-type="fig" rid="f4-cmar-6-149">Figures 4</xref> and <xref ref-type="fig" rid="f5-cmar-6-149">5</xref>). However, due to the <sup>18</sup>F-FDG uptake in normal brain, the sensitivity of detecting recurrent or residual tumor is low.<xref rid="b103-cmar-6-149" ref-type="bibr">103</xref>,<xref rid="b104-cmar-6-149" ref-type="bibr">104</xref> The specificity is also low in the initial few weeks post-therapy due to radiation necrosis. A study showed a sensitivity of 81%–86% and a specificity of 40%–94% for distinguishing between radiation necrosis and tumor.<xref rid="b105-cmar-6-149" ref-type="bibr">105</xref> It is thus recommended that <sup>18</sup>F-FDG PET should not be performed before 6 weeks after the completion of radiation treatment.</p><p>Recently, new issues have emerged regarding the evaluation of disease response, and also with the identification of patterns such as pseudoprogression, frequently indistinguishable from real disease progression,<xref rid="b106-cmar-6-149" ref-type="bibr">106</xref> and pseudoresponse. The Macdonald criteria,<xref rid="b107-cmar-6-149" ref-type="bibr">107</xref> widely used clinically as a guideline for evaluating therapeutic response in high-grade gliomas, uses contrast-enhanced CT and MRI, and defines progression as greater than a 25% increase in size of enhancing tumor. Enhancement of brain tumors, however, primarily reflects a disturbed BBB.</p><p>By definition, pseudoprogression of gliomas is a treatment-related reaction of the tumor with an increase in enhancement and/or edema on MRI, suggestive of tumor progression, but without increased tumor activity (<xref ref-type="fig" rid="f6-cmar-6-149">Figure 6</xref>). Typically, the absence of true tumor progression is shown by a stabilization or decrease in size of the lesion during further follow-up and without new treatment. Pseudoprogression occurs frequently after combined chemo-irradiation with temozolomide, the current standard of care for glioblastomas.<xref rid="b20-cmar-6-149" ref-type="bibr">20</xref>,<xref rid="b65-cmar-6-149" ref-type="bibr">65</xref></p><p>In an effort to identify patients likely to exhibit pseudoprogression, some studies have attempted to correlate MGMT promoter methylation status with pseudoprogression.<xref rid="b20-cmar-6-149" ref-type="bibr">20</xref> Studies have demonstrated that MGMT methylation status is an important biomarker for assessing primary brain tumors, as MGMT status has been shown to correlate with both therapy response and OS in GBM when therapy includes alkylating agents.<xref rid="b19-cmar-6-149" ref-type="bibr">19</xref>,<xref rid="b108-cmar-6-149" ref-type="bibr">108</xref> However, similar studies of MGMT promoter methylation in anaplastic oligodendrogliomas were unable to find a correlation between MGMT methylation status and either response rate, time-to-progression, or OS, suggesting that MGMT promoter methylation patterns may be dependent on cell type.<xref rid="b109-cmar-6-149" ref-type="bibr">109</xref></p><p>Another phenomenon, pseudoresponse, is the decrease in contrast-enhancement and/or edema of brain tumors on MRI without a true antitumor effect. It occurs after treatment with agents that induce a rapid normalization of abnormally permeable blood vessels or regional cerebral blood flow.<xref rid="b110-cmar-6-149" ref-type="bibr">110</xref> Recent trials on high-grade gliomas with agents that modify the signaling pathways of vascular endothelial growth factor (VEGF), formerly also known as the vascular permeability factor<xref rid="b111-cmar-6-149" ref-type="bibr">111</xref>,<xref rid="b112-cmar-6-149" ref-type="bibr">112</xref> (eg, bevacizumab, cediranib), have shown a rapid decrease in contrast enhancement with high response rate and 6-month PFS (PFS-6), but with rather modest effects on OS.<xref rid="b111-cmar-6-149" ref-type="bibr">111</xref>–<xref rid="b113-cmar-6-149" ref-type="bibr">113</xref></p><p>These two opposing phenomena emphasize that enhancement by itself is not a measure of tumor activity, but only reflects a disturbed BBB. A recent case report by our group emphasizes the value of <sup>18</sup>F-FDG PET when pseudoprogression is strongly suspected by the referring physician.<xref rid="b56-cmar-6-149" ref-type="bibr">56</xref> Currently, <sup>18</sup>F-FDG PET is not a clinically standard method for evaluating therapeutic response in high-grade gliomas, as it is only used for initial staging and to confirm suspected recurrence observed on gadolinium MRI (Gd-MRI). However, a central advantage of <sup>18</sup>F-FDG PET is that it can be used to determine the metabolic state of tumor cells, in contrast to Gd-MRI, which is limited to evaluating changes in size of contrast enhancement. This is an important distinction in comparing <sup>18</sup>F-FDG PET and Gd-MRI results, as changes in contrast enhancement are generally a conglomeration of many effects, such as local vascularity, changes in both normal and tumor cell density, necrosis, apoptosis, and BBB breakdown. All of these morphological changes are presumably preceded by changes in tumor metabolism, suggesting that, in many cases, <sup>18</sup>F-FDG PET may allow for comparatively faster discrimination of pseudoprogression from true progression and pseudoresponse from true response.</p><p>Recent efforts have focused on the coregistration of PET and MRI images, which has increased sensitivity over using either modality alone.<xref rid="b114-cmar-6-149" ref-type="bibr">114</xref>,<xref rid="b115-cmar-6-149" ref-type="bibr">115</xref> The simultaneous PET–MRI scan, which offers better MRI-based motion correction of PET data, is also being studied in more centers.<xref rid="b116-cmar-6-149" ref-type="bibr">116</xref>,<xref rid="b117-cmar-6-149" ref-type="bibr">117</xref></p></sec><sec><title>Amino acid PET tracers</title><p>Amino acid and amino acid analog PET tracers are better suited than <sup>18</sup>F-FDG for quantitative monitoring of tumor response due to higher tumor-to-normal-tissue contrast.<xref rid="b118-cmar-6-149" ref-type="bibr">118</xref>–<xref rid="b122-cmar-6-149" ref-type="bibr">122</xref> The use of amino acids for tumor imaging is based on the observation that amino acid transport is upregulated in malignant transformation.<xref rid="b123-cmar-6-149" ref-type="bibr">123</xref>,<xref rid="b124-cmar-6-149" ref-type="bibr">124</xref> Response after chemotherapy can be detected by amino acid PET early in the course of treatment,<xref rid="b125-cmar-6-149" ref-type="bibr">125</xref>–<xref rid="b127-cmar-6-149" ref-type="bibr">127</xref> suggesting that deactivation of amino acid transport is an early sign of response to chemotherapy. Amino acids are transported across the cell via a carrier-mediated mechanism.<xref rid="b128-cmar-6-149" ref-type="bibr">128</xref> For example, transport of the <sup>18</sup>F amino acid analog 3-O-methyl-6-<sup>18</sup>F-fluoro-L-DOPA via sodium-independent, high-capacity amino acid transport systems has been demonstrated in tumor cell lines.<xref rid="b129-cmar-6-149" ref-type="bibr">129</xref> In gliomas, increased amino acid uptake is mediated by type L amino acid carriers, which are upregulated in tumor vasculature.<xref rid="b124-cmar-6-149" ref-type="bibr">124</xref>,<xref rid="b130-cmar-6-149" ref-type="bibr">130</xref> This is in part attributed to the increased metabolic demand of tumor cells. Several amino acid tracers are available, though they are not FDA-approved in the US; eg, O-(2-<sup>18</sup>F-fluoroethyl)-L-tyrosine (FET), 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanine, and of <sup>11</sup>C methionine (MET).<xref rid="b131-cmar-6-149" ref-type="bibr">131</xref>,<xref rid="b132-cmar-6-149" ref-type="bibr">132</xref></p><p><italic>MET</italic>: The best-studied PET amino acid isotope has been l-[methyl-<sup>11</sup>C] methionine (<sup>11</sup>C-MET),<xref rid="b133-cmar-6-149" ref-type="bibr">133</xref> which is able to differentiate tumor recurrence from radiation necrosis.<xref rid="b134-cmar-6-149" ref-type="bibr">134</xref> However, due to the relatively short <sup>11</sup>C half-life of 20 minutes, it requires a nearby cyclotron. The extent of tracer uptake is greater than the degree of contrast enhancement indicative of better delineation of tumor margins.<xref rid="b135-cmar-6-149" ref-type="bibr">135</xref> In low-grade gliomas, the uptake is increased in the absence of BBB breakdown, which is a significant advantage over CT, conventional MRI, and <sup>18</sup>F-FDG PET.<xref rid="b136-cmar-6-149" ref-type="bibr">136</xref>,<xref rid="b137-cmar-6-149" ref-type="bibr">137</xref> The tracer uptake has been shown to correlate with prognosis and survival in low-grade gliomas.<xref rid="b138-cmar-6-149" ref-type="bibr">138</xref>,<xref rid="b139-cmar-6-149" ref-type="bibr">139</xref> In high-grade gliomas, <sup>11</sup>C-MET uptake is greater than in low-grade tumors,<xref rid="b140-cmar-6-149" ref-type="bibr">140</xref>–<xref rid="b142-cmar-6-149" ref-type="bibr">142</xref> establishing its potential for use in monitoring anaplastic transformation. In fact, recent findings show that increased <sup>11</sup>C-MET uptake during tumor growth parallels an upregulation of angiogenic markers such as VEGF.<xref rid="b143-cmar-6-149" ref-type="bibr">143</xref> Moreover, the addition of <sup>11</sup>C-MET PET changed patient management in half the cases.<xref rid="b144-cmar-6-149" ref-type="bibr">144</xref></p><p><sup>18</sup>F-FET (fluoro-3′-deoxy-3′-l-fluorothymidine) is another PET tracer studied for its potential role in the differentiation of radiation necrosis and residual tumor. Indeed, the absence of <sup>18</sup>F-FET uptake in a case of radiation necrosis was shown,<xref rid="b131-cmar-6-149" ref-type="bibr">131</xref> but further systematic studies are necessary to confirm this finding. In contrast to <sup>18</sup>F-FDG, <sup>18</sup>F-FET uptake was absent from macrophages, a common inflammatory mediator.<xref rid="b145-cmar-6-149" ref-type="bibr">145</xref> In another study, the ratio of <sup>18</sup>F-FET uptake in radiation necrosis to that in normal cortex was much lower than the corresponding ratios for <sup>18</sup>F-FDG and <sup>18</sup>F choline, supportive of its potential for differentiating radiation necrosis from tumor recurrence.<xref rid="b146-cmar-6-149" ref-type="bibr">146</xref></p><p>In the last decade, studies on combined <sup>18</sup>F-FET and MRI have shown improved identification of tumor tissue as compared with either modality alone.<xref rid="b147-cmar-6-149" ref-type="bibr">147</xref>,<xref rid="b148-cmar-6-149" ref-type="bibr">148</xref> The specificity of distinguishing gliomas from normal tissue could be increased from 68% with the use of MRI alone to 97% with the use of MRI in conjunction with <sup>18</sup>F-FET PET and MRI spectroscopy.<xref rid="b149-cmar-6-149" ref-type="bibr">149</xref></p></sec><sec><title>Nucleic acid analogs – <sup>18</sup>F-FLT</title><p>The pyrimidine analog, <sup>18</sup>F-FLT, is a PET radiotracer specifically used for noninvasive in vivo evaluation of the cell proliferation rate. <sup>18</sup>F-FLT reflects the activity of thymidine kinase-1 during phase S of DNA synthesis.<xref rid="b150-cmar-6-149" ref-type="bibr">150</xref><sup>18</sup>F-FLT, introduced by Shields et al for PET imaging of tumor proliferation in animals and humans,<xref rid="b151-cmar-6-149" ref-type="bibr">151</xref> has been used in both preclinical and clinical studies.<xref rid="b152-cmar-6-149" ref-type="bibr">152</xref>,<xref rid="b153-cmar-6-149" ref-type="bibr">153</xref> Transport of <sup>18</sup>F-FLT is mediated by both passive diffusion and Na<sup>+</sup>-dependent carriers. The tracer is subsequently phosphorylated by thymidine kinase 1 (TK<sub>1</sub>) into <sup>18</sup>F-FLT-monophosphate, where TK<sub>1</sub> is a principal enzyme in the salvage pathway of DNA synthesis. Whereas the TK<sub>1</sub> activity is virtually absent in quiescent cells, its activity reaches the maximum in the late G<sub>1</sub> and S phases of the cell cycle in proliferating cells.<xref rid="b154-cmar-6-149" ref-type="bibr">154</xref> The phosphorylation of the tracer by TK<sub>1,</sub> therefore, makes <sup>18</sup>F-FLT a good marker for tumor proliferation.</p><p>Recent findings suggest that <sup>18</sup>F-FLT is a promising biomarker for differentiating between radiation necrosis and tumor recurrence (<xref ref-type="fig" rid="f7-cmar-6-149">Figure 7</xref>).<xref rid="b155-cmar-6-149" ref-type="bibr">155</xref>,<xref rid="b156-cmar-6-149" ref-type="bibr">156</xref> A study by Hatakeyama et al<xref rid="b155-cmar-6-149" ref-type="bibr">155</xref> showed its superiority over <sup>11</sup>C-MET in tumor grading. Chen et al demonstrated <sup>18</sup>F-FLT PET as a promising imaging biomarker that seems to be predictive of OS in bevacizumab and irinotecan treatment of recurrent gliomas in which both early and later <sup>18</sup>F-FLT PET responses were more significant predictors of OS compared with the MRI responses.<xref rid="b157-cmar-6-149" ref-type="bibr">157</xref> In addition, a recent prospective study by Schwarzenberg et al<xref rid="b158-cmar-6-149" ref-type="bibr">158</xref> showed that <sup>18</sup>F-FLT uptake was highly predictive of PFS and OS in patients with recurrent gliomas on bevacizumab therapy (Avastin®; Genentec, South San Francisco, CA, USA; a recombinant humanized monoclonal antibody targeting VEGF, a protein released by tumor cells to recruit novel blood vessels to support tumor growth),<xref rid="b159-cmar-6-149" ref-type="bibr">159</xref>,<xref rid="b160-cmar-6-149" ref-type="bibr">160</xref> and that <sup>18</sup>F-FLT PET seems to be more predictive than MRI for early treatment response.</p></sec><sec><title>Hypoxia imaging – <sup>18</sup>F-fluoromisonidazole</title><p><sup>18</sup>F-Fluoromisonidazole is a nitroimidazole derivative PET agent used to image hypoxia,<xref rid="b161-cmar-6-149" ref-type="bibr">161</xref> a physiologic marker for tumor progression and resistance to radiotherapy (RT).<xref rid="b162-cmar-6-149" ref-type="bibr">162</xref> Its preferential uptake in high-grade rather than low-grade gliomas,<xref rid="b163-cmar-6-149" ref-type="bibr">163</xref> a significant relationship with upregulation of angiogenic markers such as VEGF receptor 1,<xref rid="b164-cmar-6-149" ref-type="bibr">164</xref> and correlation to progression and survival after RT,<xref rid="b165-cmar-6-149" ref-type="bibr">165</xref> suggest its potential role in monitoring response to therapy targeting hypoxic tissue.</p></sec></sec></sec><sec><title>Biopsy</title><p>A tissue diagnosis can be obtained at the time of surgical resection or through stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, or when a meaningful amount of tumor tissue cannot be resected, or the patient’s overall clinical condition will not permit invasive surgery.</p><p>Stereotactic image-guided brain biopsy is an accurate and safe diagnostic procedure in patients with focal lesions.<xref rid="b166-cmar-6-149" ref-type="bibr">166</xref>,<xref rid="b167-cmar-6-149" ref-type="bibr">167</xref> The combined use of computerized imaging and stereotactic framing devices allows neurosurgeons to perform deep brain biopsies with continuous and accurate intraoperative tumor localization. Frameless stereotaxy establishes a computerized link between the preoperative three-dimensional tumor volume and the surface landmarks of the patient. This link permits the neurosurgeon to be aware of the three-dimensional position of surgical instruments within the intracranial space during the biopsy based upon the preoperative imaging, with an accuracy of 1 mm within the intracranial space.</p></sec></sec><sec><title>Treatment</title><p>After decades of minimal incremental advances in outcomes for multimodality treatment of malignant gliomas, the last decade has seen a series of transformative clinical trials establish new standards of care. At the same time, the limitations of these transformative strategies have raised new questions for therapeutic clinical trials. Addressing these questions requires innovative neuroimaging strategies to better assess treatment response. The application of molecular neuropathology, quantitative imaging of tumor response, and systematic evaluation of molecularly targeted therapies, as well as cytotoxic chemotherapy are expected to improve outcomes even further.</p><sec><title>Surgery</title><p>Surgical resection has been a critical component of the multimodality management of malignant gliomas since the advent of modern neurosurgery and the original case series by Cushing and Dandy.<xref rid="b168-cmar-6-149" ref-type="bibr">168</xref> The role of neurosurgery has expanded in recent years to include techniques for intratumoral delivery of drugs, monoclonal antibodies, viral gene vectors, and immunotherapeutics. Resection or image-guided techniques for accessing the tumor microenvironment are increasingly critical components of therapeutic clinical trials as they help to show drug delivery to the tumor site and to verify that the anticipated physiologic effects relevant to the mode of action of the drug have occurred.<xref rid="b169-cmar-6-149" ref-type="bibr">169</xref>,<xref rid="b170-cmar-6-149" ref-type="bibr">170</xref> In the era of molecularly-targeted therapies and personalized therapeutics, determination of the pattern of genetic and epigenetic changes in tumor tissue is critical to understanding the mechanisms of tumor response and resistance.<xref rid="b171-cmar-6-149" ref-type="bibr">171</xref></p><p>For GBM patients, there is compelling, though not level-one evidence, that maximal resection of newly diagnosed tumor improves survival.<xref rid="b172-cmar-6-149" ref-type="bibr">172</xref>–<xref rid="b174-cmar-6-149" ref-type="bibr">174</xref> For anaplastic astrocytoma and anaplastic oligodendrogliomas, the survival benefit of aggressive surgical resection is less clearly documented, but expert consensus supports similar resection goals as for GBM patients.<xref rid="b175-cmar-6-149" ref-type="bibr">175</xref> Maximal surgical resection provides the advantages of rapid cytoreduction, relief of symptoms related to mass effect, allows for institution of fractionated radiation therapy and chemotherapy with reduced target volumes, and provides tissue for diagnosis.<xref rid="b168-cmar-6-149" ref-type="bibr">168</xref></p><p>Image-guided resection and the incorporation of functional MRI information as well as intraoperative mapping has allowed for resection of tumors in close proximity to eloquent cortical structures and expanded the indications for resection.<xref rid="b176-cmar-6-149" ref-type="bibr">176</xref>–<xref rid="b181-cmar-6-149" ref-type="bibr">181</xref> Innovations in MRI design have allowed for intraoperative MRI, in which the neurosurgeon can assess completeness of resection prior to closure of the craniotomy.</p><p>Minimally invasive neurosurgical techniques, exemplified by endoscopic resection techniques<xref rid="b182-cmar-6-149" ref-type="bibr">182</xref> are being applied to resection of malignant gliomas, facilitating more complete resection of deeply located tumors, and intraventricular or periventricular tumors.<xref rid="b183-cmar-6-149" ref-type="bibr">183</xref> Neurosurgical techniques for intratumoral drug delivery are also being investigated. Stereotactic MRI or CT-guided techniques allow for biopsy and intratumoral delivery of therapeutic agents, though limited capacity for diffusion limits this technique in most settings. Microdialysis catheters placed at the time of tumor resection allow direct measurement of drug pharmacodynamics in clinical trials of systemically administered agents.</p></sec><sec><title>RT</title><p>Shortly after the initial attempts to control malignant gliomas with aggressive surgical resection, neurosurgeons and oncologists turned to EBRT as the second component of multimodality therapy. Seminal clinical trials by the early brain tumor clinical trial collaborative groups demonstrated that EBRT prolongs survival as compared with surgery alone, for GBM, anaplastic astrocytoma, and anaplastic oligodendrogliomas.<xref rid="b184-cmar-6-149" ref-type="bibr">184</xref>–<xref rid="b186-cmar-6-149" ref-type="bibr">186</xref> Collaborative group trials established optimal dose and fractionation schema for the different histologies and grades of malignant tumors.</p><p>Involved field radiation therapy, which involved delivery of RT only to involved regions of the brain, has become the standard approach for adjuvant RT. The rationale for limiting the RT field is based upon the observation that, following whole brain radiation therapy, recurrent malignant gliomas develop within 2 cm of the original tumor site in 80%–90% of cases, while fewer than 10% are multifocal.<xref rid="b187-cmar-6-149" ref-type="bibr">187</xref>–<xref rid="b189-cmar-6-149" ref-type="bibr">189</xref> To encompass infiltrating tumor cells, the RT dose of typically 60 Gray is usually delivered to the tumor plus a margin of radiographically apparently normal tissue. If the tumor is defined based upon contrast enhancement, a margin of 2.0 to 3.0 cm is often used, while if the RT field is defined by T2-weighted MRI abnormality, a 1.0 to 2.0 cm margin is used.</p><p>Over the past 3 decades, innovations in computer-based three-dimensional treatment planning have led to an increase in conformal radiation therapy. In academic centers of excellence, as well as in the community, these techniques have provided a new approach to treat malignant gliomas using an increased dose with less morbidity. Current three-dimensional conformal radiation therapy utilizes CT-based treatment planning with dosimetric software to create composite treatment plans. The fusion of planning CT with MRI is extremely helpful in assisting with target definition.<xref rid="b190-cmar-6-149" ref-type="bibr">190</xref>,<xref rid="b191-cmar-6-149" ref-type="bibr">191</xref> The incorporation of PET or MRS data is still largely investigational and most commonly used to define boost volumes rather than primary target volumes. Photons of 6 to 8 MV are most commonly used with three to four angled radiation fields. Radiation oncologists work with medical physicists and dosimetrists to design optimal treatment plans. Optimization requires the consideration of beam energy, field size and shape, beam modifiers, irradiated tissue density and heterogeneity, and radiation tolerance of surrounding normal tissues. No benefit in PFS or OS has been demonstrated, although these techniques help avoid excess RT to normal brain.<xref rid="b192-cmar-6-149" ref-type="bibr">192</xref>,<xref rid="b193-cmar-6-149" ref-type="bibr">193</xref></p><p>In the past several years, intensity-modulated radiation therapy (IMRT), at least for academic radiation oncology centers, has been the technique of choice due to the elegance and precision of the dosimetry, especially if the tumor is in close proximity to radiosensitive structures such as the optic nerve. The IMRT technique uses advanced technology to manipulate beams of radiation to conform to the shape of a tumor. It uses nonuniform small radiation beams of varying intensities to deliver a treatment plan that maximizes the homogenous delivery of radiation to the intended treatment volume, while minimizing irradiation to normal tissue outside the target. The radiation intensity of each beam is controlled, and the beam shape changes throughout each treatment. The goal of IMRT is to bend the radiation dose to avoid or reduce exposure of healthy tissue and limit the side effects of treatment. The application of IMRT in the treatment of malignant gliomas has become increasingly prevalent as it may decrease radiation-related adverse effects.<xref rid="b194-cmar-6-149" ref-type="bibr">194</xref> IMRT can also be used to escalate doses to the tumor, but there are no proven benefits to delivering doses beyond 60 Gray.<xref rid="b195-cmar-6-149" ref-type="bibr">195</xref> The most appropriate application of IMRT in the brain will likely be when the radiation target abuts radiation-sensitive structures such as the eyes, optic nerves, optic chiasm, or brainstem. The disadvantages of IMRT include increased radiation scattering to surrounding non-target tissues and the complexity of radiation planning, which requires adaptation of the hardware of linear accelerators, skilled physicist support, and increased delivery time for treatment.</p><p>Despite decades of trials investigating permutations of total dose and fractionation schemes, the typical one per day treatment with external beam, 5 days per week, has remained the standard of care. With present technologies and strategies for radioprotection of normal structures, improvements in survival are unlikely to result from modifications in total dose or fraction size.</p><p>Proton beam RT is being investigated in the treatment of low-grade gliomas, medulloblastomas and ependymomas, and in malignant gliomas. At present, there is no level-one evidence that proton beam therapy improves survival in either the newly diagnosed or recurrent setting for GBM or anaplastic astrocytoma and oligodendroglioma. As with IMRT, proton techniques may have a specialized role in treatment of targets close to critical radiosensitivestructures.</p><p>Stereotactic radiosurgery has been used to boost fractionated RT for the treatment of newly diagnosed GBM following either biopsy or resection.<xref rid="b196-cmar-6-149" ref-type="bibr">196</xref>–<xref rid="b198-cmar-6-149" ref-type="bibr">198</xref> Stereotactic radiosurgery uses three-dimensional planning techniques to precisely deliver narrowly collimated beams of ionizing radiation in a single high-dose fraction to small (<4 cm) intracranial targets. When this approach is divided into several factions it is called stereotactic RT.</p><p>In some centers, Gamma Knife radiosurgery is used, in which a hemispherical compartment with an array of cobalt-60 sources is the source of collimated beams. The Gamma Knife uses a fixed frame to stabilize the head relative to the radiation sources.</p><p>Frameless linear-accelerator-based stereotactic radiosurgery employs a linear accelerator that moves in multiple arcs around the target volume. The linear accelerator techniques do not employ a fixed frame, and the relationship of the target volume to the radiation source is determined by registration of fiducials.</p><p>Radiosurgery has transformed the treatment of brain metastasis and benign tumors such as acoustic schwannoma, but has yet to claim a clear role in the treatment of malignant gliomas.<xref rid="b199-cmar-6-149" ref-type="bibr">199</xref>–<xref rid="b202-cmar-6-149" ref-type="bibr">202</xref> In the newly diagnosed setting, radiosurgery in conjunction with fractionated EBRT has not improved survival outcomes. However, in the recurrent setting, radiosurgery is an FDA-approved treatment modality, but progression at the margin of the target is a ubiquitous pattern of failure. More recently, radiosurgery has been combined with bevacizumab therapy. Initial institutional Phase II trials of this combination have not demonstrated superior time-to-progression or OS than either treatment alone, but some patients have durable tumor control.<xref rid="b203-cmar-6-149" ref-type="bibr">203</xref> The nuances in designing treatment fields may be critical in this setting.<xref rid="b204-cmar-6-149" ref-type="bibr">204</xref></p></sec><sec><title>Chemotherapy/drug therapy</title><p>The current standard of care for newly diagnosed GBM combines surgical resection, RT and adjuvant temozolomide treatment, leading to an increased median survival time<xref rid="b205-cmar-6-149" ref-type="bibr">205</xref> of approximately 14.6 months. The EORTC trial<xref rid="b206-cmar-6-149" ref-type="bibr">206</xref> established that concomitant low-dose temozolomide and external beam fractionated radiation followed by adjuvant temozolomide results in a survival benefit to the chemotherapy arm versus radiation alone. The trial demonstrated a benefit in OS to the group receiving chemotherapy, and a tripling of the percentage of patients alive 2 years after therapy. Subsequent prospective trials showed that a dose-intensive adjuvant temozolomide regimen in which patients received 75 mg/m<sup>2</sup> daily for 21 days followed by a 7-day rest was not superior to the shorter monthly courses of temozolomide.</p><p>Management of newly diagnosed anaplastic oligodendroglioma is now based on level-one evidence. Two prospective randomized trials comparing external beam radiation alone to radiation therapy plus alkylator-based adjuvant or neoadjuvant chemotherapy were initially reported as showing no survival benefit with the addition of chemotherapy.<xref rid="b11-cmar-6-149" ref-type="bibr">11</xref>,<xref rid="b13-cmar-6-149" ref-type="bibr">13</xref> However, long-term follow-up demonstrated that for patients with tumors expressing 1p/19q deletions, chemotherapy confers a significant survival advantage.<xref rid="b11-cmar-6-149" ref-type="bibr">11</xref>,<xref rid="b13-cmar-6-149" ref-type="bibr">13</xref> The predictive value of the 1p deletion status makes this one of the first robust predictive biomarkers for malignant gliomas. In addition to the impact of 1p deletion status on outcome, these anaplastic oligodendroglioma studies also led to the delineation of subgroups of tumors with prognostic significance using microarray genome-wide expression analysis.<xref rid="b207-cmar-6-149" ref-type="bibr">207</xref> It is clear that future studies of anaplastic oligodendrogliomas and astrocytomas will need to include stratification by prognostic subgroups.</p><p>For newly diagnosed anaplastic astrocytoma, the optimal application of radiation and chemotherapy is an active clinical trial question.<xref rid="b208-cmar-6-149" ref-type="bibr">208</xref> The EORTC and the Radiation Therapy Oncology Group (RTOG) are conducting a randomized prospective trial comparing fractionated radiation therapy alone, to 1) radiation followed by adjuvant temozolomide, to 2) concurrent chemoradiation without subsequent adjuvant therapy, and to 3) the regimen of concurrent chemoradiation followed by adjuvant chemotherapy that is the standard treatment for GBM.<xref rid="b209-cmar-6-149" ref-type="bibr">209</xref>,<xref rid="b210-cmar-6-149" ref-type="bibr">210</xref> In addition, these prospective randomized trials are stratifying tumors based on MGMT promoter methylation status and molecular biomarkers.<xref rid="b208-cmar-6-149" ref-type="bibr">208</xref></p><p>For patients with recurrent GBM, treatment outcomes are poor; the median time to tumor progression is 9 weeks, and the median survival is 25 weeks.<xref rid="b211-cmar-6-149" ref-type="bibr">211</xref> PFS is correlated with OS and has become the benchmark for assessing treatment efficacy in patients with recurrent GBM in whom the PFS-6 rate ranges between 9% and 15%.<xref rid="b211-cmar-6-149" ref-type="bibr">211</xref>–<xref rid="b213-cmar-6-149" ref-type="bibr">213</xref> For recurrent GBM and anaplastic astrocytoma, the transformative trials involve the use of anti-angiogenic drugs.<xref rid="b214-cmar-6-149" ref-type="bibr">214</xref> The RTOG has completed two prospective randomized trials; one comparing two different adjuvant temozolomide regimens and another evaluating the efficacy of bevacizumab.<xref rid="b215-cmar-6-149" ref-type="bibr">215</xref>,<xref rid="b216-cmar-6-149" ref-type="bibr">216</xref></p><p>Glioblastomas due to expression of a variety of pro-angiogenic factors are among the most vascular tumors. Angiogenesis is a critical process in the progression of gliomas.<xref rid="b217-cmar-6-149" ref-type="bibr">217</xref> One of the main determinants of angiogenesis is VEGF, which is secreted by glioma cells to induce the tumor vascularization that in turn facilitates growth of the tumor.<xref rid="b218-cmar-6-149" ref-type="bibr">218</xref> High expression of VEGF is correlated with poor clinical outcome, and it has been demonstrated that inhibition of VEGF decreases the growth of glioma cell lines.<xref rid="b219-cmar-6-149" ref-type="bibr">219</xref> High-grade gliomas with a high degree of VEGF expression and vessel density respond best to anti-angiogenic therapy.<xref rid="b220-cmar-6-149" ref-type="bibr">220</xref></p><p>Bevacizumab is an anti-angiogenic agent for GBM and received accelerated FDA approval for use in patients with recurrent GBM in 2009.<xref rid="b221-cmar-6-149" ref-type="bibr">221</xref> Bevacizumab (Avastin) is a humanized monoclonal antibody that binds VEGF, thereby preventing the interaction of VEGF with its receptors VEGF receptor 1 and VEGF receptor 2. Blocking VEGF activity halts angiogenesis. The half-life of bevacizumab is approximately 20 days, so it is administered every 2 weeks and sometimes every 3 weeks. In Phase II studies in previously treated patients with malignant glioma, bevacizumab reduced requirements for steroids and was associated with imaging evidence of tumor response. These results have led to approval of bevacizumab for recurrent malignant glioma as well as investigation of bevacizumab as a component of initial combined modality therapy.<xref rid="b222-cmar-6-149" ref-type="bibr">222</xref></p><p>Bevacizumab has demonstrated significant activity in Phase II trials.<xref rid="b221-cmar-6-149" ref-type="bibr">221</xref> Bevacizumab alone or in combination with irinotecan resulted in response rates and time-to-progression that were substantially superior to historical controls with a range of cytotoxic regimens, and superior to results with any other molecularly-targeted drug therapy evaluated previously.<xref rid="b223-cmar-6-149" ref-type="bibr">223</xref> However, the value of bevacizumab in the treatment of recurrent GBM remains uncertain since responses in GBM trials have not been durable. Norden et al<xref rid="b224-cmar-6-149" ref-type="bibr">224</xref> compared PFS and OS of patients treated with bevacizumab with two contemporaneous trials of cytotoxic chemotherapy testing gimatecan and edotecarin. Median PFS in the bevacizumab cohort was 22 weeks, compared to only 8 weeks for the chemotherapy cohorts, and PFS-6 was 40% versus 11%. However, median OS was only 37 weeks in the bevacizumab cohort versus 39 weeks for the chemotherapy cohorts.<xref rid="b224-cmar-6-149" ref-type="bibr">224</xref> Bevacizumab appears to have an effect on PFS, but only modest effects on OS.<xref rid="b225-cmar-6-149" ref-type="bibr">225</xref> When patients progress through bevacizumab, the prognosis is dismal, with PFS of subsequent therapies being 4 weeks and PFS-6 being only 14%.<xref rid="b226-cmar-6-149" ref-type="bibr">226</xref>,<xref rid="b227-cmar-6-149" ref-type="bibr">227</xref> Current and future trials evaluating combination therapies with molecularly-targeted drugs and bevacizumab have evolved a template structure in which bevacizumab is administered every 2 weeks in 28-day cycles, and the investigational agent is added to the monthly cycles with the scheduling dependent upon the biologic effect of the agent.</p><p>Although bevacizumab clearly produces a clinical improvement by decreasing the size of the contrast-enhancing mass lesion as well as ameliorating perilesion edema, the extent to which the drug is modifying the physiology of the BBB rather than killing tumor cells remains complex. When tumors progress after exposure to bevacizumab, subsequent therapies with cytotoxic chemotherapy are uniformly ineffective. In current practice, there is an emerging consensus that bevacizumab should be reserved for patients in whom the tumor is causing neurologic symptoms due to its size and surrounding edema.<xref rid="b228-cmar-6-149" ref-type="bibr">228</xref> The ability of bevacizumab to suppress the early toxicities of radiation therapy has facilitated re-exploration of reirradiation with fractionated external beam techniques as well as radiosurgery for recurrent malignant gliomas. Several institutional trials<xref rid="b229-cmar-6-149" ref-type="bibr">229</xref>,<xref rid="b230-cmar-6-149" ref-type="bibr">230</xref> have reported results of combining radiosurgery with Avastin in recurrent GBM and anaplastic astrocytoma. Although bevacizumab clearly reduces the early perilesion edema associated with radiosurgical treatment of recurrent malignant gliomas and produces radiologic responses by RANO criteria, it remains unproven whether the combination of radiosurgery and Avastin produces a more durable response, as measured by OS, than radiosurgery or bevacizumab alone.</p><p>Preliminary randomized Phase III trial results do not recommend the routine use of bevacizumab in combination with standard RT and temozolomide in patients with newly diagnosed glioblastoma.<xref rid="b231-cmar-6-149" ref-type="bibr">231</xref>,<xref rid="b232-cmar-6-149" ref-type="bibr">232</xref> This recommendation is based on the lack of proven survival benefit for bevacizumab when used as part of initial therapy and the increased risk of toxicity associated with combination therapy. Certain subsets of patients may ultimately be shown to benefit from early use of bevacizumab, such as those patients with bulky, nonresectable tumors, but further study is needed. Preliminary results from two Phase III clinical trials<xref rid="b231-cmar-6-149" ref-type="bibr">231</xref>,<xref rid="b232-cmar-6-149" ref-type="bibr">232</xref> assessing the role of bevacizumab in conjunction with RT plus temozolomide include the AVAglio study, in which 921 patients were randomly assigned to receive bevacizumab or placebo in conjunction with RT and temozolomide.<xref rid="b231-cmar-6-149" ref-type="bibr">231</xref> After completion of RT, patients were treated with six cycles of monthly temozolomide plus bevacizumab or placebo every 2 weeks, followed by maintenance bevacizumab or placebo every 3 weeks until progression. At the time of the preliminary analysis, 76% of the expected events had occurred. They concluded that median PFS was improved in patients treated with bevacizumab compared with placebo (10.6 versus 6.2 months; hazard ratio 0.64, 95% confidence interval 0.55 to 0.74). However, median OS was not significantly different (hazard ratio 0.89, 95% confidence interval 0.75 to 1.07). As well, there was an increase in the rate of serious adverse events in patients treated with bevacizumab.</p><p>In the RTOG 0825 study, 637 patients were randomly assigned to receive bevacizumab or placebo starting at week 4 of standard chemoradiation with temozolomide, followed by six to 12 cycles of maintenance temozolomide plus bevacizumab or placebo.<xref rid="b232-cmar-6-149" ref-type="bibr">232</xref> The conclusion was that PFS was extended in patients treated with bevacizumab (10.7 versus 7.3 months; <italic>P</italic>=0.004), but the result did not meet the predefined significance threshold of <italic>P</italic><0.002. Median OS did not differ in patients treated with bevacizumab compared with placebo (15.7 versus 16.1 months, <italic>P</italic>=0.11). Notably, MGMT promoter methylation was strongly associated with improved PFS (14 versus 8 months for methylated versus unmethylated promoter, respectively) and OS (23 versus 14 months, respectively). In the subset of patients whose tumors exhibited both MGMT promoter methylation and a favorable nine-gene signature, there was a trend towards worse survival in patients treated with bevacizumab compared with placebo (15.7 versus 25 months, <italic>P</italic>=0.08). In addition, there was an increased rate of serious adverse events in patients treated with bevacizumab; primarily neutropenia, hypertension, and thromboembolism.</p><p>For recurrent anaplastic astrocytomas, the optimal chemotherapy regimens remain an active clinical trial question. A randomized prospective trial<xref rid="b233-cmar-6-149" ref-type="bibr">233</xref> for anaplastic astrocytomas at first relapse after fractionated RT alone compared the older regimen PCV to standard (150–200 mg/m<sup>2</sup>/day for days 1–5 of 28-day cycles) temozolomide and dose-intensive temozolomide (75 mg/m<sup>2</sup>/day for days 1–21 of 28-day cycles). The day 1–5 regimen was not inferior to PCV, but the more dose-intense regimen was counterintuitively less effective. The optimal regimens for patients relapsing after prior chemoradiation or adjuvant chemotherapy remain to be determined.</p><p>For recurrent anaplastic oligodendrogliomas, alkylator-based chemotherapy is the mainstay of treatment, but as for astrocytomas, the optimal regimen and schedules are currently being pursued.<xref rid="b12-cmar-6-149" ref-type="bibr">12</xref>,<xref rid="b234-cmar-6-149" ref-type="bibr">234</xref>–<xref rid="b236-cmar-6-149" ref-type="bibr">236</xref> A study by Lassman<xref rid="b12-cmar-6-149" ref-type="bibr">12</xref> of anaplastic oligodendrogliomas suggest that for 1p/19q deleted tumors, the older PCV regimen may be associated with better outcomes. Despite this retrospective data, temozolomide continues to be more widely used in the US.</p><p>Despite a quarter century of disappointing results and evidence that the malignant gliomas microenvironment was inhospitable to cytotoxic T cells and natural killer cells, a relentless cadre of investigators has produced Phase II data suggesting that vaccine immunotherapy strategies can produce antitumor immune responses.<xref rid="b237-cmar-6-149" ref-type="bibr">237</xref> In a study of newly diagnosed GBM tumors expressing the EGFRvIII oncoprotein antigen, an anti-EGFRviii dendritic cell vaccine demonstrated improved time-to-progression and OS as compared with a contemporaneous historical control data set.<xref rid="b238-cmar-6-149" ref-type="bibr">238</xref> With all the caveats pertaining to historical control analysis and potential differences in distribution of molecular prognostic subgroups, vaccine therapies are demonstrating sufficient evidence of efficacy to warrant Phase III trials. As with clinical trials evaluating anti-angiogenic agents, criteria for determining tumor response and progression must be adapted to account for transient immune-mediated inflammatory responses that might be mistaken for development of tumor progression.<xref rid="b239-cmar-6-149" ref-type="bibr">239</xref></p></sec></sec><sec><title>Summary</title><p>In recent times, there has been important progress in our understanding of the molecular pathogenesis of malignant gliomas, leading to the development of targeted chemotherapeutic agents. Additionally, advances in diagnostic imaging have allowed for early diagnosis and treatment of malignant gliomas. As our understanding of the molecular pathogenesis and molecular imaging improves, it may be possible to select the most appropriate therapies on the basis of the patient’s tumor genotype. Furthermore, quantitative imaging biomarker assessment in the early phase of clinical trials could provide a novel approach for testing new therapies, and importantly, for facilitating patient management, sparing patients from weeks or months of toxicity due to ineffective treatment.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was support by the US National Institutes of Health research grant U01 CA140230, as well as the University of Pittsburgh Cancer Institute shared resources award P30CA047904. We also acknowledge the editorial support from Ms Moira Hitchens, Administrator, Department of Radiology, University of Pittsburgh.</p><p>This work was performed at the Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cmar-6-149"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>HR</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title><source>Int J Cancer</source><year>2010</year><volume>127</volume><issue>12</issue><fpage>2893</fpage><lpage>2917</lpage><pub-id pub-id-type="pmid">21351269</pub-id></element-citation></ref><ref id="b2-cmar-6-149"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Ohgaki</surname><given-names>H</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><etal></etal></person-group><article-title>The 2007 WHO classification of tumours of the central nervous system</article-title><source>Acta Neuropathol</source><year>2007</year><volume>114</volume><issue>2</issue><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">17618441</pub-id></element-citation></ref><ref id="b3-cmar-6-149"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Gittleman</surname><given-names>H</given-names></name><name><surname>Farah</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2006–2010</article-title><source>Neuro-Oncol</source><year>2013</year><volume>15</volume><issue>sup 2</issue><fpage>ii1</fpage><lpage>ii56</lpage><pub-id pub-id-type="pmid">24137015</pub-id></element-citation></ref><ref id="b4-cmar-6-149"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleihues</surname><given-names>P</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><etal></etal></person-group><article-title>The WHO classification of tumors of the nervous system</article-title><source>J Neuropathol Exp Neurol</source><year>2002</year><volume>61</volume><issue>3</issue><fpage>215</fpage><lpage>225</lpage><comment>discussion 226–229</comment><pub-id pub-id-type="pmid">11895036</pub-id></element-citation></ref><ref id="b5-cmar-6-149"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>JL</given-names></name><name><surname>Schwartzbaum</surname><given-names>JA</given-names></name><name><surname>Wrensch</surname><given-names>M</given-names></name><name><surname>Wiemels</surname><given-names>JL</given-names></name></person-group><article-title>Epidemiology of brain tumors</article-title><source>Neurol Clin</source><year>2007</year><volume>25</volume><issue>4</issue><fpage>867</fpage><lpage>890</lpage><comment>vii</comment><pub-id pub-id-type="pmid">17964019</pub-id></element-citation></ref><ref id="b6-cmar-6-149"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name><name><surname>Sloan</surname><given-names>AE</given-names></name><name><surname>Davis</surname><given-names>FG</given-names></name><name><surname>Vigneau</surname><given-names>FD</given-names></name><name><surname>Lai</surname><given-names>P</given-names></name><name><surname>Sawaya</surname><given-names>RE</given-names></name></person-group><article-title>Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>14</issue><fpage>2865</fpage><lpage>2872</lpage><pub-id pub-id-type="pmid">15254054</pub-id></element-citation></ref><ref id="b7-cmar-6-149"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>FG</given-names></name><name><surname>Dolecek</surname><given-names>TA</given-names></name><name><surname>McCarthy</surname><given-names>BJ</given-names></name><name><surname>Villano</surname><given-names>JL</given-names></name></person-group><article-title>Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data</article-title><source>Neuro Oncol</source><year>2012</year><volume>14</volume><issue>9</issue><fpage>1171</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">22898372</pub-id></element-citation></ref><ref id="b8-cmar-6-149"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Salunke</surname><given-names>P</given-names></name></person-group><article-title>Molecular markers of glioma: an update on recent progress and perspectives</article-title><source>J Cancer Res Clin Oncol</source><year>2012</year><volume>138</volume><issue>12</issue><fpage>1971</fpage><lpage>1981</lpage><pub-id pub-id-type="pmid">23052697</pub-id></element-citation></ref><ref id="b9-cmar-6-149"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olar</surname><given-names>A</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name></person-group><article-title>Biomarkers classification and therapeutic decision-making for malignant gliomas</article-title><source>Curr Treat Options Oncol</source><year>2012</year><volume>13</volume><issue>4</issue><fpage>417</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">22956341</pub-id></element-citation></ref><ref id="b10-cmar-6-149"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>KH</given-names></name><name><surname>Villano</surname><given-names>JL</given-names></name><name><surname>Nikiforova</surname><given-names>MN</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Horbinski</surname><given-names>C</given-names></name></person-group><article-title>1p/19q testing has no significance in the workup of glioblastomas</article-title><source>Neuropathol Appl Neurobiol</source><year>2013</year><volume>39</volume><issue>6</issue><fpage>706</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">23363074</pub-id></element-citation></ref><ref id="b11-cmar-6-149"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairncross</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>3</issue><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">23071247</pub-id></element-citation></ref><ref id="b12-cmar-6-149"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassman</surname><given-names>AB</given-names></name></person-group><article-title>Success at last: a molecular factor that informs treatment</article-title><source>Curr Oncol Rep</source><year>2013</year><volume>15</volume><issue>1</issue><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">23247800</pub-id></element-citation></ref><ref id="b13-cmar-6-149"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Brandes</surname><given-names>AA</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>3</issue><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">23071237</pub-id></element-citation></ref><ref id="b14-cmar-6-149"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bello</surname><given-names>MJ</given-names></name><name><surname>de Campos</surname><given-names>JM</given-names></name><name><surname>Kusak</surname><given-names>ME</given-names></name><etal></etal></person-group><article-title>Allelic loss at 1p is associated with tumor progression of meningiomas</article-title><source>Genes Chromosomes Cancer</source><year>1994</year><volume>9</volume><issue>4</issue><fpage>296</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">7519053</pub-id></element-citation></ref><ref id="b15-cmar-6-149"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reifenberger</surname><given-names>J</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>James</surname><given-names>CD</given-names></name><name><surname>Wechsler</surname><given-names>W</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name></person-group><article-title>Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p</article-title><source>Am J Pathol</source><year>1994</year><volume>145</volume><issue>5</issue><fpage>1175</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">7977648</pub-id></element-citation></ref><ref id="b16-cmar-6-149"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichimura</surname><given-names>K</given-names></name></person-group><article-title>Molecular pathogenesis of IDH mutations in gliomas</article-title><source>Brain Tumor Pathol</source><year>2012</year><volume>29</volume><issue>3</issue><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">22399191</pub-id></element-citation></ref><ref id="b17-cmar-6-149"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>C</given-names></name><name><surname>Hentschel</surname><given-names>B</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas</article-title><source>Acta Neuropathol</source><year>2010</year><volume>120</volume><issue>6</issue><fpage>707</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">21088844</pub-id></element-citation></ref><ref id="b18-cmar-6-149"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>RA</given-names></name><name><surname>Brastianos</surname><given-names>PK</given-names></name><name><surname>Palma</surname><given-names>DA</given-names></name></person-group><article-title>Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis</article-title><source>J Neurooncol</source><year>2011</year><volume>105</volume><issue>2</issue><fpage>325</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">21523485</pub-id></element-citation></ref><ref id="b19-cmar-6-149"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Diserens</surname><given-names>AC</given-names></name><name><surname>Gorlia</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>MGMT gene silencing and benefit from temozolomide in glioblastoma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>10</issue><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">15758010</pub-id></element-citation></ref><ref id="b20-cmar-6-149"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>AA</given-names></name><name><surname>Franceschi</surname><given-names>E</given-names></name><name><surname>Tosoni</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>13</issue><fpage>2192</fpage><lpage>2197</lpage><pub-id pub-id-type="pmid">18445844</pub-id></element-citation></ref><ref id="b21-cmar-6-149"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohgaki</surname><given-names>H</given-names></name><name><surname>Kleihues</surname><given-names>P</given-names></name></person-group><article-title>Genetic pathways to primary and secondary glioblastoma</article-title><source>Am J Pathol</source><year>2007</year><volume>170</volume><issue>5</issue><fpage>1445</fpage><lpage>1453</lpage><pub-id pub-id-type="pmid">17456751</pub-id></element-citation></ref><ref id="b22-cmar-6-149"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olar</surname><given-names>A</given-names></name><name><surname>Raghunathan</surname><given-names>A</given-names></name><name><surname>Albarracin</surname><given-names>CT</given-names></name><etal></etal></person-group><article-title>Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults</article-title><source>Ann Diagn Pathol</source><year>2012</year><volume>16</volume><issue>3</issue><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">22197544</pub-id></element-citation></ref><ref id="b23-cmar-6-149"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhaak</surname><given-names>RG</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Purdom</surname><given-names>E</given-names></name><etal></etal><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1</article-title><source>Cancer Cell</source><year>2010</year><volume>17</volume><issue>1</issue><fpage>98</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">20129251</pub-id></element-citation></ref><ref id="b24-cmar-6-149"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>HS</given-names></name><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><issue>3</issue><fpage>157</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">16530701</pub-id></element-citation></ref><ref id="b25-cmar-6-149"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title><source>Nature</source><year>2008</year><volume>455</volume><issue>7216</issue><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">18772890</pub-id></element-citation></ref><ref id="b26-cmar-6-149"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Diefes</surname><given-names>K</given-names></name><etal></etal><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma</article-title><source>Cancer Cell</source><year>2010</year><volume>17</volume><issue>5</issue><fpage>510</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">20399149</pub-id></element-citation></ref><ref id="b27-cmar-6-149"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>HK</given-names></name><name><surname>Kaye</surname><given-names>AH</given-names></name><name><surname>Luwor</surname><given-names>RB</given-names></name></person-group><article-title>The EGFRvIII variant in glioblastoma multiforme</article-title><source>J Clin Neurosci</source><year>2009</year><volume>16</volume><issue>6</issue><fpage>748</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">19324552</pub-id></element-citation></ref><ref id="b28-cmar-6-149"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Mischel</surname><given-names>PS</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name></person-group><article-title>Will kinase inhibitors make it as glioblastoma drugs?</article-title><source>Curr Top Microbiol Immunol</source><year>2012</year><volume>355</volume><fpage>135</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">22015553</pub-id></element-citation></ref><ref id="b29-cmar-6-149"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><name><surname>Mischel</surname><given-names>PS</given-names></name></person-group><article-title>PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>2 Pt 1</issue><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">17255257</pub-id></element-citation></ref><ref id="b30-cmar-6-149"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Nonoguchi</surname><given-names>N</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss</article-title><source>Brain Pathol</source><year>2012</year><volume>22</volume><issue>6</issue><fpage>834</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">22568401</pub-id></element-citation></ref><ref id="b31-cmar-6-149"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>AK</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name></person-group><article-title>BRAF in Melanoma: Current strategies and future directions</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><issue>16</issue><fpage>4326</fpage><lpage>4334</lpage><pub-id pub-id-type="pmid">23770823</pub-id></element-citation></ref><ref id="b32-cmar-6-149"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang-Xuan</surname><given-names>K</given-names></name><name><surname>Capelle</surname><given-names>L</given-names></name><name><surname>Kujas</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>15</issue><fpage>3133</fpage><lpage>3138</lpage><pub-id pub-id-type="pmid">15284265</pub-id></element-citation></ref><ref id="b33-cmar-6-149"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><etal></etal></person-group><article-title>Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>25</issue><fpage>4189</fpage><lpage>4199</lpage><pub-id pub-id-type="pmid">18757334</pub-id></element-citation></ref><ref id="b34-cmar-6-149"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas-Kogan</surname><given-names>DA</given-names></name><name><surname>Prados</surname><given-names>MD</given-names></name><name><surname>Tihan</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><issue>12</issue><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">15956649</pub-id></element-citation></ref><ref id="b35-cmar-6-149"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Wang</surname><given-names>MY</given-names></name><name><surname>Vivanco</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><issue>19</issue><fpage>2012</fpage><lpage>2024</lpage><pub-id pub-id-type="pmid">16282176</pub-id></element-citation></ref><ref id="b36-cmar-6-149"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>JN</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Peery</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Phase II trial of gefitinib in recurrent glioblastoma</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>1</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">14638850</pub-id></element-citation></ref><ref id="b37-cmar-6-149"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kienast</surname><given-names>Y</given-names></name><name><surname>von Baumgarten</surname><given-names>L</given-names></name><name><surname>Fuhrmann</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Real-time imaging reveals the single steps of brain metastasis formation</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">20023634</pub-id></element-citation></ref><ref id="b38-cmar-6-149"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seike</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Yamakawa</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis</article-title><source>Clin Exp Metastasis</source><year>2011</year><volume>28</volume><issue>1</issue><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">20953899</pub-id></element-citation></ref><ref id="b39-cmar-6-149"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stemmler</surname><given-names>HJ</given-names></name><name><surname>Kahlert</surname><given-names>S</given-names></name><name><surname>Siekiera</surname><given-names>W</given-names></name><name><surname>Untch</surname><given-names>M</given-names></name><name><surname>Heinrich</surname><given-names>B</given-names></name><name><surname>Heinemann</surname><given-names>V</given-names></name></person-group><article-title>Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer</article-title><source>Breast</source><year>2006</year><volume>15</volume><issue>2</issue><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">16026983</pub-id></element-citation></ref><ref id="b40-cmar-6-149"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Weathers</surname><given-names>T</given-names></name><name><surname>Haney</surname><given-names>LG</given-names></name><etal></etal></person-group><article-title>Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><issue>7</issue><fpage>1072</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">12853349</pub-id></element-citation></ref><ref id="b41-cmar-6-149"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabos</surname><given-names>Z</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Hanson</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>36</issue><fpage>5658</fpage><lpage>5663</lpage><pub-id pub-id-type="pmid">17102066</pub-id></element-citation></ref><ref id="b42-cmar-6-149"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>NU</given-names></name><name><surname>Bellon</surname><given-names>JR</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name></person-group><article-title>CNS metastases in breast cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>17</issue><fpage>3608</fpage><lpage>3617</lpage><pub-id pub-id-type="pmid">15337811</pub-id></element-citation></ref><ref id="b43-cmar-6-149"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Wnt/beta-catenin signaling and disease</article-title><source>Cell</source><year>2012</year><volume>149</volume><issue>6</issue><fpage>1192</fpage><lpage>1205</lpage><pub-id pub-id-type="pmid">22682243</pub-id></element-citation></ref><ref id="b44-cmar-6-149"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><article-title>Metastasis: from dissemination to organ-specific colonization</article-title><source>Nat Rev Cancer</source><year>2009</year><volume>9</volume><issue>4</issue><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">19308067</pub-id></element-citation></ref><ref id="b45-cmar-6-149"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>PJ</given-names></name><name><surname>Daumas-Duport</surname><given-names>C</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Kall</surname><given-names>BA</given-names></name><name><surname>Kispert</surname><given-names>DB</given-names></name></person-group><article-title>Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms</article-title><source>Mayo Clin Proc</source><year>1987</year><volume>62</volume><issue>6</issue><fpage>450</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">3553757</pub-id></element-citation></ref><ref id="b46-cmar-6-149"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Earnest</surname><given-names>F</given-names><suffix>4th</suffix></name><name><surname>Kelly</surname><given-names>PJ</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><etal></etal></person-group><article-title>Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy</article-title><source>Radiology</source><year>1988</year><volume>166</volume><issue>3</issue><fpage>823</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">2829270</pub-id></element-citation></ref><ref id="b47-cmar-6-149"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckner</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PD</given-names></name><name><surname>O’Neill</surname><given-names>BP</given-names></name><name><surname>Meyer</surname><given-names>FB</given-names></name><name><surname>Wetmore</surname><given-names>CJ</given-names></name><name><surname>Uhm</surname><given-names>JH</given-names></name></person-group><article-title>Central nervous system tumors</article-title><source>Mayo Clin Proc</source><year>2007</year><volume>82</volume><issue>10</issue><fpage>1271</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">17908533</pub-id></element-citation></ref><ref id="b48-cmar-6-149"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>BC</given-names></name><name><surname>Slattery</surname><given-names>J</given-names></name><name><surname>Greenberg</surname><given-names>HS</given-names></name><name><surname>Junck</surname><given-names>L</given-names></name></person-group><article-title>Chemotherapy response criteria in malignant glioma</article-title><source>Neurology</source><year>1997</year><volume>48</volume><issue>5</issue><fpage>1336</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">9153469</pub-id></element-citation></ref><ref id="b49-cmar-6-149"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilms</surname><given-names>G</given-names></name><name><surname>Marchal</surname><given-names>G</given-names></name><name><surname>Demaerel</surname><given-names>PH</given-names></name><name><surname>Van Hecke</surname><given-names>P</given-names></name><name><surname>Baert</surname><given-names>AL</given-names></name></person-group><article-title>Gadolinium-enhanced MRI of intracranial lesions. A review of indications and results</article-title><source>Clin Imaging</source><year>1991</year><volume>15</volume><issue>3</issue><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">1933642</pub-id></element-citation></ref><ref id="b50-cmar-6-149"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valk</surname><given-names>PE</given-names></name><name><surname>Dillon</surname><given-names>WP</given-names></name></person-group><article-title>Radiation-Injury of the Brain. <italic>Am J Roentgenol</italic></article-title><source>Apr</source><year>1991</year><volume>156</volume><issue>4</issue><fpage>689</fpage><lpage>706</lpage></element-citation></ref><ref id="b51-cmar-6-149"><label>51</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mountz</surname><given-names>JM</given-names></name><name><surname>Deutsch</surname><given-names>G</given-names></name><name><surname>Kuzniecky</surname><given-names>R</given-names></name><name><surname>Rosenfeld</surname><given-names>SS</given-names></name></person-group><article-title>Brain SPECT 1994 update</article-title><person-group person-group-type="editor"><name><surname>Freeman</surname><given-names>LM</given-names></name></person-group><source>Nuclear medicine annual 1994</source><publisher-loc>New York</publisher-loc><publisher-name>Raven Press</publisher-name><year>1994</year><fpage>1</fpage><lpage>54</lpage></element-citation></ref><ref id="b52-cmar-6-149"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>RB</given-names></name><name><surname>Holman</surname><given-names>BL</given-names></name><name><surname>Polak</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy</article-title><source>J Neurosurg</source><year>1998</year><volume>89</volume><issue>1</issue><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">9647173</pub-id></element-citation></ref><ref id="b53-cmar-6-149"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>WD</given-names></name><name><surname>Takvorian</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Rumbaugh</surname><given-names>CL</given-names></name><name><surname>Connolly</surname><given-names>BT</given-names></name><name><surname>Atkins</surname><given-names>HL</given-names></name></person-group><article-title>Thallium-201 brain tumor imaging: a comparative study with pathologic correlation</article-title><source>J Nucl Med</source><year>1987</year><volume>28</volume><issue>1</issue><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">3467030</pub-id></element-citation></ref><ref id="b54-cmar-6-149"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Hawkins</surname><given-names>RA</given-names></name><name><surname>Kim</surname><given-names>KT</given-names></name><name><surname>Becker</surname><given-names>DP</given-names></name><name><surname>Lerner</surname><given-names>C</given-names></name><name><surname>Marciano</surname><given-names>D</given-names></name></person-group><article-title>Use of thallium-201 SPECT to quantitate malignancy grade of gliomas</article-title><source>J Neurosurg</source><year>1989</year><volume>71</volume><issue>3</issue><fpage>342</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">2549223</pub-id></element-citation></ref><ref id="b55-cmar-6-149"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Macdonald</surname><given-names>DR</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><etal></etal></person-group><article-title>Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>11</issue><fpage>1963</fpage><lpage>1972</lpage><pub-id pub-id-type="pmid">20231676</pub-id></element-citation></ref><ref id="b56-cmar-6-149"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oborski</surname><given-names>MJ</given-names></name><name><surname>Laymon</surname><given-names>CM</given-names></name><name><surname>Lieberman</surname><given-names>FS</given-names></name><name><surname>Mountz</surname><given-names>JM</given-names></name></person-group><article-title>Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET</article-title><source>Clin Nucl Med</source><year>2013</year><volume>38</volume><issue>5</issue><fpage>381</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">23510887</pub-id></element-citation></ref><ref id="b57-cmar-6-149"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>AH</given-names></name><name><surname>Snelling</surname><given-names>B</given-names></name><name><surname>Bregy</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?</article-title><source>J Neurooncol</source><year>2013</year><volume>112</volume><issue>2</issue><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">23344789</pub-id></element-citation></ref><ref id="b58-cmar-6-149"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>S</given-names></name></person-group><article-title>Update on brain tumor imaging: from anatomy to physiology</article-title><source>AJNR Am J Neuroradiol</source><year>2006</year><volume>27</volume><issue>3</issue><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">16551981</pub-id></element-citation></ref><ref id="b59-cmar-6-149"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>GS</given-names></name></person-group><article-title>Advanced MRI of adult brain tumors</article-title><source>Neurol Clin</source><year>2007</year><volume>25</volume><issue>4</issue><fpage>947</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">17964022</pub-id></element-citation></ref><ref id="b60-cmar-6-149"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levivier</surname><given-names>M</given-names></name><name><surname>Becerra</surname><given-names>A</given-names></name><name><surname>De Witte</surname><given-names>O</given-names></name><name><surname>Brotchi</surname><given-names>J</given-names></name><name><surname>Goldman</surname><given-names>S</given-names></name></person-group><article-title>Radiation necrosis or recurrence</article-title><source>J Neurosurg</source><year>1996</year><volume>84</volume><issue>1</issue><fpage>148</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">8613825</pub-id></element-citation></ref><ref id="b61-cmar-6-149"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Sole</surname><given-names>A</given-names></name><name><surname>Falini</surname><given-names>A</given-names></name><name><surname>Ravasi</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Anatomical and biochemical investigation of primary brain tumours</article-title><source>Eur J Nucl Med</source><year>2001</year><volume>28</volume><issue>12</issue><fpage>1851</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">11734927</pub-id></element-citation></ref><ref id="b62-cmar-6-149"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>LE</given-names></name><name><surname>Fuller</surname><given-names>GN</given-names></name><name><surname>Hashmi</surname><given-names>M</given-names></name><name><surname>Leeds</surname><given-names>NE</given-names></name><name><surname>Schomer</surname><given-names>DF</given-names></name></person-group><article-title>The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series</article-title><source>Surg Neurol</source><year>1998</year><volume>49</volume><issue>4</issue><fpage>436</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">9537664</pub-id></element-citation></ref><ref id="b63-cmar-6-149"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JN</given-names></name><name><surname>Brasher</surname><given-names>PM</given-names></name><name><surname>Sevick</surname><given-names>RJ</given-names></name><name><surname>Rewcastle</surname><given-names>NB</given-names></name><name><surname>Forsyth</surname><given-names>PA</given-names></name></person-group><article-title>How often are nonenhancing supratentorial gliomas malignant? A population study</article-title><source>Neurology</source><year>2002</year><volume>59</volume><issue>6</issue><fpage>947</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">12297589</pub-id></element-citation></ref><ref id="b64-cmar-6-149"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Vogelbaum</surname><given-names>MA</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Macdonald</surname><given-names>DR</given-names></name><name><surname>Chang</surname><given-names>SM</given-names></name></person-group><article-title>End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>18</issue><fpage>2905</fpage><lpage>2908</lpage><pub-id pub-id-type="pmid">19451418</pub-id></element-citation></ref><ref id="b65-cmar-6-149"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taal</surname><given-names>W</given-names></name><name><surname>Brandsma</surname><given-names>D</given-names></name><name><surname>de Bruin</surname><given-names>HG</given-names></name><etal></etal></person-group><article-title>Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide</article-title><source>Cancer</source><year>2008</year><volume>113</volume><issue>2</issue><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">18484594</pub-id></element-citation></ref><ref id="b66-cmar-6-149"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamstra</surname><given-names>DA</given-names></name><name><surname>Galbán</surname><given-names>CJ</given-names></name><name><surname>Meyer</surname><given-names>CR</given-names></name><etal></etal></person-group><article-title>Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>20</issue><fpage>3387</fpage><lpage>3394</lpage><pub-id pub-id-type="pmid">18541899</pub-id></element-citation></ref><ref id="b67-cmar-6-149"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamstra</surname><given-names>DA</given-names></name><name><surname>Chenevert</surname><given-names>TL</given-names></name><name><surname>Moffat</surname><given-names>BA</given-names></name><etal></etal></person-group><article-title>Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>46</issue><fpage>16759</fpage><lpage>16764</lpage><pub-id pub-id-type="pmid">16267128</pub-id></element-citation></ref><ref id="b68-cmar-6-149"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowosielski</surname><given-names>M</given-names></name><name><surname>Recheis</surname><given-names>W</given-names></name><name><surname>Goebel</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma</article-title><source>Neuroradiology</source><year>2011</year><volume>53</volume><issue>4</issue><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">21125399</pub-id></element-citation></ref><ref id="b69-cmar-6-149"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>WB</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Huo</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment</article-title><source>Radiology</source><year>2009</year><volume>252</volume><issue>1</issue><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">19561256</pub-id></element-citation></ref><ref id="b70-cmar-6-149"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norden</surname><given-names>AD</given-names></name><name><surname>Young</surname><given-names>GS</given-names></name><name><surname>Setayesh</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence</article-title><source>Neurology</source><year>2008</year><volume>70</volume><issue>10</issue><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">18316689</pub-id></element-citation></ref><ref id="b71-cmar-6-149"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>M</given-names></name><name><surname>Kwock</surname><given-names>L</given-names></name><name><surname>Mukherji</surname><given-names>SK</given-names></name></person-group><article-title>Clinical applications of proton MR spectroscopy</article-title><source>AJNR Am J Neuroradiol</source><year>1996</year><volume>17</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">8770242</pub-id></element-citation></ref><ref id="b72-cmar-6-149"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>BL</given-names></name></person-group><article-title>A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline</article-title><source>NMR Biomed</source><year>1991</year><volume>4</volume><issue>2</issue><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">1650241</pub-id></element-citation></ref><ref id="b73-cmar-6-149"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>M</given-names></name><name><surname>Kwock</surname><given-names>L</given-names></name><name><surname>Scatliff</surname><given-names>J</given-names></name><name><surname>Mukherji</surname><given-names>SK</given-names></name></person-group><article-title>Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders</article-title><source>Magn Reson Imaging Clin N Am</source><year>1998</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9449737</pub-id></element-citation></ref><ref id="b74-cmar-6-149"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>T</given-names></name><name><surname>Merboldt</surname><given-names>KD</given-names></name><name><surname>Bruhn</surname><given-names>H</given-names></name><name><surname>Hänicke</surname><given-names>W</given-names></name><name><surname>Frahm</surname><given-names>J</given-names></name></person-group><article-title>Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra</article-title><source>Radiology</source><year>1993</year><volume>187</volume><issue>1</issue><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">8451417</pub-id></element-citation></ref><ref id="b75-cmar-6-149"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herminghaus</surname><given-names>S</given-names></name><name><surname>Pilatus</surname><given-names>U</given-names></name><name><surname>Möller-Hartmann</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors</article-title><source>NMR Biomed</source><year>2002</year><volume>15</volume><issue>6</issue><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">12357552</pub-id></element-citation></ref><ref id="b76-cmar-6-149"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreis</surname><given-names>R</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Ross</surname><given-names>BD</given-names></name></person-group><article-title>Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy</article-title><source>Magn Reson Med</source><year>1993</year><volume>30</volume><issue>4</issue><fpage>424</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">8255190</pub-id></element-citation></ref><ref id="b77-cmar-6-149"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Pirzkall</surname><given-names>A</given-names></name><name><surname>McKnight</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>SJ</given-names></name></person-group><article-title>Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients</article-title><source>J Magn Reson Imaging</source><year>2002</year><volume>16</volume><issue>3</issue><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">12205577</pub-id></element-citation></ref><ref id="b78-cmar-6-149"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattingen</surname><given-names>E</given-names></name><name><surname>Delic</surname><given-names>O</given-names></name><name><surname>Franz</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>(1)H MRSI and progression-free survival in patients with WHO grades II and III gliomas</article-title><source>Neurol Res</source><year>2010</year><volume>32</volume><issue>6</issue><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">19726017</pub-id></element-citation></ref><ref id="b79-cmar-6-149"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattingen</surname><given-names>E</given-names></name><name><surname>Raab</surname><given-names>P</given-names></name><name><surname>Franz</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Prognostic value of choline and creatine in WHO grade II gliomas</article-title><source>Neuroradiology</source><year>2008</year><volume>50</volume><issue>9</issue><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">18523762</pub-id></element-citation></ref><ref id="b80-cmar-6-149"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imani</surname><given-names>F</given-names></name><name><surname>Boada</surname><given-names>FE</given-names></name><name><surname>Lieberman</surname><given-names>FS</given-names></name><name><surname>Davis</surname><given-names>DK</given-names></name><name><surname>Deeb</surname><given-names>EL</given-names></name><name><surname>Mountz</surname><given-names>JM</given-names></name></person-group><article-title>Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression</article-title><source>J Neuroimaging</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">21155917</pub-id></element-citation></ref><ref id="b81-cmar-6-149"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkhaled</surname><given-names>A</given-names></name><name><surname>Jalbert</surname><given-names>LE</given-names></name><name><surname>Phillips</surname><given-names>JJ</given-names></name><etal></etal></person-group><article-title>Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><issue>116</issue><fpage>116ra5</fpage></element-citation></ref><ref id="b82-cmar-6-149"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalinina</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma</article-title><source>J Mol Med (Berl)</source><year>2012</year><volume>90</volume><issue>10</issue><fpage>1161</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">22426639</pub-id></element-citation></ref><ref id="b83-cmar-6-149"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>WB</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Albert Thomas</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy</article-title><source>J Neurooncol</source><year>2012</year><volume>107</volume><issue>1</issue><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">22015945</pub-id></element-citation></ref><ref id="b84-cmar-6-149"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bihan</surname><given-names>D</given-names></name></person-group><article-title>Molecular diffusion, tissue microdynamics and microstructure</article-title><source>NMR Biomed</source><year>1995</year><volume>8</volume><issue>7–8</issue><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">8739274</pub-id></element-citation></ref><ref id="b85-cmar-6-149"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvinda</surname><given-names>HR</given-names></name><name><surname>Kesavadas</surname><given-names>C</given-names></name><name><surname>Sarma</surname><given-names>PS</given-names></name><etal></etal></person-group><article-title>Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging</article-title><source>J Neurooncol</source><year>2009</year><volume>94</volume><issue>1</issue><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">19229590</pub-id></element-citation></ref><ref id="b86-cmar-6-149"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>JH</given-names></name><name><surname>Helpern</surname><given-names>JA</given-names></name></person-group><article-title>MRI quantification of non-Gaussian water diffusion by kurtosis analysis</article-title><source>NMR Biomed</source><year>2010</year><volume>23</volume><issue>7</issue><fpage>698</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">20632416</pub-id></element-citation></ref><ref id="b87-cmar-6-149"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raab</surname><given-names>P</given-names></name><name><surname>Hattingen</surname><given-names>E</given-names></name><name><surname>Franz</surname><given-names>K</given-names></name><name><surname>Zanella</surname><given-names>FE</given-names></name><name><surname>Lanfermann</surname><given-names>H</given-names></name></person-group><article-title>Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences</article-title><source>Radiology</source><year>2010</year><volume>254</volume><issue>3</issue><fpage>876</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">20089718</pub-id></element-citation></ref><ref id="b88-cmar-6-149"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>S</given-names></name><name><surname>Knopp</surname><given-names>EA</given-names></name><name><surname>Johnson</surname><given-names>G</given-names></name><name><surname>Wetzel</surname><given-names>SG</given-names></name><name><surname>Litt</surname><given-names>AW</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name></person-group><article-title>Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging</article-title><source>Radiology</source><year>2002</year><volume>223</volume><issue>1</issue><fpage>11</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">11930044</pub-id></element-citation></ref><ref id="b89-cmar-6-149"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boxerman</surname><given-names>JL</given-names></name><name><surname>Schmainda</surname><given-names>KM</given-names></name><name><surname>Weisskoff</surname><given-names>RM</given-names></name></person-group><article-title>Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not</article-title><source>AJNR Am J Neuroradiol</source><year>2006</year><volume>27</volume><issue>4</issue><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">16611779</pub-id></element-citation></ref><ref id="b90-cmar-6-149"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>LS</given-names></name><name><surname>Baxter</surname><given-names>LC</given-names></name><name><surname>Pinnaduwage</surname><given-names>DS</given-names></name><etal></etal></person-group><article-title>Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas</article-title><source>AJNR Am J Neuroradiol</source><year>2010</year><volume>31</volume><issue>1</issue><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">19749223</pub-id></element-citation></ref><ref id="b91-cmar-6-149"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging</article-title><source>AJNR Am J Neuroradiol</source><year>2003</year><volume>24</volume><issue>10</issue><fpage>1989</fpage><lpage>1998</lpage><pub-id pub-id-type="pmid">14625221</pub-id></element-citation></ref><ref id="b92-cmar-6-149"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provenzale</surname><given-names>JM</given-names></name><name><surname>York</surname><given-names>G</given-names></name><name><surname>Moya</surname><given-names>MG</given-names></name><etal></etal></person-group><article-title>Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms</article-title><source>AJR Am J Roentgenol</source><year>2006</year><volume>187</volume><issue>4</issue><fpage>1036</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">16985154</pub-id></element-citation></ref><ref id="b93-cmar-6-149"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Issa</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>A</given-names></name><name><surname>Waterton</surname><given-names>JC</given-names></name><name><surname>Parker</surname><given-names>GJ</given-names></name></person-group><article-title>Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies</article-title><source>J Magn Reson Imaging</source><year>2006</year><volume>23</volume><issue>4</issue><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">16506143</pub-id></element-citation></ref><ref id="b94-cmar-6-149"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spampinato</surname><given-names>MV</given-names></name><name><surname>Smith</surname><given-names>JK</given-names></name><name><surname>Kwock</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors</article-title><source>AJR Am J Roentgenol</source><year>2007</year><volume>188</volume><issue>1</issue><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">17179366</pub-id></element-citation></ref><ref id="b95-cmar-6-149"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danchaivijitr</surname><given-names>N</given-names></name><name><surname>Waldman</surname><given-names>AD</given-names></name><name><surname>Tozer</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?</article-title><source>Radiology</source><year>2008</year><volume>247</volume><issue>1</issue><fpage>170</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">18372467</pub-id></element-citation></ref><ref id="b96-cmar-6-149"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O</given-names></name></person-group><article-title>On the origin of cancer cells</article-title><source>Science</source><year>1956</year><volume>123</volume><issue>3191</issue><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">13298683</pub-id></element-citation></ref><ref id="b97-cmar-6-149"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krohn</surname><given-names>KA</given-names></name><name><surname>Mankoff</surname><given-names>DA</given-names></name><name><surname>Muzi</surname><given-names>M</given-names></name><name><surname>Link</surname><given-names>JM</given-names></name><name><surname>Spence</surname><given-names>AM</given-names></name></person-group><article-title>True tracers: comparing FDG with glucose and FLT with thymidine</article-title><source>Nucl Med Biol</source><year>2005</year><volume>32</volume><issue>7</issue><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">16243640</pub-id></element-citation></ref><ref id="b98-cmar-6-149"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padma</surname><given-names>MV</given-names></name><name><surname>Said</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Prediction of pathology and survival by FDG PET in gliomas</article-title><source>J Neurooncol</source><year>2003</year><volume>64</volume><issue>3</issue><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">14558598</pub-id></element-citation></ref><ref id="b99-cmar-6-149"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Witte</surname><given-names>O</given-names></name><name><surname>Levivier</surname><given-names>M</given-names></name><name><surname>Violon</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma</article-title><source>Neurosurgery</source><year>1996</year><volume>39</volume><issue>3</issue><fpage>470</fpage><lpage>476</lpage><comment>discussion 476–477</comment><pub-id pub-id-type="pmid">8875476</pub-id></element-citation></ref><ref id="b100-cmar-6-149"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delbeke</surname><given-names>D</given-names></name><name><surname>Meyerowitz</surname><given-names>C</given-names></name><name><surname>Lapidus</surname><given-names>RL</given-names></name><etal></etal></person-group><article-title>Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET</article-title><source>Radiology</source><year>1995</year><volume>195</volume><issue>1</issue><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">7892494</pub-id></element-citation></ref><ref id="b101-cmar-6-149"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>AM</given-names></name><name><surname>Muzi</surname><given-names>M</given-names></name><name><surname>Mankoff</surname><given-names>DA</given-names></name><etal></etal></person-group><article-title>18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter</article-title><source>J Nucl Med</source><year>2004</year><volume>45</volume><issue>10</issue><fpage>1653</fpage><lpage>1659</lpage><pub-id pub-id-type="pmid">15471829</pub-id></element-citation></ref><ref id="b102-cmar-6-149"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TZ</given-names></name><name><surname>van der Westhuizen</surname><given-names>GJ</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name></person-group><article-title>Positron emission tomography imaging of brain tumors</article-title><source>Neuroimaging Clin N Am</source><year>2002</year><volume>12</volume><issue>4</issue><fpage>615</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">12687915</pub-id></element-citation></ref><ref id="b103-cmar-6-149"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Würker</surname><given-names>M</given-names></name><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Voges</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy</article-title><source>Eur J Nucl Med</source><year>1996</year><volume>23</volume><issue>5</issue><fpage>583</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">8698067</pub-id></element-citation></ref><ref id="b104-cmar-6-149"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>PE</given-names></name><name><surname>Karis</surname><given-names>JP</given-names></name><name><surname>Heiserman</surname><given-names>JE</given-names></name><name><surname>Fram</surname><given-names>EK</given-names></name><name><surname>Bice</surname><given-names>AN</given-names></name><name><surname>Drayer</surname><given-names>BP</given-names></name></person-group><article-title>Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?</article-title><source>AJNR Am J Neuroradiol</source><year>1998</year><volume>19</volume><issue>3</issue><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">9541290</pub-id></element-citation></ref><ref id="b105-cmar-6-149"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langleben</surname><given-names>DD</given-names></name><name><surname>Segall</surname><given-names>GM</given-names></name></person-group><article-title>PET in differentiation of recurrent brain tumor from radiation injury</article-title><source>J Nucl Med</source><year>2000</year><volume>41</volume><issue>11</issue><fpage>1861</fpage><lpage>1867</lpage><pub-id pub-id-type="pmid">11079496</pub-id></element-citation></ref><ref id="b106-cmar-6-149"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschi</surname><given-names>E</given-names></name><name><surname>Tosoni</surname><given-names>A</given-names></name><name><surname>Bartolini</surname><given-names>S</given-names></name><name><surname>Mazzocchi</surname><given-names>V</given-names></name><name><surname>Fioravanti</surname><given-names>A</given-names></name><name><surname>Brandes</surname><given-names>AA</given-names></name></person-group><article-title>Treatment options for recurrent glioblastoma: pitfalls and future trends</article-title><source>Expert Rev Anticancer Ther</source><year>2009</year><volume>9</volume><issue>5</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">19445578</pub-id></element-citation></ref><ref id="b107-cmar-6-149"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>DR</given-names></name><name><surname>Cascino</surname><given-names>TL</given-names></name><name><surname>Schold</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Cairncross</surname><given-names>JG</given-names></name></person-group><article-title>Response criteria for phase II studies of supratentorial malignant glioma</article-title><source>J Clin Oncol</source><year>1990</year><volume>8</volume><issue>7</issue><fpage>1277</fpage><lpage>1280</lpage><pub-id pub-id-type="pmid">2358840</pub-id></element-citation></ref><ref id="b108-cmar-6-149"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J</given-names></name><name><surname>Andion</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>19</issue><fpage>1350</fpage><lpage>1354</lpage><pub-id pub-id-type="pmid">11070098</pub-id></element-citation></ref><ref id="b109-cmar-6-149"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>AA</given-names></name><name><surname>Tosoni</surname><given-names>A</given-names></name><name><surname>Cavallo</surname><given-names>G</given-names></name><etal></etal><collab>GICNO</collab></person-group><article-title>Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>29</issue><fpage>4746</fpage><lpage>4753</lpage><pub-id pub-id-type="pmid">16954518</pub-id></element-citation></ref><ref id="b110-cmar-6-149"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>JL</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name></person-group><article-title>Pseudoprogression and pseudoresponse: challenges in brain tumor imaging</article-title><source>Curr Neurol Neurosci Rep</source><year>2009</year><volume>9</volume><issue>3</issue><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">19348713</pub-id></element-citation></ref><ref id="b111-cmar-6-149"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name><etal></etal></person-group><article-title>Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>4</issue><fpage>1253</fpage><lpage>1259</lpage><pub-id pub-id-type="pmid">17317837</pub-id></element-citation></ref><ref id="b112-cmar-6-149"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batchelor</surname><given-names>TT</given-names></name><name><surname>Sorensen</surname><given-names>AG</given-names></name><name><surname>di Tomaso</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients</article-title><source>Cancer Cell</source><year>2007</year><volume>11</volume><issue>1</issue><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">17222792</pub-id></element-citation></ref><ref id="b113-cmar-6-149"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name><etal></etal></person-group><article-title>Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>21</issue><fpage>7068</fpage><lpage>7073</lpage><pub-id pub-id-type="pmid">18981004</pub-id></element-citation></ref><ref id="b114-cmar-6-149"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>ST</given-names></name><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Raja</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Barnett</surname><given-names>G</given-names></name></person-group><article-title>The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery</article-title><source>Int J Cancer</source><year>2001</year><volume>96</volume><issue>3</issue><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">11410888</pub-id></element-citation></ref><ref id="b115-cmar-6-149"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SX</given-names></name><name><surname>Boethius</surname><given-names>J</given-names></name><name><surname>Ericson</surname><given-names>K</given-names></name></person-group><article-title>FDG-PET on irradiated brain tumor: ten years’ summary</article-title><source>Acta Radiol</source><year>2006</year><volume>47</volume><issue>1</issue><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16498938</pub-id></element-citation></ref><ref id="b116-cmar-6-149"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlemmer</surname><given-names>HP</given-names></name><name><surname>Pichler</surname><given-names>BJ</given-names></name><name><surname>Schmand</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Simultaneous MR/PET imaging of the human brain: feasibility study</article-title><source>Radiology</source><year>2008</year><volume>248</volume><issue>3</issue><fpage>1028</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">18710991</pub-id></element-citation></ref><ref id="b117-cmar-6-149"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boss</surname><given-names>A</given-names></name><name><surname>Bisdas</surname><given-names>S</given-names></name><name><surname>Kolb</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT</article-title><source>J Nucl Med</source><year>2010</year><volume>51</volume><issue>8</issue><fpage>1198</fpage><lpage>1205</lpage><pub-id pub-id-type="pmid">20660388</pub-id></element-citation></ref><ref id="b118-cmar-6-149"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nariai</surname><given-names>T</given-names></name><name><surname>Momose</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Glioma surgery using a multimodal navigation system with integrated metabolic images</article-title><source>J Neurosurg</source><year>2009</year><volume>110</volume><issue>1</issue><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">18847337</pub-id></element-citation></ref><ref id="b119-cmar-6-149"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosu</surname><given-names>AL</given-names></name><name><surname>Weber</surname><given-names>WA</given-names></name><name><surname>Riedel</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><issue>1</issue><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16111573</pub-id></element-citation></ref><ref id="b120-cmar-6-149"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>DC</given-names></name><name><surname>Zilli</surname><given-names>T</given-names></name><name><surname>Buchegger</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>[(18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma</article-title><source>Radiat Oncol</source><year>2008</year><volume>3</volume><fpage>44</fpage><pub-id pub-id-type="pmid">19108742</pub-id></element-citation></ref><ref id="b121-cmar-6-149"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vees</surname><given-names>H</given-names></name><name><surname>Senthamizhchelvan</surname><given-names>S</given-names></name><name><surname>Miralbell</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>DC</given-names></name><name><surname>Ratib</surname><given-names>O</given-names></name><name><surname>Zaidi</surname><given-names>H</given-names></name></person-group><article-title>Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">18818918</pub-id></element-citation></ref><ref id="b122-cmar-6-149"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nariai</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma</article-title><source>J Neurosurg</source><year>2005</year><volume>103</volume><issue>3</issue><fpage>498</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">16235683</pub-id></element-citation></ref><ref id="b123-cmar-6-149"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>JR</given-names></name><name><surname>Honig</surname><given-names>GR</given-names></name><name><surname>Anderson</surname><given-names>DC</given-names></name><name><surname>Nair</surname><given-names>PV</given-names></name><name><surname>Nyhan</surname><given-names>WL</given-names></name></person-group><article-title>The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues</article-title><source>Cancer Res</source><year>1959</year><volume>19</volume><fpage>1030</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">13806375</pub-id></element-citation></ref><ref id="b124-cmar-6-149"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyagawa</surname><given-names>T</given-names></name><name><surname>Oku</surname><given-names>T</given-names></name><name><surname>Uehara</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>“Facilitated” amino acid transport is upregulated in brain tumors</article-title><source>J Cereb Blood Flow Metab</source><year>1998</year><volume>18</volume><issue>5</issue><fpage>500</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">9591842</pub-id></element-citation></ref><ref id="b125-cmar-6-149"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galldiks</surname><given-names>N</given-names></name><name><surname>Kracht</surname><given-names>LW</given-names></name><name><surname>Burghaus</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2006</year><volume>33</volume><issue>5</issue><fpage>516</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">16450140</pub-id></element-citation></ref><ref id="b126-cmar-6-149"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyss</surname><given-names>M</given-names></name><name><surname>Hofer</surname><given-names>S</given-names></name><name><surname>Bruehlmeier</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Early metabolic responses in temozolomide treated low-grade glioma patients</article-title><source>J Neurooncol</source><year>2009</year><volume>95</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">19381442</pub-id></element-citation></ref><ref id="b127-cmar-6-149"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galldiks</surname><given-names>N</given-names></name><name><surname>Kracht</surname><given-names>LW</given-names></name><name><surname>Burghaus</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma</article-title><source>Mol Imaging</source><year>2010</year><volume>9</volume><issue>1</issue><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">20128997</pub-id></element-citation></ref><ref id="b128-cmar-6-149"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jager</surname><given-names>PL</given-names></name><name><surname>Vaalburg</surname><given-names>W</given-names></name><name><surname>Pruim</surname><given-names>J</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><name><surname>Langen</surname><given-names>KJ</given-names></name><name><surname>Piers</surname><given-names>DA</given-names></name></person-group><article-title>Radiolabeled amino acids: basic aspects and clinical applications in oncology</article-title><source>J Nucl Med</source><year>2001</year><volume>42</volume><issue>3</issue><fpage>432</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">11337520</pub-id></element-citation></ref><ref id="b129-cmar-6-149"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergmann</surname><given-names>R</given-names></name><name><surname>Pietzsch</surname><given-names>J</given-names></name><name><surname>Fuechtner</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro</article-title><source>J Nucl Med</source><year>2004</year><volume>45</volume><issue>12</issue><fpage>2116</fpage><lpage>2122</lpage><pub-id pub-id-type="pmid">15585490</pub-id></element-citation></ref><ref id="b130-cmar-6-149"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>RT</given-names></name><name><surname>Kracht</surname><given-names>LW</given-names></name><name><surname>Jacobs</surname><given-names>AH</given-names></name></person-group><article-title>Neuroimaging in patients with gliomas</article-title><source>Semin Neurol</source><year>2008</year><volume>28</volume><issue>4</issue><fpage>484</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">18843576</pub-id></element-citation></ref><ref id="b131-cmar-6-149"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>WA</given-names></name><name><surname>Wester</surname><given-names>HJ</given-names></name><name><surname>Grosu</surname><given-names>AL</given-names></name><etal></etal></person-group><article-title>O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><issue>5</issue><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">10853810</pub-id></element-citation></ref><ref id="b132-cmar-6-149"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becherer</surname><given-names>A</given-names></name><name><surname>Karanikas</surname><given-names>G</given-names></name><name><surname>Szabó</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2003</year><volume>30</volume><issue>11</issue><fpage>1561</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">14579097</pub-id></element-citation></ref><ref id="b133-cmar-6-149"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Hölzer</surname><given-names>T</given-names></name><name><surname>Bauer</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>11C-methionine PET for differential diagnosis of low-grade gliomas</article-title><source>Neurology</source><year>1998</year><volume>50</volume><issue>5</issue><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">9595980</pub-id></element-citation></ref><ref id="b134-cmar-6-149"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hustinx</surname><given-names>R</given-names></name><name><surname>Pourdehnad</surname><given-names>M</given-names></name><name><surname>Kaschten</surname><given-names>B</given-names></name><name><surname>Alavi</surname><given-names>A</given-names></name></person-group><article-title>PET imaging for differentiating recurrent brain tumor from radiation necrosis</article-title><source>Radiol Clin North Am</source><year>2005</year><volume>43</volume><issue>1</issue><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15693646</pub-id></element-citation></ref><ref id="b135-cmar-6-149"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ericson</surname><given-names>K</given-names></name><name><surname>Lilja</surname><given-names>A</given-names></name><name><surname>Bergström</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga] EDTA in supratentorial tumors</article-title><source>J Comput Assist Tomogr</source><year>1985</year><volume>9</volume><issue>4</issue><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">3926834</pub-id></element-citation></ref><ref id="b136-cmar-6-149"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Inugami</surname><given-names>A</given-names></name><name><surname>Hatazawa</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine</article-title><source>AJNR Am J Neuroradiol</source><year>1996</year><volume>17</volume><issue>2</issue><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">8938309</pub-id></element-citation></ref><ref id="b137-cmar-6-149"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Kuwana</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Yokoyama</surname><given-names>T</given-names></name><name><surname>Kanno</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>I</given-names></name></person-group><article-title>Cerebral haemodynamics in patients with hydrocephalus after subarachnoid haemorrhage due to ruptured aneurysm</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2003</year><volume>30</volume><issue>1</issue><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">12483419</pub-id></element-citation></ref><ref id="b138-cmar-6-149"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Witte</surname><given-names>O</given-names></name><name><surname>Goldberg</surname><given-names>I</given-names></name><name><surname>Wikler</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Positron emission tomography with injection of methionine as a prognostic factor in glioma</article-title><source>J Neurosurg</source><year>2001</year><volume>95</volume><issue>5</issue><fpage>746</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">11702862</pub-id></element-citation></ref><ref id="b139-cmar-6-149"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribom</surname><given-names>D</given-names></name><name><surname>Eriksson</surname><given-names>A</given-names></name><name><surname>Hartman</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas</article-title><source>Cancer</source><year>2001</year><volume>92</volume><issue>6</issue><fpage>1541</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">11745233</pub-id></element-citation></ref><ref id="b140-cmar-6-149"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaschten</surname><given-names>B</given-names></name><name><surname>Stevenaert</surname><given-names>A</given-names></name><name><surname>Sadzot</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine</article-title><source>J Nucl Med</source><year>1998</year><volume>39</volume><issue>5</issue><fpage>778</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">9591574</pub-id></element-citation></ref><ref id="b141-cmar-6-149"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Kuwabara</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Carbon-11-methionine PET in focal cortical dysplasia: a comparison with fluorine-18-FDG PET and technetium-99m-ECD SPECT</article-title><source>J Nucl Med</source><year>1998</year><volume>39</volume><issue>6</issue><fpage>974</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">9627328</pub-id></element-citation></ref><ref id="b142-cmar-6-149"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustany</surname><given-names>P</given-names></name><name><surname>Chatel</surname><given-names>M</given-names></name><name><surname>Derlon</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-Methionine</article-title><source>J Neurooncol</source><year>1986</year><volume>3</volume><issue>4</issue><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">3485705</pub-id></element-citation></ref><ref id="b143-cmar-6-149"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>RT</given-names></name><name><surname>Kracht</surname><given-names>L</given-names></name><name><surname>Brunn</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma</article-title><source>J Nucl Med</source><year>2009</year><volume>50</volume><issue>12</issue><fpage>1962</fpage><lpage>1968</lpage><pub-id pub-id-type="pmid">19910435</pub-id></element-citation></ref><ref id="b144-cmar-6-149"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamane</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Senda</surname><given-names>M</given-names></name></person-group><article-title>Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2010</year><volume>37</volume><issue>4</issue><fpage>685</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">19915838</pub-id></element-citation></ref><ref id="b145-cmar-6-149"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaeth</surname><given-names>N</given-names></name><name><surname>Wyss</surname><given-names>MT</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence</article-title><source>J Nucl Med</source><year>2004</year><volume>45</volume><issue>11</issue><fpage>1931</fpage><lpage>1938</lpage><pub-id pub-id-type="pmid">15534065</pub-id></element-citation></ref><ref id="b146-cmar-6-149"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Silverman</surname><given-names>DH</given-names></name><name><surname>Delaloye</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy</article-title><source>J Nucl Med</source><year>2006</year><volume>47</volume><issue>6</issue><fpage>904</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">16741298</pub-id></element-citation></ref><ref id="b147-cmar-6-149"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauleit</surname><given-names>D</given-names></name><name><surname>Floeth</surname><given-names>F</given-names></name><name><surname>Hamacher</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas</article-title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 3</issue><fpage>678</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">15689365</pub-id></element-citation></ref><ref id="b148-cmar-6-149"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachinger</surname><given-names>W</given-names></name><name><surname>Goetz</surname><given-names>C</given-names></name><name><surname>Pöpperl</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas</article-title><source>Neurosurgery</source><year>2005</year><volume>57</volume><issue>3</issue><fpage>505</fpage><lpage>511</lpage><comment>discussion 505–511</comment><pub-id pub-id-type="pmid">16145529</pub-id></element-citation></ref><ref id="b149-cmar-6-149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floeth</surname><given-names>FW</given-names></name><name><surname>Pauleit</surname><given-names>D</given-names></name><name><surname>Wittsack</surname><given-names>HJ</given-names></name><etal></etal></person-group><article-title>Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy</article-title><source>J Neurosurg</source><year>2005</year><volume>102</volume><issue>2</issue><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">15739561</pub-id></element-citation></ref><ref id="b150-cmar-6-149"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasey</surname><given-names>JS</given-names></name><name><surname>Grierson</surname><given-names>JR</given-names></name><name><surname>Wiens</surname><given-names>LW</given-names></name><name><surname>Kolb</surname><given-names>PD</given-names></name><name><surname>Schwartz</surname><given-names>JL</given-names></name></person-group><article-title>Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells</article-title><source>J Nucl Med</source><year>2002</year><volume>43</volume><issue>9</issue><fpage>1210</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">12215561</pub-id></element-citation></ref><ref id="b151-cmar-6-149"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>AF</given-names></name><name><surname>Grierson</surname><given-names>JR</given-names></name><name><surname>Dohmen</surname><given-names>BM</given-names></name><etal></etal></person-group><article-title>Imaging proliferation in vivo with [F-18]FLT and positron emission tomography</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><issue>11</issue><fpage>1334</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">9809561</pub-id></element-citation></ref><ref id="b152-cmar-6-149"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthel</surname><given-names>H</given-names></name><name><surname>Cleij</surname><given-names>MC</given-names></name><name><surname>Collingridge</surname><given-names>DR</given-names></name><etal></etal></person-group><article-title>3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>13</issue><fpage>3791</fpage><lpage>3798</lpage><pub-id pub-id-type="pmid">12839975</pub-id></element-citation></ref><ref id="b153-cmar-6-149"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Cloughesy</surname><given-names>T</given-names></name><name><surname>Kamdar</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG</article-title><source>J Nucl Med</source><year>2005</year><volume>46</volume><issue>6</issue><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">15937304</pub-id></element-citation></ref><ref id="b154-cmar-6-149"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munch-Petersen</surname><given-names>B</given-names></name><name><surname>Cloos</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>HK</given-names></name><name><surname>Tyrsted</surname><given-names>G</given-names></name></person-group><article-title>Human thymidine kinase 1. Regulation in normal and malignant cells</article-title><source>Adv Enzyme Regul</source><year>1995</year><volume>35</volume><fpage>69</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">7572355</pub-id></element-citation></ref><ref id="b155-cmar-6-149"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>N</given-names></name><name><surname>Nishiyama</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2008</year><volume>35</volume><issue>11</issue><fpage>2009</fpage><lpage>2017</lpage><pub-id pub-id-type="pmid">18542957</pub-id></element-citation></ref><ref id="b156-cmar-6-149"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>AH</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Kracht</surname><given-names>LW</given-names></name><etal></etal></person-group><article-title>18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors</article-title><source>J Nucl Med</source><year>2005</year><volume>46</volume><issue>12</issue><fpage>1948</fpage><lpage>1958</lpage><pub-id pub-id-type="pmid">16330557</pub-id></element-citation></ref><ref id="b157-cmar-6-149"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Delaloye</surname><given-names>S</given-names></name><name><surname>Silverman</surname><given-names>DH</given-names></name><etal></etal></person-group><article-title>Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>30</issue><fpage>4714</fpage><lpage>4721</lpage><pub-id pub-id-type="pmid">17947718</pub-id></element-citation></ref><ref id="b158-cmar-6-149"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarzenberg</surname><given-names>J</given-names></name><name><surname>Czernin</surname><given-names>J</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><etal></etal></person-group><article-title>3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab</article-title><source>J Nucl Med</source><year>2012</year><volume>53</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">22159180</pub-id></element-citation></ref><ref id="b159-cmar-6-149"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name></person-group><article-title>Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>5</issue><fpage>1011</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">15585754</pub-id></element-citation></ref><ref id="b160-cmar-6-149"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name></person-group><article-title>Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>333</volume><issue>2</issue><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">15961063</pub-id></element-citation></ref><ref id="b161-cmar-6-149"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasey</surname><given-names>JS</given-names></name><name><surname>Koh</surname><given-names>WJ</given-names></name><name><surname>Evans</surname><given-names>ML</given-names></name><etal></etal></person-group><article-title>Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: a pretherapy study of 37 patients</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1996</year><volume>36</volume><issue>2</issue><fpage>417</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">8892467</pub-id></element-citation></ref><ref id="b162-cmar-6-149"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><article-title>Therapeutic targets in radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>49</volume><issue>2</issue><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">11173124</pub-id></element-citation></ref><ref id="b163-cmar-6-149"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeto</surname><given-names>MD</given-names></name><name><surname>Chakraborty</surname><given-names>G</given-names></name><name><surname>Hadley</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><issue>10</issue><fpage>4502</fpage><lpage>4509</lpage><pub-id pub-id-type="pmid">19366800</pub-id></element-citation></ref><ref id="b164-cmar-6-149"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cher</surname><given-names>LM</given-names></name><name><surname>Murone</surname><given-names>C</given-names></name><name><surname>Lawrentschuk</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies</article-title><source>J Nucl Med</source><year>2006</year><volume>47</volume><issue>3</issue><fpage>410</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">16513609</pub-id></element-citation></ref><ref id="b165-cmar-6-149"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>AM</given-names></name><name><surname>Muzi</surname><given-names>M</given-names></name><name><surname>Swanson</surname><given-names>KR</given-names></name><etal></etal></person-group><article-title>Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>9</issue><fpage>2623</fpage><lpage>2630</lpage><pub-id pub-id-type="pmid">18451225</pub-id></element-citation></ref><ref id="b166-cmar-6-149"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paleologos</surname><given-names>TS</given-names></name><name><surname>Dorward</surname><given-names>NL</given-names></name><name><surname>Wadley</surname><given-names>JP</given-names></name><name><surname>Thomas</surname><given-names>DG</given-names></name></person-group><article-title>Clinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive cases</article-title><source>Neurosurgery</source><year>2001</year><volume>49</volume><issue>4</issue><fpage>830</fpage><lpage>835</lpage><comment>discussion 835–837</comment><pub-id pub-id-type="pmid">11564243</pub-id></element-citation></ref><ref id="b167-cmar-6-149"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Yu</surname><given-names>LL</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Stereotactic biopsy of 100 intracerebral lesions at Sir Charles Gairdner Hospital</article-title><source>Pathology</source><year>1994</year><volume>26</volume><issue>4</issue><fpage>410</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">7892040</pub-id></element-citation></ref><ref id="b168-cmar-6-149"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanai</surname><given-names>N</given-names></name></person-group><article-title>Emerging operative strategies in neurosurgical oncology</article-title><source>Curr Opin Neurol</source><year>2012</year><volume>25</volume><issue>6</issue><fpage>756</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">23160424</pub-id></element-citation></ref><ref id="b169-cmar-6-149"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Curry</surname><given-names>WT</given-names></name><name><surname>Batchelor</surname><given-names>TT</given-names></name><name><surname>Dietrich</surname><given-names>J</given-names></name></person-group><article-title>Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?</article-title><source>Nat Rev Clin Oncol</source><year>2013</year><volume>10</volume><issue>1</issue><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23183634</pub-id></element-citation></ref><ref id="b170-cmar-6-149"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>MR</given-names></name></person-group><article-title>Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches</article-title><source>Semin Oncol</source><year>2011</year><volume>38</volume><issue>Suppl 4</issue><fpage>S21</fpage><lpage>S33</lpage><pub-id pub-id-type="pmid">22078645</pub-id></element-citation></ref><ref id="b171-cmar-6-149"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Tabatabai</surname><given-names>G</given-names></name></person-group><article-title>Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?</article-title><source>Future Oncol</source><year>2010</year><volume>6</volume><issue>9</issue><fpage>1407</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">20919826</pub-id></element-citation></ref><ref id="b172-cmar-6-149"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keles</surname><given-names>GE</given-names></name><name><surname>Anderson</surname><given-names>B</given-names></name><name><surname>Berger</surname><given-names>MS</given-names></name></person-group><article-title>The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere</article-title><source>Surg Neurol</source><year>1999</year><volume>52</volume><issue>4</issue><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">10555843</pub-id></element-citation></ref><ref id="b173-cmar-6-149"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>WB</given-names></name><name><surname>Sayre</surname><given-names>J</given-names></name><name><surname>Perlina</surname><given-names>A</given-names></name><name><surname>Villablanca</surname><given-names>JP</given-names></name><name><surname>Mischel</surname><given-names>PS</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name></person-group><article-title>MR imaging correlates of survival in patients with high-grade gliomas</article-title><source>AJNR Am J Neuroradiol</source><year>2005</year><volume>26</volume><issue>10</issue><fpage>2466</fpage><lpage>2474</lpage><pub-id pub-id-type="pmid">16286386</pub-id></element-citation></ref><ref id="b174-cmar-6-149"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>M</given-names></name><name><surname>Abi-Said</surname><given-names>D</given-names></name><name><surname>Fourney</surname><given-names>DR</given-names></name><etal></etal></person-group><article-title>A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival</article-title><source>J Neurosurg</source><year>2001</year><volume>95</volume><issue>2</issue><fpage>190</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">11780887</pub-id></element-citation></ref><ref id="b175-cmar-6-149"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keles</surname><given-names>GE</given-names></name><name><surname>Chang</surname><given-names>EF</given-names></name><name><surname>Lamborn</surname><given-names>KR</given-names></name><etal></etal></person-group><article-title>Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma</article-title><source>J Neurosurg</source><year>2006</year><volume>105</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16871879</pub-id></element-citation></ref><ref id="b176-cmar-6-149"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffau</surname><given-names>H</given-names></name><name><surname>Capelle</surname><given-names>L</given-names></name><name><surname>Sichez</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Intra-operative direct electrical stimulations of the central nervous system: the Salpetriere experience with 60 patients</article-title><source>Acta Neurochir (Wien)</source><year>1999</year><volume>141</volume><issue>11</issue><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">10592115</pub-id></element-citation></ref><ref id="b177-cmar-6-149"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffau</surname><given-names>H</given-names></name><name><surname>Capelle</surname><given-names>L</given-names></name><name><surname>Sichez</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Intraoperative mapping of the subcortical language pathways using direct stimulations. An anatomo-functional study</article-title><source>Brain</source><year>2002</year><volume>125</volume><issue>Pt 1</issue><fpage>199</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">11834604</pub-id></element-citation></ref><ref id="b178-cmar-6-149"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffau</surname><given-names>H</given-names></name><name><surname>Capelle</surname><given-names>L</given-names></name><name><surname>Denvil</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Usefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions: functional results in a consecutive series of 103 patients</article-title><source>J Neurosurg</source><year>2003</year><volume>98</volume><issue>4</issue><fpage>764</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">12691401</pub-id></element-citation></ref><ref id="b179-cmar-6-149"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SK</given-names></name></person-group><article-title>Diffusion tensor and perfusion imaging of brain tumors in high-field MR imaging</article-title><source>Neuroimaging Clin N Am</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>123</fpage><lpage>134</lpage><comment>ix</comment><pub-id pub-id-type="pmid">22548924</pub-id></element-citation></ref><ref id="b180-cmar-6-149"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>SJ</given-names></name><name><surname>Gillard</surname><given-names>JH</given-names></name></person-group><article-title>Imaging biomarkers of brain tumour margin and tumour invasion</article-title><source>Br J Radiol</source><year>2011</year><volume>84</volume><issue>Spec 2</issue><fpage>S159</fpage><lpage>S167</lpage><pub-id pub-id-type="pmid">22433826</pub-id></element-citation></ref><ref id="b181-cmar-6-149"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanai</surname><given-names>N</given-names></name><name><surname>Mirzadeh</surname><given-names>Z</given-names></name><name><surname>Berger</surname><given-names>MS</given-names></name></person-group><article-title>Functional outcome after language mapping for glioma resection</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>1</issue><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">18172171</pub-id></element-citation></ref><ref id="b182-cmar-6-149"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyderman</surname><given-names>CH</given-names></name><name><surname>Pant</surname><given-names>H</given-names></name><name><surname>Carrau</surname><given-names>RL</given-names></name><name><surname>Prevedello</surname><given-names>D</given-names></name><name><surname>Gardner</surname><given-names>P</given-names></name><name><surname>Kassam</surname><given-names>AB</given-names></name></person-group><article-title>What are the limits of endoscopic sinus surgery?: the expanded endonasal approach to the skull base</article-title><source>Keio J Med</source><year>2009</year><volume>58</volume><issue>3</issue><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">19826209</pub-id></element-citation></ref><ref id="b183-cmar-6-149"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>N</given-names></name><name><surname>Prevedello</surname><given-names>DM</given-names></name><name><surname>Engh</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>DF</given-names></name><name><surname>Kassam</surname><given-names>AB</given-names></name></person-group><article-title>Endoneurosurgical resection of intraventricular and intraparenchymal lesions using the port technique</article-title><source>World Neurosurg</source><year>2013</year><volume>79</volume><issue>Suppl 2</issue><fpage>S18.e1</fpage><lpage>S18.e8</lpage><pub-id pub-id-type="pmid">22381841</pub-id></element-citation></ref><ref id="b184-cmar-6-149"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MD</given-names></name><name><surname>Alexander</surname><given-names>E</given-names><suffix>Jr</suffix></name><name><surname>Hunt</surname><given-names>WE</given-names></name><etal></etal></person-group><article-title>Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial</article-title><source>J Neurosurg</source><year>1978</year><volume>49</volume><issue>3</issue><fpage>333</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">355604</pub-id></element-citation></ref><ref id="b185-cmar-6-149"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MD</given-names></name><name><surname>Strike</surname><given-names>TA</given-names></name><name><surname>Sheline</surname><given-names>GE</given-names></name></person-group><article-title>An analysis of dose-effect relationship in the radiotherapy of malignant gliomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1979</year><volume>5</volume><issue>10</issue><fpage>1725</fpage><lpage>1731</lpage><pub-id pub-id-type="pmid">231022</pub-id></element-citation></ref><ref id="b186-cmar-6-149"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheline</surname><given-names>GE</given-names></name></person-group><article-title>Radiotherapy for high grade gliomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1990</year><volume>18</volume><issue>4</issue><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">2182578</pub-id></element-citation></ref><ref id="b187-cmar-6-149"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>FH</given-names></name><name><surname>Pruitt</surname><given-names>A</given-names></name></person-group><article-title>Assumptions in the radiotherapy of glioblastoma</article-title><source>Neurology</source><year>1980</year><volume>30</volume><issue>9</issue><fpage>907</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">6252514</pub-id></element-citation></ref><ref id="b188-cmar-6-149"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallner</surname><given-names>KE</given-names></name><name><surname>Galicich</surname><given-names>JH</given-names></name><name><surname>Krol</surname><given-names>G</given-names></name><name><surname>Arbit</surname><given-names>E</given-names></name><name><surname>Malkin</surname><given-names>MG</given-names></name></person-group><article-title>Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1989</year><volume>16</volume><issue>6</issue><fpage>1405</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">2542195</pub-id></element-citation></ref><ref id="b189-cmar-6-149"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choucair</surname><given-names>AK</given-names></name><name><surname>Levin</surname><given-names>VA</given-names></name><name><surname>Gutin</surname><given-names>PH</given-names></name><etal></etal></person-group><article-title>Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas</article-title><source>J Neurosurg</source><year>1986</year><volume>65</volume><issue>5</issue><fpage>654</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">3021931</pub-id></element-citation></ref><ref id="b190-cmar-6-149"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ten Haken</surname><given-names>RK</given-names></name><name><surname>Thornton</surname><given-names>AF</given-names><suffix>Jr</suffix></name><name><surname>Sandler</surname><given-names>HM</given-names></name><etal></etal></person-group><article-title>A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors</article-title><source>Radiother Oncol</source><year>1992</year><volume>25</volume><issue>2</issue><fpage>121</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">1332134</pub-id></element-citation></ref><ref id="b191-cmar-6-149"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glatstein</surname><given-names>E</given-names></name><name><surname>Lichter</surname><given-names>AS</given-names></name><name><surname>Fraass</surname><given-names>BA</given-names></name><name><surname>Kelly</surname><given-names>BA</given-names></name><name><surname>van de Geijn</surname><given-names>J</given-names></name></person-group><article-title>The imaging revolution and radiation oncology: use of CT, ultrasound, and NMR for localization, treatment planning and treatment delivery</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1985</year><volume>11</volume><issue>2</issue><fpage>299</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">3882642</pub-id></element-citation></ref><ref id="b192-cmar-6-149"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>MW</given-names></name><name><surname>Weber</surname><given-names>WA</given-names></name><name><surname>Feldmann</surname><given-names>HJ</given-names></name><name><surname>Bartenstein</surname><given-names>P</given-names></name><name><surname>Schwaiger</surname><given-names>M</given-names></name><name><surname>Molls</surname><given-names>M</given-names></name></person-group><article-title>The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1998</year><volume>41</volume><issue>5</issue><fpage>989</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">9719107</pub-id></element-citation></ref><ref id="b193-cmar-6-149"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>JG</given-names></name><name><surname>Stelzer</surname><given-names>KJ</given-names></name><name><surname>Mankoff</surname><given-names>DA</given-names></name><etal></etal></person-group><article-title>[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>64</volume><issue>3</issue><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">16242251</pub-id></element-citation></ref><ref id="b194-cmar-6-149"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayana</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>J</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>64</volume><issue>3</issue><fpage>892</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">16458777</pub-id></element-citation></ref><ref id="b195-cmar-6-149"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Fraass</surname><given-names>BA</given-names></name><etal></etal></person-group><article-title>Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><issue>6</issue><fpage>1635</fpage><lpage>1642</lpage><pub-id pub-id-type="pmid">11896114</pub-id></element-citation></ref><ref id="b196-cmar-6-149"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrieve</surname><given-names>DC</given-names></name><name><surname>Alexander</surname><given-names>E</given-names><suffix>3rd</suffix></name><name><surname>Black</surname><given-names>PM</given-names></name><etal></etal></person-group><article-title>Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome</article-title><source>J Neurosurg</source><year>1999</year><volume>90</volume><issue>1</issue><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10413158</pub-id></element-citation></ref><ref id="b197-cmar-6-149"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prisco</surname><given-names>FE</given-names></name><name><surname>Weltman</surname><given-names>E</given-names></name><name><surname>de Hanriot</surname><given-names>RM</given-names></name><name><surname>Brandt</surname><given-names>RA</given-names></name></person-group><article-title>Radiosurgical boost for primary high-grade gliomas</article-title><source>J Neurooncol</source><year>2002</year><volume>57</volume><issue>2</issue><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">12125977</pub-id></element-citation></ref><ref id="b198-cmar-6-149"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nwokedi</surname><given-names>EC</given-names></name><name><surname>DiBiase</surname><given-names>SJ</given-names></name><name><surname>Jabbour</surname><given-names>S</given-names></name><name><surname>Herman</surname><given-names>J</given-names></name><name><surname>Amin</surname><given-names>P</given-names></name><name><surname>Chin</surname><given-names>LS</given-names></name></person-group><article-title>Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme</article-title><source>Neurosurgery</source><year>2002</year><volume>50</volume><issue>1</issue><fpage>41</fpage><lpage>46</lpage><comment>discussion 46–47</comment><pub-id pub-id-type="pmid">11844233</pub-id></element-citation></ref><ref id="b199-cmar-6-149"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>MP</given-names></name><name><surname>Masciopinto</surname><given-names>J</given-names></name><name><surname>Rozental</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1994</year><volume>30</volume><issue>3</issue><fpage>541</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">7928484</pub-id></element-citation></ref><ref id="b200-cmar-6-149"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Extended field stereotactic radiosurgery for recurrent glioblastoma</article-title><source>Cancer</source><year>2012</year><volume>118</volume><issue>17</issue><fpage>4193</fpage><lpage>4200</lpage><pub-id pub-id-type="pmid">22180028</pub-id></element-citation></ref><ref id="b201-cmar-6-149"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondziolka</surname><given-names>D</given-names></name><name><surname>Flickinger</surname><given-names>JC</given-names></name><name><surname>Bissonette</surname><given-names>DJ</given-names></name><name><surname>Bozik</surname><given-names>M</given-names></name><name><surname>Lunsford</surname><given-names>LD</given-names></name></person-group><article-title>Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms</article-title><source>Neurosurgery</source><month>10</month><year>1997</year><volume>41</volume><issue>4</issue><fpage>776</fpage><lpage>783</lpage><comment>discussion 783–775</comment><pub-id pub-id-type="pmid">9316038</pub-id></element-citation></ref><ref id="b202-cmar-6-149"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souhami</surname><given-names>L</given-names></name><name><surname>Seiferheld</surname><given-names>W</given-names></name><name><surname>Brachman</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>60</volume><issue>3</issue><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">15465203</pub-id></element-citation></ref><ref id="b203-cmar-6-149"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KJ</given-names></name><name><surname>Kano</surname><given-names>H</given-names></name><name><surname>Iyer</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study</article-title><source>J Neurooncol</source><year>2012</year><volume>107</volume><issue>2</issue><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">22057917</pub-id></element-citation></ref><ref id="b204-cmar-6-149"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Shin</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name></person-group><article-title>Role of gamma knife radiosurgery in neurosurgery: past and future perspectives</article-title><source>Neurol Med Chir (Tokyo)</source><year>2010</year><volume>50</volume><issue>9</issue><fpage>737</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">20885108</pub-id></element-citation></ref><ref id="b205-cmar-6-149"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><etal></etal><collab>European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups</collab><collab>National Cancer Institute of Canada Clinical Trials Group</collab></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>10</issue><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">15758009</pub-id></element-citation></ref><ref id="b206-cmar-6-149"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><etal></etal><collab>European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups</collab><collab>National Cancer Institute of Canada Clinical Trials Group</collab></person-group><article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><issue>5</issue><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">19269895</pub-id></element-citation></ref><ref id="b207-cmar-6-149"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdem-Eraslan</surname><given-names>L</given-names></name><name><surname>Gravendeel</surname><given-names>LA</given-names></name><name><surname>de Rooi</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>3</issue><fpage>328</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">23269986</pub-id></element-citation></ref><ref id="b208-cmar-6-149"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name></person-group><article-title>Understanding high grade glioma: molecular mechanism, therapy and comprehensive management</article-title><source>Cancer Lett</source><year>2013</year><volume>331</volume><issue>2</issue><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">23340179</pub-id></element-citation></ref><ref id="b209-cmar-6-149"><label>209</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Alliance for Clinical Trials in Oncology</collab></person-group><article-title>Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma</article-title><source>ClinicalTrials.gov [website on the Internet]</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>US National Library of Medicine</publisher-name><year>2009</year><comment>[updated November 7, 2013]. Available from: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/study/NCT00887146">http://clinicaltrials.gov/ct2/show/study/NCT00887146</ext-link>. NLM identifier: NCT00887146</comment><date-in-citation>Accessed February 5, 2014</date-in-citation></element-citation></ref><ref id="b210-cmar-6-149"><label>210</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Organisation for Research and Treatment of Cancer – EORTC</collab></person-group><article-title>Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma</article-title><source>ClinicalTrials.gov [website on the Internet]</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>US National Library of Medicine</publisher-name><year>2008</year><comment>[updated September 16, 2011]. Available from: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT00626990">http://clinicaltrials.gov/show/NCT00626990</ext-link>. NLM identifier: NCT00626990</comment><date-in-citation>Accessed February 5, 2014</date-in-citation></element-citation></ref><ref id="b211-cmar-6-149"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>ET</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Gleason</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><issue>8</issue><fpage>2572</fpage><lpage>2578</lpage><pub-id pub-id-type="pmid">10561324</pub-id></element-citation></ref><ref id="b212-cmar-6-149"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamborn</surname><given-names>KR</given-names></name><name><surname>Yung</surname><given-names>WK</given-names></name><name><surname>Chang</surname><given-names>SM</given-names></name><etal></etal><collab>North American Brain Tumor Consortium</collab></person-group><article-title>Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas</article-title><source>Neuro Oncol</source><year>2008</year><volume>10</volume><issue>2</issue><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">18356283</pub-id></element-citation></ref><ref id="b213-cmar-6-149"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballman</surname><given-names>KV</given-names></name><name><surname>Buckner</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PD</given-names></name><etal></etal></person-group><article-title>The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme</article-title><source>Neuro Oncol</source><year>2007</year><volume>9</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17108063</pub-id></element-citation></ref><ref id="b214-cmar-6-149"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstner</surname><given-names>ER</given-names></name><name><surname>Batchelor</surname><given-names>TT</given-names></name></person-group><article-title>Antiangiogenic therapy for glioblastoma</article-title><source>Cancer J</source><year>2012</year><volume>18</volume><issue>1</issue><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">22290257</pub-id></element-citation></ref><ref id="b215-cmar-6-149"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><etal></etal></person-group><article-title>The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><issue>12</issue><fpage>4119</fpage><lpage>4124</lpage><pub-id pub-id-type="pmid">21531816</pub-id></element-citation></ref><ref id="b216-cmar-6-149"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haslinghuis</surname><given-names>LM</given-names></name><name><surname>Krenning</surname><given-names>EP</given-names></name><name><surname>De Herder</surname><given-names>WW</given-names></name><name><surname>Reijs</surname><given-names>AE</given-names></name><name><surname>Kwekkeboom</surname><given-names>DJ</given-names></name></person-group><article-title>Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer</article-title><source>J Endocrinol Invest</source><year>2001</year><volume>24</volume><issue>6</issue><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">11434665</pub-id></element-citation></ref><ref id="b217-cmar-6-149"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>di Tomaso</surname><given-names>E</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Loeffler</surname><given-names>JS</given-names></name><name><surname>Sorensen</surname><given-names>AG</given-names></name><name><surname>Batchelor</surname><given-names>TT</given-names></name></person-group><article-title>Angiogenesis in brain tumours</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><issue>8</issue><fpage>610</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">17643088</pub-id></element-citation></ref><ref id="b218-cmar-6-149"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Radotra</surname><given-names>BD</given-names></name><name><surname>Banerjee</surname><given-names>AK</given-names></name><name><surname>Nijhawan</surname><given-names>R</given-names></name></person-group><article-title>Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors</article-title><source>Anal Quant Cytol Histol</source><year>2004</year><volume>26</volume><issue>4</issue><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">15457675</pub-id></element-citation></ref><ref id="b219-cmar-6-149"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Suh</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance</article-title><source>Oncol Rep</source><year>2004</year><volume>11</volume><issue>4</issue><fpage>863</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">15010886</pub-id></element-citation></ref><ref id="b220-cmar-6-149"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>S</given-names></name><name><surname>Tsuboi</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>A</given-names></name><name><surname>Nose</surname><given-names>T</given-names></name></person-group><article-title>Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts</article-title><source>Neuro Oncol</source><year>2003</year><volume>5</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12626127</pub-id></element-citation></ref><ref id="b221-cmar-6-149"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>MH</given-names></name><name><surname>Shen</surname><given-names>YL</given-names></name><name><surname>Keegan</surname><given-names>P</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name></person-group><article-title>FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme</article-title><source>Oncologist</source><year>2009</year><volume>14</volume><issue>11</issue><fpage>1131</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">19897538</pub-id></element-citation></ref><ref id="b222-cmar-6-149"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>A</given-names></name><name><surname>Nghiemphu</surname><given-names>PL</given-names></name><etal></etal></person-group><article-title>Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>2</issue><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">21135282</pub-id></element-citation></ref><ref id="b223-cmar-6-149"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Turner</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>KB</given-names></name><etal></etal></person-group><article-title>A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma</article-title><source>J Natl Compr Canc Netw</source><year>2011</year><volume>9</volume><issue>4</issue><fpage>414</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">21464146</pub-id></element-citation></ref><ref id="b224-cmar-6-149"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norden</surname><given-names>AD</given-names></name><name><surname>Drappatz</surname><given-names>J</given-names></name><name><surname>Muzikansky</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma</article-title><source>J Neurooncol</source><year>2009</year><volume>92</volume><issue>2</issue><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">19043778</pub-id></element-citation></ref><ref id="b225-cmar-6-149"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>K</given-names></name><name><surname>Abrey</surname><given-names>LE</given-names></name><name><surname>Gutin</surname><given-names>PH</given-names></name></person-group><article-title>Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches</article-title><source>Radiat Oncol</source><year>2011</year><volume>6</volume><fpage>2</fpage><pub-id pub-id-type="pmid">21214925</pub-id></element-citation></ref><ref id="b226-cmar-6-149"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreisl</surname><given-names>TN</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>5</issue><fpage>740</fpage><lpage>745</lpage><pub-id pub-id-type="pmid">19114704</pub-id></element-citation></ref><ref id="b227-cmar-6-149"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khasraw</surname><given-names>M</given-names></name><name><surname>Lassman</surname><given-names>AB</given-names></name></person-group><article-title>Advances in the treatment of malignant gliomas</article-title><source>Curr Oncol Rep</source><year>2010</year><volume>12</volume><issue>1</issue><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20425605</pub-id></element-citation></ref><ref id="b228-cmar-6-149"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunnakkat</surname><given-names>S</given-names></name><name><surname>Narayana</surname><given-names>A</given-names></name></person-group><article-title>Bevacizumab in the treatment of high-grade gliomas: an overview</article-title><source>Angiogenesis</source><year>2011</year><volume>14</volume><issue>4</issue><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">21858651</pub-id></element-citation></ref><ref id="b229-cmar-6-149"><label>229</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Memorial Sloan-Kettering Cancer Center</collab></person-group><article-title>Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma</article-title><source>ClinicalTrials.gov [website on the Internet]</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>US National Library of Medicine</publisher-name><year>2011</year><comment>[updated December 17, 2013]. Available from <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01392209">http://clinicaltrials.gov/ct2/show/NCT01392209</ext-link>. NLM identifier: NCT01392209</comment><date-in-citation>Accessed February 5, 2014</date-in-citation></element-citation></ref><ref id="b230-cmar-6-149"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>AR</given-names></name><name><surname>Cuneo</surname><given-names>KC</given-names></name><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name><name><surname>Kirkpatrick</surname><given-names>JP</given-names></name></person-group><article-title>Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme</article-title><source>J Natl Compr Canc Netw</source><year>2012</year><volume>10</volume><issue>6</issue><fpage>695</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">22679114</pub-id></element-citation></ref><ref id="b231-cmar-6-149"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloughsey</surname><given-names>T</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Mason</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: Final progression-free survival and preliminary overall survival results from AVAglio</article-title><source>Neurology</source><year>2013</year><volume>80</volume><issue>Meeting Abstracts 1</issue><fpage>PL02.002</fpage></element-citation></ref><ref id="b232-cmar-6-149"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>MR</given-names></name><name><surname>Dignam</surname><given-names>J</given-names></name><name><surname>Won</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>Suppl</issue><comment>abstr 1</comment></element-citation></ref><ref id="b233-cmar-6-149"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Chinot</surname><given-names>O</given-names></name><name><surname>Boogerd</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><issue>4</issue><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">12649108</pub-id></element-citation></ref><ref id="b234-cmar-6-149"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Galanis</surname><given-names>E</given-names></name><name><surname>DeGroot</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Clinical trial end points for high-grade glioma: the evolving landscape</article-title><source>Neuro Oncol</source><year>2011</year><volume>13</volume><issue>3</issue><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">21310734</pub-id></element-citation></ref><ref id="b235-cmar-6-149"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrey</surname><given-names>LE</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Paleologos</surname><given-names>N</given-names></name><etal></etal><collab>Oligodendroglioma Study Group</collab></person-group><article-title>Survey of treatment recommendations for anaplastic oligodendroglioma</article-title><source>Neuro Oncol</source><year>2007</year><volume>9</volume><issue>3</issue><fpage>314</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">17435180</pub-id></element-citation></ref><ref id="b236-cmar-6-149"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeAngelis</surname><given-names>LM</given-names></name></person-group><article-title>Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>35</issue><fpage>5861</fpage><lpage>5862</lpage><pub-id pub-id-type="pmid">19901101</pub-id></element-citation></ref><ref id="b237-cmar-6-149"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murrell</surname><given-names>J</given-names></name><name><surname>Board</surname><given-names>R</given-names></name></person-group><article-title>The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions</article-title><source>Cancer Treat Rev</source><year>2013</year><volume>39</volume><issue>8</issue><fpage>833</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">23845462</pub-id></element-citation></ref><ref id="b238-cmar-6-149"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>JH</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Archer</surname><given-names>GE</given-names></name><etal></etal></person-group><article-title>Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma</article-title><source>Neuro Oncol</source><year>2011</year><volume>13</volume><issue>3</issue><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">21149254</pub-id></element-citation></ref><ref id="b239-cmar-6-149"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>O’Day</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><issue>23</issue><fpage>7412</fpage><lpage>7420</lpage><pub-id pub-id-type="pmid">19934295</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-cmar-6-149" position="float"><label>Figure 1</label><caption><p>Magnetic resonance findings in GBM.</p><p><bold>Notes:</bold> (<bold>A</bold>) T1 pre-contrast images exhibit a hypointense lesion in the left frontal lobe region (arrow). (<bold>B</bold>) Axial T1 post-contrast images, after injection of 20 cc of intravenous MultiHance®, demonstrate a focus of enhancement in left frontal lobe. (<bold>C</bold>) Axial T2 FLAIR images show increase in FLAIR signal in the left frontal lobe, which demonstrates enhancement. (<bold>D</bold>) T2 FSE images also demonstrate increase in signal in the region of the left frontal lobe.</p><p><bold>Abbreviations:</bold> FLAIR, fluid-attenuated inversion recovery; FSE, fast spin-echo; GBM, glioblastoma multiforme.</p></caption><graphic xlink:href="cmar-6-149Fig1"></graphic></fig><fig id="f2-cmar-6-149" position="float"><label>Figure 2</label><caption><p>Radiation necrosis versus viable tumor on MRI.</p><p><bold>Notes:</bold> Sixty-nine-year-old male with glioblastoma multiforme, status post-chemotherapy presented with dizziness. Contrast MRI and <sup>18</sup>F-FDG PET were performed to evaluate for progression. Post-contrast T1 MR (<bold>A</bold>) is suggestive of rim enhancement of tumor (arrow). <sup>18</sup>F-FDG PET (<bold>B</bold>) and PET-MR fusion (<bold>C</bold>) images show an area of relatively decreased activity corresponding to the area of rim enhancement. PET findings were diagnostic for nonviable tissue. In this case, MR was unable to differentiate between radiation changes and viable tumor.</p><p><bold>Abbreviations:</bold> FDG, 2-fluorodeoxyglucose; MR, magnetic resonance; MRI, magnetic resonance imaging; PET, positron emission tomography.</p></caption><graphic xlink:href="cmar-6-149Fig2"></graphic></fig><fig id="f3-cmar-6-149" position="float"><label>Figure 3</label><caption><p>Magnetic resonance spectroscopy.</p><p><bold>Notes:</bold> Anaplastic astrocytoma, WHO grade III. Multiple-voxel spectra coregistered with post-contrast T1-weighted MRI <bold>(A)</bold>. Map of Cho/Cr demonstrates a focus of signal intensity in the right frontal lobe <bold>(B)</bold>. MRSI signal intensity is presented on a rainbow color scale where blue-green is normal background and bright red corresponds to greatly elevated signal intensity. Spectral analysis of the voxel demonstrating maximal Cho/Cr ratio <bold>(C)</bold>. T1-weighted MRI (post-contrast) demonstrating enhancing lesion in the right frontal lobe <bold>(D)</bold>. <sup>18</sup>F-FDG PET scan shows a focus of increased tracer activity greater than white matter in the right frontal lobe <bold>(E)</bold>. <sup>18</sup>F-FDG PET image coregistered with post-contrast T1-weighted MRI <bold>(F)</bold>. Reproduced with permission from John Wiley and Sons. Imani F, Boada FE, Lieberman FS, Davis DK, Deeb EL, Mountz JM. Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression. <italic>J Neuroimaging</italic>. 2012;22(2):184–190.<xref rid="b80-cmar-6-149" ref-type="bibr">80</xref> Copyright © 2010 by the American Society of Neuroimaging.</p><p><bold>Abbreviations:</bold> Cho/Cr, choline/creatine; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate; WHO, World Health Organization; FDG, 2-fluorodeoxyglucose; PET, positron emission tomography.</p></caption><graphic xlink:href="cmar-6-149Fig3"></graphic></fig><fig id="f4-cmar-6-149" position="float"><label>Figure 4</label><caption><p>Tumor recurrence versus radiation induced changes: images of a 77-year-old male who was originally diagnosed with glioblastoma multiforme, treated with external beam radiation and adjuvant chemotherapy with temozolomide.</p><p><bold>Notes:</bold> Ten-month follow-up MR T1 post-contrast images (<bold>A</bold>) demonstrate a distinct area of enhancement (arrow) in the left temporoparietal lobe region of prior tumor. T2-weighted MR images (<bold>B</bold>) demonstrate hyperintense signal in the left parietal lobe extending to the left temporal lobe. This pathologic contrast enhancement is suggestive of an infiltrative mass. FDG PET only (<bold>C</bold>) and PET-CT fusion images (<bold>D</bold>) demonstrate a focus of increased FDG activity corresponding to an enhanced area of uptake on post-contrast T1 images. These findings are consistent with tumor recurrence. There is also decreased tracer uptake surrounding these areas consistent with vasogenic edema.</p><p><bold>Abbreviations:</bold> CT, computed tomography; FDG, 2-fluorodeoxyglucose; MR, magnetic resonance; PET, positron emission tomography.</p></caption><graphic xlink:href="cmar-6-149Fig4"></graphic></fig><fig id="f5-cmar-6-149" position="float"><label>Figure 5</label><caption><p><sup>18</sup>F-FDG PET for tumor recurrence: 71-year-old male patient with history of glioblastoma multiforme, status post-resection presents for evaluation of recurrence.</p><p><bold>Notes:</bold> Contrast-enhanced MR T1 images (<bold>A</bold>) demonstrate a large cavity in the left posterotemporal-parietal junction with an irregular rim of enhancement. T2-weighted MR images (<bold>B</bold>) demonstrate hyperintensity in the posterotemporal and parietal lobes. These findings are suspicious for tumor recurrence around the periphery of previous location of mass in the left posterior temporoparietal region. (<bold>C</bold>) <sup>18</sup>F-FDG PET only and (<bold>D</bold>) PET-CT fusion images demonstrate a relatively large area of absent <sup>18</sup>F-FDG uptake corresponding to the cavity noted on MRI, with no area of abnormally increased <sup>18</sup>F-FDG to suggest the presence of residual or recurrent high-grade viable tumor.</p><p><bold>Abbreviations:</bold> CT, computed tomography; FDG, 2-fluorodeoxyglucose; MR, magnetic resonance; MRI, magnetic resonance imaging; PET, positron emission tomography.</p></caption><graphic xlink:href="cmar-6-149Fig5"></graphic></fig><fig id="f6-cmar-6-149" position="float"><label>Figure 6</label><caption><p><sup>18</sup>F-FDG PET diagnosis of pseudoprogression.</p><p><bold>Notes:</bold> Patient with a history of glioblastoma, status post-resection, now after treatment with total dose of 60 Gy in 2-Gy fractions presents for a follow-up, 1 month after radiation therapy. MRI (<bold>A</bold>) demonstrates enhancement posterior to the prior resection cavity in the left frontal lobe (arrowhead). However, the patient showed clinical improvement, and therefore an <sup>18</sup>F-FDG PET scan was done to assess for tumor progression. On PET (<bold>B</bold>), no abnormal areas of increased <sup>18</sup>F-FDG uptake in the region of MRI contrast enhancement were identified (<bold>C</bold>), thus additional therapy was deemed not indicated; the patient was monitored on follow-up contrast-enhanced MRI scans, which were negative. Thus, PET scan was helpful in differentiating pseudoprogression from true progression. Adapted with permission from Lippincott Williams and Wilkins/Wolters Kluwer Health: Oborski MJ, Laymon CM, Lieberman FS, Mountz JM. Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET. <italic>Clin Nucl Med</italic>. 2013;38(5):381–384.<xref rid="b56-cmar-6-149" ref-type="bibr">56</xref> Copyright © 2013. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Lippincott Williams and Wilkins. Please contact journalpermissions@lww.com for further information.</p><p><bold>Abbreviations:</bold> FDG, 2-fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.</p></caption><graphic xlink:href="cmar-6-149Fig6"></graphic></fig><fig id="f7-cmar-6-149" position="float"><label>Figure 7</label><caption><p><sup>18</sup>F-FLT PET.</p><p><bold>Notes:</bold> Sixty-five-year-old female who initially presented with glioblastoma multiforme, now presents after completion of 6 weeks of temozolomide chemotherapy and a total of 60 Gy radiotherapy to the tumor. T1 post-contrast enhanced images (<bold>A</bold>) demonstrate slight progression as compared to prior study. However, FLT uptake post-therapy (<bold>C</bold>) was significantly decreased as compared to baseline scan (<bold>B</bold>). This finding was suggestive of a response to therapy.</p><p><bold>Abbreviations:</bold> FLT, fluoro-3′-deoxy-3′-l-fluorothymidine; PET, positron emission tomography; SUV, standardized uptake value.</p></caption><graphic xlink:href="cmar-6-149Fig7"></graphic></fig></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001F28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.38. |  |